LAMICTAL (lamotrigine) Tablets
LAMICTAL (lamotrigine) Chewable Dispersible Tablets
LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets

Initial U.S. Approval: 1994

**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL.

LAMICTAL is an antiepileptic drug (AED) indicated for:

- **Epilepsy**—monotherapy in patients aged 16 years and older: primary generalized tonic-clonic seizures.
- **Epilepsy**—adjunctive therapy in patients aged 2 years and older:
  - partial-onset seizures.
  - primary generalized tonic-clonic seizures.
  - generalized seizures of Lennox-Gastaut syndrome.
- **Bipolar disorder** in patients aged 18 years and older:
  - maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy.

**INDICATIONS AND USAGE**

- **Epilepsy**—adjunctive therapy in patients aged 2 years and older:
  - primary generalized tonic-clonic seizures.
  - primary generalized tonic-clonic seizures.
  - generalized seizures of Lennox-Gastaut syndrome.
- **Bipolar disorder** in patients aged 18 years and older: Maintenance treatment of bipolar I disorder.

**WARNINGS AND PRECAUTIONS**

- **Life-threatening serious rash and/or rash-related death:** Discontinue at the first sign of rash, unless the rash is clearly not drug related. (Boxed Warning, 5.1)
- **Fatal or life-threatening hypersensitivity reaction:** Multiorgan hypersensitivity reactions, also known as drug reaction with eosinophilia and systemic symptoms (DRESS), may be fatal or life threatening. Early signs may include rash, fever, and lymphadenopathy. These reactions may be associated with other organ involvement, such as hepatitis, hepatic failure, blood dyscrasias, or acute multiorgan failure. LAMICTAL should be discontinued if alternate etiology for this reaction is not found. (5.2)
- **Blood dyscrasias (e.g., neutropenia, thrombocytopenia, pancytopenia):** May occur, either with or without an associated hypersensitivity syndrome. Monitor for signs of anemia, unexpected infection, or bleeding. (5.3)
- **Suicidal behavior and ideation:** Monitor for suicidal thoughts or behaviors. (5.4)
- **Clinical worsening, emergence of new symptoms, and suicidal ideation/behaviors:** may be associated with treatment of bipolar disorder. Patients should be closely monitored, particularly early in treatment or during dosage changes. (5.5)
- **Aseptic meningitis:** Monitor for signs of meningitis. (5.6)
- **Medication errors due to product name confusion:** Strongly advise patients to visually inspect tablets to verify the received drug is correct. (3.4, 5.7, 16, 17)

**ADVERSE REACTIONS**

- **Most common adverse reactions:** (incidence ≥10%) in adult epilepsy clinical trials were dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, pharyngitis, and rash. Additional adverse reactions (incidence ≥10%) reported in children in epilepsy clinical trials included vomiting, diarrhea, infection, fever, accidental injury, abdominal pain, and tremor. (6.1)
- **Most common adverse reactions:** (incidence >5%) in adult bipolar clinical trials were nausea, insomnia, somnolence, back pain, fatigue, rash, rhinitis, abdominal pain, and xerostomia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DRUG INTERACTIONS**

- **Valproate increases lamotrigine concentrations more than 2-fold.** (7, 12.3)
- **Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease lamotrigine concentrations by approximately 40%**. (7, 12.3)
- **Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%.** (7, 12.3)
- **Protease inhibitors lopinavir/ritonavir and atazanavir/lopinavir decrease lamotrigine exposure by approximately 50% and 32%, respectively.** (7, 12.3)

**USE IN SPECIFIC POPULATIONS**

- **Pregnancy:** Based on animal data may cause fetal harm. (8.1)
- **Efficacy of LAMICTAL, used as adjunctive treatment for partial-onset seizures, was not demonstrated in a small, randomized, double-blind, placebo-controlled trial in very young pediatric patients (1 to 24 months).** (8.4)
- **Hepatic impairment:** Dosage adjustments required in patients with moderate and severe liver impairment. (2.1, 8.6)
- **Renal impairment:** Reduced maintenance doses may be effective for patients with significant renal impairment. (2.1, 8.7)

See 17 for **PATIENT COUNSELING INFORMATION AND Medication Guide.**

Revised: 12/2014
FULL PRESCRIBING INFORMATION

WARNING: SERIOUS SKIN RASHES

LAMICTAL® can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving LAMICTAL as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08% (0.8 per 1,000) in adult patients receiving LAMICTAL as initial monotherapy and 0.13% (1.3 per 1,000) in adult patients receiving LAMICTAL as adjunctive therapy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive LAMICTAL, there was 1 rash-related death. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by LAMICTAL. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of LAMICTAL with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of LAMICTAL, or (3) exceeding the recommended dose escalation for LAMICTAL. However, cases have occurred in the absence of these factors.

Nearly all cases of life-threatening rashes caused by LAMICTAL have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.

Although benign rashes are also caused by LAMICTAL, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, LAMICTAL should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE
1.1 Epilepsy

Adjunctive Therapy: LAMICTAL is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older:

- partial-onset seizures.
- primary generalized tonic-clonic (PGTC) seizures.
- generalized seizures of Lennox-Gastaut syndrome.

Monotherapy: LAMICTAL is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).

Safety and effectiveness of LAMICTAL have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

1.2 Bipolar Disorder

LAMICTAL is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (aged 18 years and older) treated for acute mood episodes with standard therapy. The effectiveness of LAMICTAL in the acute treatment of mood episodes has not been established.

The effectiveness of LAMICTAL as maintenance treatment was established in 2 placebo-controlled trials in patients with bipolar I disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe LAMICTAL for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
DOSE AND ADMINISTRATION

2.1 General Dosing Considerations

Rash: There are suggestions, yet to be proven, that the risk of severe, potentially life-threatening rash may be increased by (1) coadministration of LAMICTAL with valproate, (2) exceeding the recommended initial dose of LAMICTAL, or (3) exceeding the recommended dose escalation for LAMICTAL. However, cases have occurred in the absence of these factors [see Boxed Warning]. Therefore, it is important that the dosing recommendations be followed closely.

The risk of nonserious rash may be increased when the recommended initial dose and/or the rate of dose escalation for LAMICTAL is exceeded and in patients with a history of allergy or rash to other AEDs.

LAMICTAL Starter Kits and LAMICTAL ODT® Patient Titration Kits provide LAMICTAL at doses consistent with the recommended titration schedule for the first 5 weeks of treatment, based upon concomitant medications, for patients with epilepsy (older than 12 years) and bipolar I disorder (aged 18 years and older) and are intended to help reduce the potential for rash. The use of LAMICTAL Starter Kits and LAMICTAL ODT Patient Titration Kits is recommended for appropriate patients who are starting or restarting LAMICTAL [see How Supplied/Storage and Handling (16)].

It is recommended that LAMICTAL not be restarted in patients who discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefits clearly outweigh the risks. If the decision is made to restart a patient who has discontinued LAMICTAL, the need to restart with the initial dosing recommendations should be assessed. The greater the interval of time since the previous dose, the greater consideration should be given to restarting with the initial dosing recommendations. If a patient has discontinued lamotrigine for a period of more than 5 half-lives, it is recommended that initial dosing recommendations and guidelines be followed. The half-life of lamotrigine is affected by other concomitant medications [see Clinical Pharmacology (12.3)].

LAMICTAL Added to Drugs Known to Induce or Inhibit Glucuronidation: Because lamotrigine is metabolized predominantly by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine. Drugs that induce glucuronidation include carbamazepine, phenytoin, phenobarbital, primidone, rifampin, estrogen-containing oral contraceptives, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Valproate inhibits glucuronidation. For dosing considerations for LAMICTAL in patients on estrogen-containing contraceptives and atazanavir/ritonavir, see below and Table 13. For dosing considerations for LAMICTAL in patients on other drugs known to induce or inhibit glucuronidation, see Table 1, Table 2, Table 5, Table 6, and Table 13.

Target Plasma Levels for Patients With Epilepsy or Bipolar Disorder: A therapeutic plasma concentration range has not been established for lamotrigine. Dosing of LAMICTAL should be based on therapeutic response [see Clinical Pharmacology (12.3)].
Women Taking Estrogen-Containing Oral Contraceptives: Starting LAMICTAL in
Women Taking Estrogen-Containing Oral Contraceptives: Although estrogen-containing
oral contraceptives have been shown to increase the clearance of lamotrigine [see Clinical
Pharmacology (12.3)], no adjustments to the recommended dose-escalation guidelines for
LAMICTAL should be necessary solely based on the use of estrogen-containing oral
contraceptives. Therefore, dose escalation should follow the recommended guidelines for
initiating adjunctive therapy with LAMICTAL based on the concomitant AED or other
concomitant medications (see Table 1 or Table 5). See below for adjustments to maintenance
doses of LAMICTAL in women taking estrogen-containing oral contraceptives.

Adjustments to the Maintenance Dose of LAMICTAL in Women Taking
Estrogen-Containing Oral Contraceptives:

(1) Taking Estrogen-Containing Oral Contraceptives: In women not taking
carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the
protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine
glucuronidation [see Drug Interactions (7), Clinical Pharmacology (12.3)], the maintenance
dose of LAMICTAL will in most cases need to be increased by as much as 2-fold over the
recommended target maintenance dose to maintain a consistent lamotrigine plasma level.

(2) Starting Estrogen-Containing Oral Contraceptives: In women taking a
stable dose of LAMICTAL and not taking carbamazepine, phenytoin, phenobarbital, primidone,
or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and
atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical
Pharmacology (12.3)], the maintenance dose will in most cases need to be increased by as much
as 2-fold to maintain a consistent lamotrigine plasma level. The dose increases should begin at
the same time that the oral contraceptive is introduced and continue, based on clinical response,
no more rapidly than 50 to 100 mg/day every week. Dose increases should not exceed the
recommended rate (see Table 1 or Table 5) unless lamotrigine plasma levels or clinical response
support larger increases. Gradual transient increases in lamotrigine plasma levels may occur
during the week of inactive hormonal preparation (pill-free week), and these increases will be
greater if dose increases are made in the days before or during the week of inactive hormonal
preparation. Increased lamotrigine plasma levels could result in additional adverse reactions,
such as dizziness, ataxia, and diplopia. If adverse reactions attributable to LAMICTAL
consistently occur during the pill-free week, dose adjustments to the overall maintenance dose
may be necessary. Dose adjustments limited to the pill-free week are not recommended. For
women taking LAMICTAL in addition to carbamazepine, phenytoin, phenobarbital, primidone,
or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and
atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical
Pharmacology (12.3)], no adjustment to the dose of LAMICTAL should be necessary.

(3) Stopping Estrogen-Containing Oral Contraceptives: In women not taking
carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the
protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine
glucuronidation [see Drug Interactions (7), Clinical Pharmacology (12.3)], the maintenance
dose of LAMICTAL will in most cases need to be decreased by as much as 50% in order to
maintain a consistent lamotrigine plasma level. The decrease in dose of LAMICTAL should not
exceed 25% of the total daily dose per week over a 2-week period, unless clinical response or
lamotrigine plasma levels indicate otherwise [see Clinical Pharmacology (12.3)]. In women
taking LAMICTAL in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other
drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir
that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical Pharmacology
(12.3)], no adjustment to the dose of LAMICTAL should be necessary.

**Women and Other Hormonal Contraceptive Preparations or Hormone Replacement Therapy:** The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of LAMICTAL in the presence of progestogens alone will likely not be needed.

**Patients Taking Atazanavir/Ritonavir:** While atazanavir/ritonavir does reduce the lamotrigine plasma concentration, no adjustments to the recommended dose-escalation guidelines for LAMICTAL should be necessary solely based on the use of atazanavir/ritonavir. Dose escalation should follow the recommended guidelines for initiating adjunctive therapy with LAMICTAL based on concomitant AED or other concomitant medications (see Tables 1, 2, and 5). In patients already taking maintenance doses of LAMICTAL and not taking glucuronidation inducers, the dose of LAMICTAL may need to be increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued [see Clinical Pharmacology (12.3)].

**Patients With Hepatic Impairment:** Experience in patients with hepatic impairment is limited. Based on a clinical pharmacology study in 24 subjects with mild, moderate, and severe liver impairment [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)], the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without ascites and 50% in patients with severe liver impairment with ascites. Escalation and maintenance doses may be adjusted according to clinical response.

**Patients With Renal Impairment:** Initial doses of LAMICTAL should be based on patients’ concomitant medications (see Tables 1-3 or Table 5); reduced maintenance doses may be effective for patients with significant renal impairment [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]. Few patients with severe renal impairment have been evaluated during chronic treatment with LAMICTAL. Because there is inadequate experience in this population, LAMICTAL should be used with caution in these patients.
Discontinuation Strategy: Epilepsy: For patients receiving LAMICTAL in combination with other AEDs, a re-evaluation of all AEDs in the regimen should be considered if a change in seizure control or an appearance or worsening of adverse reactions is observed. If a decision is made to discontinue therapy with LAMICTAL, a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety concerns require a more rapid withdrawal [see Warnings and Precautions (5.9)].

Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine; discontinuing valproate should shorten the half-life of lamotrigine.

Bipolar Disorder: In the controlled clinical trials, there was no increase in the incidence, type, or severity of adverse reactions following abrupt termination of LAMICTAL. In clinical trials in patients with bipolar disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL. However, there were confounding factors that may have contributed to the occurrence of seizures in these patients with bipolar disorder. Discontinuation of LAMICTAL should involve a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) unless safety concerns require a more rapid withdrawal [see Warnings and Precautions (5.9)].

2.2 Epilepsy—Adjunctive Therapy

This section provides specific dosing recommendations for patients older than 12 years and patients aged 2 to 12 years. Within each of these age-groups, specific dosing recommendations are provided depending upon concomitant AEDs or other concomitant medications (see Table 1 for patients older than 12 years and Table 2 for patients aged 2 to 12 years). A weight-based dosing guide for patients aged 2 to 12 years on concomitant valproate is provided in Table 3.

Patients Older Than 12 Years: Recommended dosing guidelines are summarized in Table 1.
Table 1. Escalation Regimen for LAMICTAL in Patients Older Than 12 Years With Epilepsy

<table>
<thead>
<tr>
<th>Time Period</th>
<th>In Patients TAKING Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>In Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone&lt;sup&gt;b&lt;/sup&gt;, or Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone&lt;sup&gt;b&lt;/sup&gt; and NOT TAKING Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks 1 and 2</td>
<td>25 mg every other day</td>
<td>25 mg every day</td>
<td>50 mg/day</td>
</tr>
<tr>
<td>Weeks 3 and 4</td>
<td>25 mg every day</td>
<td>50 mg/day</td>
<td>100 mg/day (in 2 divided doses)</td>
</tr>
<tr>
<td>Week 5 onward to maintenance</td>
<td>Increase by 25 to 50 mg/day every 1 to 2 weeks</td>
<td>Increase by 50 mg/day every 1 to 2 weeks.</td>
<td>Increase by 100 mg/day every 1 to 2 weeks.</td>
</tr>
<tr>
<td>Usual maintenance dose</td>
<td>100 to 200 mg/day with valproate alone</td>
<td>225 to 375 mg/day (in 2 divided doses)</td>
<td>300 to 500 mg/day (in 2 divided doses)</td>
</tr>
<tr>
<td></td>
<td>100 to 400 mg/day with valproate and other drugs that induce glucuronidation (in 1 or 2 divided doses)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see Drug Interactions (7), Clinical Pharmacology (12.3)].

<sup>b</sup> Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations [see Dosage and Administration (2.1)]. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance [see Dosage and Administration (2.1), Drug Interactions (7), and Clinical Pharmacology (12.3)].

Patients Aged 2 to 12 Years: Recommended dosing guidelines are summarized in Table 2.

Smaller starting doses and slower dose escalations than those used in clinical trials are recommended because of the suggestion that the risk of rash may be decreased by smaller starting doses and slower dose escalations. Therefore, maintenance doses will take longer to
reach in clinical practice than in clinical trials. It may take several weeks to months to achieve an
individualized maintenance dose. Maintenance doses in patients weighing less than 30 kg,
regardless of age or concomitant AED, may need to be increased as much as 50%, based on
clinical response.

The smallest available strength of LAMICTAL Chewable Dispersible Tablets is
2 mg, and only whole tablets should be administered. If the calculated dose cannot be
achieved using whole tablets, the dose should be rounded down to the nearest whole tablet
[see How Supplied/Storage and Handling (16) and Medication Guide].

Table 2. Escalation Regimen for LAMICTAL in Patients Aged 2 to 12 Years With Epilepsy

<table>
<thead>
<tr>
<th></th>
<th>In Patients TAKING Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>In Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone&lt;sup&gt;b&lt;/sup&gt; or Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone&lt;sup&gt;b&lt;/sup&gt; and NOT TAKING Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks 1 and 2</td>
<td>0.15 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet (see Table 3 for weight-based dosing guide)</td>
<td>0.3 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet</td>
<td>0.6 mg/kg/day in 2 divided doses, rounded down to the nearest whole tablet</td>
</tr>
<tr>
<td>Weeks 3 and 4</td>
<td>0.3 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet (see Table 3 for weight-based dosing guide)</td>
<td>0.6 mg/kg/day in 2 divided doses, rounded down to the nearest whole tablet</td>
<td>1.2 mg/kg/day in 2 divided doses, rounded down to the nearest whole tablet</td>
</tr>
<tr>
<td>Week 5 onward to maintenance</td>
<td>The dose should be increased every 1 to 2 weeks as follows: calculate 0.3 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose.</td>
<td>The dose should be increased every 1 to 2 weeks as follows: calculate 0.6 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose.</td>
<td>The dose should be increased every 1 to 2 weeks as follows: calculate 1.2 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Usual maintenance dose</td>
<td><strong>1 to 5 mg/kg/day</strong> (maximum 200 mg/day in 1 or 2 divided doses)</td>
<td><strong>4.5 to 7.5 mg/kg/day</strong> (maximum 300 mg/day in 2 divided doses)</td>
<td><strong>5 to 15 mg/kg/day</strong> (maximum 400 mg/day in 2 divided doses)</td>
</tr>
<tr>
<td>Maintenance dose in patients less than 30 kg</td>
<td>May need to be increased by as much as 50%, based on clinical response.</td>
<td>May need to be increased by as much as 50%, based on clinical response.</td>
<td>May need to be increased by as much as 50%, based on clinical response.</td>
</tr>
</tbody>
</table>

**Note: Only whole tablets should be used for dosing.**

Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see Drug Interactions (7), Clinical Pharmacology (12.3)].

Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations [see Dosage and Administration (2.1)]. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance [see Dosage and Administration (2.1), Drug Interactions (7), and Clinical Pharmacology (12.3)].
Table 3. The Initial Weight-Based Dosing Guide for Patients Aged 2 to 12 Years Taking Valproate (Weeks 1 to 4) With Epilepsy

<table>
<thead>
<tr>
<th>If the patient’s weight is</th>
<th>Give this daily dose, using the most appropriate combination of LAMICTAL 2- and 5-mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater than 6.7 kg</td>
<td>And less than 14 kg</td>
</tr>
<tr>
<td>14 kg</td>
<td>2 mg every other day</td>
</tr>
<tr>
<td>14.1 kg</td>
<td>27 kg</td>
</tr>
<tr>
<td>27.1 kg</td>
<td>34 kg</td>
</tr>
<tr>
<td>34.1 kg</td>
<td>40 kg</td>
</tr>
</tbody>
</table>

Usual Adjunctive Maintenance Dose for Epilepsy: The usual maintenance doses identified in Tables 1 and 2 are derived from dosing regimens employed in the placebo-controlled adjunctive trials in which the efficacy of LAMICTAL was established. In patients receiving multidrug regimens employing carbamazepine, phenytoin, phenobarbital, or primidone without valproate, maintenance doses of adjunctive LAMICTAL as high as 700 mg/day have been used. In patients receiving valproate alone, maintenance doses of adjunctive LAMICTAL as high as 200 mg/day have been used. The advantage of using doses above those recommended in Tables 1-4 has not been established in controlled trials.

2.3 Epilepsy—Conversion From Adjunctive Therapy to Monotherapy

The goal of the transition regimen is to attempt to maintain seizure control while mitigating the risk of serious rash associated with the rapid titration of LAMICTAL.

The recommended maintenance dose of LAMICTAL as monotherapy is 500 mg/day given in 2 divided doses.

To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations for LAMICTAL should not be exceeded [see Boxed Warning].

Conversion From Adjunctive Therapy With Carbamazepine, Phenytoin, Phenobarbital, or Primidone to Monotherapy With LAMICTAL: After achieving a dose of 500 mg/day of LAMICTAL using the guidelines in Table 1, the concomitant enzyme-inducing AED should be withdrawn by 20% decrements each week over a 4-week period. The regimen for the withdrawal of the concomitant AED is based on experience gained in the controlled monotherapy clinical trial.

Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL: The conversion regimen involves the 4 steps outlined in Table 4.
Table 4. Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL in Patients Aged 16 Years and Older With Epilepsy

<table>
<thead>
<tr>
<th>LAMICTAL</th>
<th>Valproate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>Achieve a dose of 200 mg/day according to guidelines in Table 1.</td>
</tr>
<tr>
<td>Step 2</td>
<td>Maintain at 200 mg/day.</td>
</tr>
<tr>
<td>Step 3</td>
<td>Increase to 300 mg/day and maintain for 1 week.</td>
</tr>
<tr>
<td>Step 4</td>
<td>Increase by 100 mg/day every week to achieve maintenance dose of 500 mg/day.</td>
</tr>
</tbody>
</table>

Conversion From Adjunctive Therapy With Antiepileptic Drugs Other Than Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate to Monotherapy With LAMICTAL: No specific dosing guidelines can be provided for conversion to monotherapy with LAMICTAL with AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate.

2.4 Bipolar Disorder
The goal of maintenance treatment with LAMICTAL is to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. The target dose of LAMICTAL is 200 mg/day (100 mg/day in patients taking valproate, which decreases the apparent clearance of lamotrigine, and 400 mg/day in patients not taking valproate and taking either carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitor lopinavir/ritonavir that increase the apparent clearance of lamotrigine). In the clinical trials, doses up to 400 mg/day as monotherapy were evaluated; however, no additional benefit was seen at 400 mg/day compared with 200 mg/day [see Clinical Studies (14.2)]. Accordingly, doses above 200 mg/day are not recommended. Treatment with LAMICTAL is introduced, based on concurrent medications, according to the regimen outlined in Table 5. If other psychotropic medications are withdrawn following stabilization, the dose of LAMICTAL should be adjusted. For patients discontinuing valproate, the dose of LAMICTAL should be doubled over a 2-week period in equal weekly increments (see Table 6). For patients discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation, the dose of LAMICTAL should remain constant for the first week and then should be decreased by half over a 2-week period in equal weekly decrements (see Table 6). The dose of LAMICTAL may then be further adjusted to the target dose (200 mg) as clinically indicated.
If other drugs are subsequently introduced, the dose of LAMICTAL may need to be adjusted. In particular, the introduction of valproate requires reduction in the dose of LAMICTAL [see Drug Interactions (7), Clinical Pharmacology (12.3)].

To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations of LAMICTAL should not be exceeded [see Boxed Warning].

Table 5. Escalation Regimen for LAMICTAL in Patients With Bipolar Disorder

<table>
<thead>
<tr>
<th>In Patients TAKING Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>In Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone&lt;sup&gt;b&lt;/sup&gt;, or Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone&lt;sup&gt;b&lt;/sup&gt; and NOT TAKING Valproate&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks 1 and 2 25 mg every other day</td>
<td>25 mg daily</td>
<td>50 mg daily</td>
</tr>
<tr>
<td>Weeks 3 and 4 25 mg daily</td>
<td>50 mg daily</td>
<td>100 mg daily, in divided doses</td>
</tr>
<tr>
<td>Week 5  50 mg daily</td>
<td>100 mg daily</td>
<td>200 mg daily, in divided doses</td>
</tr>
<tr>
<td>Week 6 100 mg daily</td>
<td>200 mg daily</td>
<td>300 mg daily, in divided doses</td>
</tr>
<tr>
<td>Week 7 100 mg daily</td>
<td>200 mg daily</td>
<td>up to 400 mg daily, in divided doses</td>
</tr>
</tbody>
</table>

<sup>a</sup> Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see Drug Interactions (7), Clinical Pharmacology (12.3)].

<sup>b</sup> Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations [see Dosage and Administration (2.1)]. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance [see Dosage and Administration (2.1), Drug Interactions (7), and Clinical Pharmacology (12.3)].
Table 6. Dosage Adjustments to LAMICTAL in Patients With Bipolar Disorder Following Discontinuation of Psychotropic Medications

<table>
<thead>
<tr>
<th>Discontinuation of Psychotropic Drugs (excluding Valproate, Carbamazepine, Phenytoin, Phenobarbital, or Primidone)</th>
<th>After Discontinuation of Valproate</th>
<th>After Discontinuation of Carbamazepine, Phenytoin, Phenobarbital, or Primidone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current dose of LAMICTAL (mg/day)</td>
<td>Current dose of LAMICTAL (mg/day)</td>
<td></td>
</tr>
<tr>
<td>Week 1 Maintain current dose of LAMICTAL</td>
<td>150</td>
<td>400</td>
</tr>
<tr>
<td>Week 2 Maintain current dose of LAMICTAL</td>
<td>200</td>
<td>300</td>
</tr>
<tr>
<td>Week 3 onward Maintain current dose of LAMICTAL</td>
<td>200</td>
<td>200</td>
</tr>
</tbody>
</table>

a Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see Drug Interactions (7), Clinical Pharmacology (12.3)].

b Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations [see Dosage and Administration (2.1)]. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used with antiepileptic drugs that induce glucuronidation and increase clearance [see Dosage and Administration (2.1), Drug Interactions (7), and Clinical Pharmacology (12.3)].

The benefit of continuing treatment in patients who had been stabilized in an 8- to 16-week open-label phase with LAMICTAL was established in 2 randomized, placebo-controlled clinical maintenance trials [see Clinical Studies (14.2)]. However, the optimal duration of treatment with LAMICTAL has not been established. Thus, patients should be periodically reassessed to determine the need for maintenance treatment.

2.5 Administration of LAMICTAL Chewable Dispersible Tablets

LAMICTAL Chewable Dispersible Tablets may be swallowed whole, chewed, or dispersed in water or diluted fruit juice. If the tablets are chewed, consume a small amount of water or diluted fruit juice to aid in swallowing.

To disperse LAMICTAL Chewable Dispersible Tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medication). Approximately 1 minute later, when the tablets are completely dispersed, swirl the solution and consume the entire quantity immediately. No attempt should be made to administer partial quantities of the dispersed tablets.
2.6 Administration of LAMICTAL ODT Orally Disintegrating Tablets

LAMICTAL ODT Orally Disintegrating Tablets should be placed onto the tongue and moved around in the mouth. The tablet will disintegrate rapidly, can be swallowed with or without water, and can be taken with or without food.

3 DOSAGE FORMS AND STRENGTHS

3.1 Tablets
25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25.”
100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100.”
150 mg, cream, scored, shield-shaped tablets debossed with “LAMICTAL” and “150.”
200 mg, blue, scored, shield-shaped tablets debossed with “LAMICTAL” and “200.”

3.2 Chewable Dispersible Tablets
2 mg, white to off-white, round tablets debossed with “LTG” over “2.”
5 mg, white to off-white, caplet-shaped tablets debossed with “GX CL2.”
25 mg, white, super elliptical-shaped tablets debossed with “GX CL5.”

3.3 Orally Disintegrating Tablets
25 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “25” on the other side.
50 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “50” on the other side.
100 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LAMICTAL” on one side and “100” on the other side.
200 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LAMICTAL” on one side and “200” on the other side.

3.4 Potential Medication Errors
Patients should be strongly advised to visually inspect their tablets to verify that they are receiving LAMICTAL, as opposed to other medications, and that they are receiving the correct formulation of lamotrigine each time they fill their prescription. Depictions of the LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets can be found in the Medication Guide.

4 CONTRAINDICATIONS

LAMICTAL is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see Boxed Warning, Warnings and Precautions (5.1, 5.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Serious Skin Rashes [see Boxed Warning]
Pediatric Population: The incidence of serious rash associated with hospitalization and discontinuation of LAMICTAL in a prospectively followed cohort of pediatric patients (aged 2
to 16 years) with epilepsy receiving adjunctive therapy was approximately 0.8% (16 of 1,983).

When 14 of these cases were reviewed by 3 expert dermatologists, there was considerable
disagreement as to their proper classification. To illustrate, one dermatologist considered none of
the cases to be Stevens-Johnson syndrome; another assigned 7 of the 14 to this diagnosis. There
was 1 rash-related death in this 1,983-patient cohort. Additionally, there have been rare cases of
toxic epidermal necrolysis with and without permanent sequelae and/or death in US and foreign
postmarketing experience.

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk
of serious, potentially life-threatening rash in pediatric patients. In pediatric patients who used
valproate concomitantly, 1.2% (6 of 482) experienced a serious rash compared with 0.6% (6 of
952) patients not taking valproate.

**Adult Population:** Serious rash associated with hospitalization and discontinuation of
LAMICTAL occurred in 0.3% (11 of 3,348) of adult patients who received LAMICTAL in
premarketing clinical trials of epilepsy. In the bipolar and other mood disorders clinical trials, the
rate of serious rash was 0.08% (1 of 1,233) of adult patients who received LAMICTAL as initial
monotherapy and 0.13% (2 of 1,538) of adult patients who received LAMICTAL as adjunctive
therapy. No fatalities occurred among these individuals. However, in worldwide postmarketing
experience, rare cases of rash-related death have been reported, but their numbers are too few to
permit a precise estimate of the rate.

Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic
epidermal necrolysis, angioedema, and those associated with multiorgan hypersensitivity [see
Warnings and Precautions (5.2)].

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk
of serious, potentially life-threatening rash in adults. Specifically, of 584 patients administered
LAMICTAL with valproate in epilepsy clinical trials, 6 (1%) were hospitalized in association
with rash; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers administered
LAMICTAL in the absence of valproate were hospitalized.

**Patients With History of Allergy or Rash to Other Antiepileptic Drugs:** The risk of
nonserious rash may be increased when the recommended initial dose and/or the rate of dose
escalation for LAMICTAL is exceeded and in patients with a history of allergy or rash to other
AEDs.

### 5.2 Multiorgan Hypersensitivity Reactions and Organ Failure

Multiorgan hypersensitivity reactions, also known as drug reaction with eosinophilia and
systemic symptoms (DRESS), have occurred with lamotrigine. Some have been fatal or life
threatening. DRESS typically, although not exclusively, presents with fever, rash, and/or
lymphadenopathy in association with other organ system involvement, such as hepatitis,
nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute
viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other
organ systems not noted here may be involved.
Fatalities associated with acute multiorgan failure and various degrees of hepatic failure have been reported in 2 of 3,796 adult patients and 4 of 2,435 pediatric patients who received lamotrigine in epilepsy clinical trials. Rare fatalities from multiorgan failure have also been reported in postmarketing use.

Isolated liver failure without rash or involvement of other organs has also been reported with lamotrigine.

It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. LAMICTAL should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

5.3 Blood Dyscrasias

There have been reports of blood dyscrasias that may or may not be associated with multiorgan hypersensitivity (also known as DRESS) [see Warnings and Precautions (5.2)]. These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.

5.4 Suicidal Behavior and Ideation

AEDs, including LAMICTAL, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated. There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanism of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 7 shows absolute and relative risk by indication for all evaluated AEDs.

**Table 7. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Placebo Patients With Events per 1,000 Patients</th>
<th>Drug Patients With Events per 1,000 Patients</th>
<th>Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th>Risk Difference: Additional Drug Patients With Events per 1,000 Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy</td>
<td>1.0</td>
<td>3.4</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>5.7</td>
<td>8.5</td>
<td>1.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
<td>1.8</td>
<td>1.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Total</td>
<td>2.4</td>
<td>4.3</td>
<td>1.8</td>
<td>1.9</td>
</tr>
</tbody>
</table>

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing LAMICTAL or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, the emergence of suicidal thoughts or suicidal behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

### 5.5 Use in Patients With Bipolar Disorder

**Acute Treatment of Mood Episodes:** Safety and effectiveness of LAMICTAL in the acute treatment of mood episodes have not been established.

**Children and Adolescents (younger than 18 years):** Safety and effectiveness of LAMICTAL in patients younger than 18 years with mood disorders have not been established.

[see Warnings and Precautions (5.4)].
Clinical Worsening and Suicide Risk Associated With Bipolar Disorder: Patients with bipolar disorder may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviors (suicidality) whether or not they are taking medications for bipolar disorder. Patients should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment or at the time of dose changes.

In addition, patients with a history of suicidal behavior or thoughts, those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, and young adults are at an increased risk of suicidal thoughts or suicide attempts and should receive careful monitoring during treatment [see Warnings and Precautions (5.4)].

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behavior, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.

Prescriptions for LAMICTAL should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. Overdoses have been reported for LAMICTAL, some of which have been fatal [see Overdosage (10.1)].

5.6 Aseptic Meningitis

Therapy with lamotrigine increases the risk of developing aseptic meningitis. Because of the potential for serious outcomes of untreated meningitis due to other causes, patients should also be evaluated for other causes of meningitis and treated as appropriate.

Postmarketing cases of aseptic meningitis have been reported in pediatric and adult patients taking lamotrigine for various indications. Symptoms upon presentation have included headache, fever, nausea, vomiting, and nuchal rigidity. Rash, photophobia, myalgia, chills, altered consciousness, and somnolence were also noted in some cases. Symptoms have been reported to occur within 1 day to one and a half months following the initiation of treatment. In most cases, symptoms were reported to resolve after discontinuation of lamotrigine. Re-exposure resulted in a rapid return of symptoms (from within 30 minutes to 1 day following re-initiation of treatment) that were frequently more severe. Some of the patients treated with lamotrigine who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus or other autoimmune diseases.

Cerebrospinal fluid (CSF) analyzed at the time of clinical presentation in reported cases was characterized by a mild to moderate pleocytosis, normal glucose levels, and mild to moderate increase in protein. CSF white blood cell count differentials showed a predominance of neutrophils in a majority of the cases, although a predominance of lymphocytes was reported in approximately one third of the cases. Some patients also had new onset of signs and symptoms of involvement of other organs (predominantly hepatic and renal involvement), which may...
suggest that in these cases the aseptic meningitis observed was part of a hypersensitivity reaction
[see Warnings and Precautions (5.2)].

5.7 Potential Medication Errors

Medication errors involving LAMICTAL have occurred. In particular, the names LAMICTAL or lamotrigine can be confused with the names of other commonly used medications. Medication errors may also occur between the different formulations of LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL clearly. Depictions of the LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets can be found in the Medication Guide that accompanies the product to highlight the distinctive markings, colors, and shapes that serve to identify the different presentations of the drug and thus may help reduce the risk of medication errors. To avoid the medication error of using the wrong drug or formulation, patients should be strongly advised to visually inspect their tablets to verify that they are LAMICTAL, as well as the correct formulation of LAMICTAL, each time they fill their prescription.

5.8 Concomitant Use With Oral Contraceptives

Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see Clinical Pharmacology (12.3)]. Dosage adjustments will be necessary in most patients who start or stop estrogen-containing oral contraceptives while taking LAMICTAL [see Dosage and Administration (2.1)]. During the week of inactive hormone preparation (pill-free week) of oral contraceptive therapy, plasma lamotrigine levels are expected to rise, as much as doubling at the end of the week. Adverse reactions consistent with elevated levels of lamotrigine, such as dizziness, ataxia, and diplopia, could occur.

5.9 Withdrawal Seizures

As with other AEDs, LAMICTAL should not be abruptly discontinued. In patients with epilepsy there is a possibility of increasing seizure frequency. In clinical trials in patients with bipolar disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL; however, there were confounding factors that may have contributed to the occurrence of seizures in these patients with bipolar disorder. Unless safety concerns require a more rapid withdrawal, the dose of LAMICTAL should be tapered over a period of at least 2 weeks (approximately 50% reduction per week) [see Dosage and Administration (2.1)].

5.10 Status Epilepticus

Valid estimates of the incidence of treatment-emergent status epilepticus among patients treated with LAMICTAL are difficult to obtain because reporters participating in clinical trials did not all employ identical rules for identifying cases. At a minimum, 7 of 2,343 adult patients had episodes that could unequivocally be described as status epilepticus. In addition, a number of reports of variably defined episodes of seizure exacerbation (e.g., seizure clusters, seizure flurries) were made.

5.11 Sudden Unexplained Death in Epilepsy (SUDEP)

Reference ID: 3677876
557 During the premarketing development of LAMICTAL, 20 sudden and unexplained
558 deaths were recorded among a cohort of 4,700 patients with epilepsy (5,747 patient-years of
559 exposure).
560 Some of these could represent seizure-related deaths in which the seizure was not
561 observed, e.g., at night. This represents an incidence of 0.0035 deaths per patient-year. Although
562 this rate exceeds that expected in a healthy population matched for age and sex, it is within the
563 range of estimates for the incidence of sudden unexplained death in epilepsy (SUDEP) in
564 patients not receiving LAMICTAL (ranging from 0.0005 for the general population of patients
565 with epilepsy, to 0.004 for a recently studied clinical trial population similar to that in the clinical
566 development program for LAMICTAL, to 0.005 for patients with refractory epilepsy).
567 Consequently, whether these figures are reassuring or suggest concern depends on the
568 comparability of the populations reported upon with the cohort receiving LAMICTAL and the
569 accuracy of the estimates provided. Probably most reassuring is the similarity of estimated
570 SUDEP rates in patients receiving LAMICTAL and those receiving other AEDs, chemically
571 unrelated to each other, that underwent clinical testing in similar populations. Importantly, that
572 drug is chemically unrelated to LAMICTAL. This evidence suggests, although it certainly does
573 not prove, that the high SUDEP rates reflect population rates, not a drug effect.
574
575 5.12 Addition of LAMICTAL to a Multidrug Regimen That Includes Valproate
576 Because valproate reduces the clearance of lamotrigine, the dosage of lamotrigine in the
577 presence of valproate is less than half of that required in its absence [see Dosage and
578 Administration (2.2, 2.3, 2.4), Drug Interactions (7)].
579
580 5.13 Binding in the Eye and Other Melanin-Containing Tissues
581 Because lamotrigine binds to melanin, it could accumulate in melanin-rich tissues over
582 time. This raises the possibility that lamotrigine may cause toxicity in these tissues after
583 extended use. Although ophthalmological testing was performed in 1 controlled clinical trial, the
584 testing was inadequate to exclude subtle effects or injury occurring after long-term exposure.
585 Moreover, the capacity of available tests to detect potentially adverse consequences, if any, of
586 lamotrigine’s binding to melanin is unknown [see Clinical Pharmacology (12.2)].
587 Accordingly, although there are no specific recommendations for periodic
588 ophthalmological monitoring, prescribers should be aware of the possibility of long-term
589 ophthalmologic effects.
590
591 5.14 Laboratory Tests
592 The value of monitoring plasma concentrations of lamotrigine in patients treated with
593 LAMICTAL has not been established. Because of the possible pharmacokinetic interactions
594 between lamotrigine and other drugs, including AEDs (see Table 15), monitoring of the plasma
595 levels of lamotrigine and concomitant drugs may be indicated, particularly during dosage
596 adjustments. In general, clinical judgment should be exercised regarding monitoring of plasma
597 levels of lamotrigine and other drugs and whether or not dosage adjustments are necessary.
6 ADVERSE REACTIONS

The following adverse reactions are described in more detail in the Warnings and Precautions section of the label:

- Serious skin rashes [see Warnings and Precautions (5.1)]
- Multiorgan hypersensitivity reactions and organ failure [see Warnings and Precautions (5.2)]
- Blood dyscrasias [see Warnings and Precautions (5.3)]
- Suicidal behavior and ideation [see Warnings and Precautions (5.4)]
- Aseptic meningitis [see Warnings and Precautions (5.6)]
- Withdrawal seizures [see Warnings and Precautions (5.9)]
- Status epilepticus [see Warnings and Precautions (5.10)]
- Sudden unexplained death in epilepsy [see Warnings and Precautions (5.11)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

LAMICTAL has been evaluated for safety in patients with epilepsy and in patients with bipolar I disorder. Adverse reactions reported for each of these patient populations are provided below. Excluded are adverse reactions considered too general to be informative and those not reasonably attributable to the use of the drug.

**Epilepsy:** Most Common Adverse Reactions in All Clinical Trials: Adjunctive Therapy in Adults With Epilepsy: The most commonly observed (≥5% for LAMICTAL and more common on drug than placebo) adverse reactions seen in association with LAMICTAL during adjunctive therapy in adults and not seen at an equivalent frequency among placebo-treated patients were: dizziness, ataxia, somnolence, headache, diplopia, blurred vision, nausea, vomiting, and rash. Dizziness, diplopia, ataxia, blurred vision, nausea, and vomiting were dose related. Dizziness, diplopia, ataxia, and blurred vision occurred more commonly in patients receiving carbamazepine with LAMICTAL than in patients receiving other AEDs with LAMICTAL. Clinical data suggest a higher incidence of rash, including serious rash, in patients receiving concomitant valproate than in patients not receiving valproate [see Warnings and Precautions (5.1)].

Approximately 11% of the 3,378 adult patients who received LAMICTAL as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were rash (3.0%), dizziness (2.8%), and headache (2.5%).

In a dose-response trial in adults, the rate of discontinuation of LAMICTAL for dizziness, ataxia, diplopia, blurred vision, nausea, and vomiting was dose related.

**Monotherapy in Adults With Epilepsy:** The most commonly observed (≥5% for LAMICTAL and more common on drug than placebo) adverse reactions seen in association with the use of LAMICTAL during the monotherapy phase of the controlled trial in adults not seen at
an equivalent rate in the control group were vomiting, coordination abnormality, dyspepsia,
nausea, dizziness, rhinitis, anxiety, insomnia, infection, pain, weight decrease, chest pain, and
dysmenorrhea. The most commonly observed (≥5% for LAMICTAL and more common on drug
than placebo) adverse reactions associated with the use of LAMICTAL during the conversion to
monotherapy (add-on) period, not seen at an equivalent frequency among low-dose valproate-
treated patients, were dizziness, headache, nausea, asthenia, coordination abnormality, vomiting,
rash, somnolence, diplopia, ataxia, accidental injury, tremor, blurred vision, insomnia,
nystagmus, diarrhea, lymphadenopathy, pruritus, and sinusitis.

Approximately 10% of the 420 adult patients who received LAMICTAL as monotherapy
in premarketing clinical trials discontinued treatment because of an adverse reaction. The
adverse reactions most commonly associated with discontinuation were rash (4.5%), headache
(3.1%), and asthenia (2.4%).

Adjunctive Therapy in Pediatric Patients With Epilepsy: The most commonly
observed (≥5% for LAMICTAL and more common on drug than placebo) adverse reactions seen
in association with the use of LAMICTAL as adjunctive treatment in pediatric patients aged 2 to
16 years and not seen at an equivalent rate in the control group were infection, vomiting, rash,
fever, somnolence, accidental injury, dizziness, diarrhea, abdominal pain, nausea, ataxia, tremor,
asthenia, bronchitis, flu syndrome, and diplopia.

In 339 patients aged 2 to 16 years with partial-onset seizures or generalized seizures of
Lennox-Gastaut syndrome, 4.2% of patients on LAMICTAL and 2.9% of patients on placebo
discontinued due to adverse reactions. The most commonly reported adverse reaction that led to
discontinuation of LAMICTAL was rash.

Approximately 11.5% of the 1,081 pediatric patients aged 2 to 16 years who received
LAMICTAL as adjunctive therapy in premarketing clinical trials discontinued treatment because
of an adverse reaction. The adverse reactions most commonly associated with discontinuation
were rash (4.4%), reaction aggravated (1.7%), and ataxia (0.6%).

Controlled Adjunctive Clinical Trials in Adults With Epilepsy: Table 8 lists
treatment-emergent adverse reactions that occurred in at least 2% of adult patients with epilepsy
treated with LAMICTAL in placebo-controlled trials and were numerically more frequent in the
patients treated with LAMICTAL. In these trials, either LAMICTAL or placebo was added to the
patient’s current AED therapy. Adverse reactions were usually mild to moderate in intensity.
Table 8. Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled Adjunctive Trials in Adult Patients With Epilepsy\textsuperscript{a} (Adverse reactions in at least 2% of patients treated with LAMICTAL and numerically more frequent than in the placebo group.)

<table>
<thead>
<tr>
<th>Body System/Adverse Reaction</th>
<th>Percent of Patients Receiving Adjunctive LAMICTAL (n = 711)</th>
<th>Percent of Patients Receiving Adjunctive Placebo (n = 419)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a whole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>29</td>
<td>19</td>
</tr>
<tr>
<td>Flu syndrome</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Fever</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Neck pain</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Reaction aggravated (seizure exacerbation)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>19</td>
<td>10</td>
</tr>
<tr>
<td>Vomiting</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Constipation</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Anorexia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Nervous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>38</td>
<td>13</td>
</tr>
<tr>
<td>Ataxia</td>
<td>22</td>
<td>6</td>
</tr>
<tr>
<td>Somnolence</td>
<td>14</td>
<td>7</td>
</tr>
<tr>
<td>Incoordination</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Tremor</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Depression</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Anxiety</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Convulsion</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Irritability</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Speech disorder</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Concentration disturbance</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

Reference ID: 3677876
Respiratory
  Rhinitis 14 9
  Pharyngitis 10 9
  Cough increased 8 6

Skin and appendages
  Rash 10 5
  Pruritus 3 2

Special senses
  Diplopia 28 7
  Blurred vision 16 5
  Vision abnormality 3 1

Urogenital
  Female patients only (n = 365) (n = 207)
  Dysmenorrhea 7 6
  Vaginitis 4 1
  Amenorrhea 2 1

Patients in these adjunctive trials were receiving 1 to 3 of the concomitant antiepileptic drugs carbamazepine, phenytoin, phenobarbital, or primidone in addition to LAMICTAL or placebo. Patients may have reported multiple adverse reactions during the trial or at discontinuation; thus, patients may be included in more than 1 category.

In a randomized, parallel trial comparing placebo with 300 and 500 mg/day of LAMICTAL, some of the more common drug-related adverse reactions were dose related (see Table 9).

### Table 9. Dose-Related Adverse Reactions From a Randomized, Placebo-Controlled, Adjunctive Trial in Adults With Epilepsy

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Percent of Patients Experiencing Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n = 73)</td>
</tr>
<tr>
<td>Ataxia</td>
<td>10</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>10</td>
</tr>
<tr>
<td>Diplopia</td>
<td>8</td>
</tr>
<tr>
<td>Dizziness</td>
<td>27</td>
</tr>
<tr>
<td>Nausea</td>
<td>11</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4</td>
</tr>
</tbody>
</table>

<sup>a</sup> Significantly greater than placebo group (P<0.05).
<sup>b</sup> Significantly greater than group receiving LAMICTAL 300 mg (P<0.05).
The overall adverse reaction profile for LAMICTAL was similar between females and males and was independent of age. Because the largest non-Caucasian racial subgroup was only 6% of patients exposed to LAMICTAL in placebo-controlled trials, there are insufficient data to support a statement regarding the distribution of adverse reaction reports by race. Generally, females receiving either LAMICTAL as adjunctive therapy or placebo were more likely to report adverse reactions than males. The only adverse reaction for which the reports on LAMICTAL were greater than 10% more frequent in females than males (without a corresponding difference by gender on placebo) was dizziness (difference = 16.5%). There was little difference between females and males in the rates of discontinuation of LAMICTAL for individual adverse reactions.

**Controlled Monotherapy Trial in Adults With Partial-Onset Seizures:** Table 10 lists treatment-emergent adverse reactions that occurred in at least 5% of patients with epilepsy treated with monotherapy with LAMICTAL in a double-blind trial following discontinuation of either concomitant carbamazepine or phenytoin not seen at an equivalent frequency in the control group.

### Table 10. Treatment-Emergent Adverse Reaction Incidence in a Controlled Monotherapy Trial in Adult Patients With Partial-Onset Seizures\(^a\) (Adverse reactions in at least 5% of patients treated with LAMICTAL and numerically more frequent than in the valproate group.)

<table>
<thead>
<tr>
<th>Body System/ Adverse Reaction</th>
<th>Percent of Patients Receiving LAMICTAL(^b) as Monotherapy (n = 43)</th>
<th>Percent of Patients Receiving Low-Dose Valproate(^c) Monotherapy (n = 44)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a whole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Infection</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Nausea</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Metabolic and nutritional</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight decrease</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Nervous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coordination abnormality</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Anxiety</td>
<td>5</td>
<td>0</td>
</tr>
</tbody>
</table>
Insomnia | 5 | 2
---|---|---
Respiratory Rhinitis | 7 | 2
Urogenital (female patients only) | (n = 21) | (n = 28)
Dysmenorrhea | 5 | 0

a Patients in this trial were converted to LAMICTAL or valproate monotherapy from
adjunctive therapy with carbamazepine or phenytoin. Patients may have reported multiple
adverse reactions during the trial; thus, patients may be included in more than 1 category.
b Up to 500 mg/day.
c 1,000 mg/day.

Adverse reactions that occurred with a frequency of less than 5% and greater than 2% of
patients receiving LAMICTAL and numerically more frequent than placebo were:

**Body as a Whole:** Asthenia, fever.

**Digestive:** Anorexia, dry mouth, rectal hemorrhage, peptic ulcer.

**Metabolic and Nutritional:** Peripheral edema.

**Nervous System:** Amnesia, ataxia, depression, hypesthesia, libido increase, decreased
reflexes, increased reflexes, nystagmus, irritability, suicidal ideation.

**Respiratory:** Epistaxis, bronchitis, dyspnea.

**Skin and Appendages:** Contact dermatitis, dry skin, sweating.

**Special Senses:** Vision abnormality.

### Table 11. Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled
Adjunctive Trials in Pediatric Patients With Epilepsy (Adverse reactions in at least
2% of patients treated with LAMICTAL and numerically more frequent than in the
placebo group.)

<table>
<thead>
<tr>
<th>Body System/Adverse Reaction</th>
<th>Percent of Patients Receiving LAMICTAL (n = 168)</th>
<th>Percent of Patients Receiving Placebo (n = 171)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a whole Infection</td>
<td>20</td>
<td>17</td>
</tr>
<tr>
<td>Fever</td>
<td>15</td>
<td>14</td>
</tr>
<tr>
<td>Accidental injury</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>Condition</td>
<td>Count</td>
<td>Reference Count</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Asthenia</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Flu syndrome</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Pain</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Facial edema</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>20</td>
<td>16</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Nausea</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Constipation</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Hemic and lymphatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Metabolic and nutritional</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edema</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Nervous system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>17</td>
<td>15</td>
</tr>
<tr>
<td>Dizziness</td>
<td>14</td>
<td>4</td>
</tr>
<tr>
<td>Ataxia</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>Tremor</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Emotional lability</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Gait abnormality</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Thinking abnormality</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Convulsions</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Nervousness</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Vertigo</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>14</td>
<td>11</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Increased cough</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Bronchospasm</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>Eczema</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Pruritus</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>
**Bipolar Disorder:** The most commonly observed (≥5%) treatment-emergent adverse reactions seen in association with the use of LAMICTAL as monotherapy (100 to 400 mg/day) in adult patients (aged 18 years and older) with bipolar disorder in the 2 double-blind, placebo-controlled trials of 18 months’ duration, and numerically more frequent than in placebo-treated patients are included in Table 12. Adverse reactions that occurred in at least 5% of patients and were numerically more frequent during the dose-escalation phase of LAMICTAL in these trials (when patients may have been receiving concomitant medications) compared with the monotherapy phase were: headache (25%), rash (11%), dizziness (10%), diarrhea (8%), dream abnormality (6%), and pruritus (6%).

During the monotherapy phase of the double-blind, placebo-controlled trials of 18 months’ duration, 13% of 227 patients who received LAMICTAL (100 to 400 mg/day), 16% of 190 patients who received placebo, and 23% of 166 patients who received lithium discontinued therapy because of an adverse reaction. The adverse reactions which most commonly led to discontinuation of LAMICTAL were rash (3%) and mania/hypomania/mixed mood adverse reactions (2%). Approximately 16% of 2,401 patients who received LAMICTAL (50 to 500 mg/day) for bipolar disorder in premarketing trials discontinued therapy because of an adverse reaction, most commonly due to rash (5%) and mania/hypomania/mixed mood adverse reactions (2%).

The overall adverse reaction profile for LAMICTAL was similar between females and males, between elderly and nonelderly patients, and among racial groups.

<table>
<thead>
<tr>
<th>Special senses</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diplopia</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Visual abnormality</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Urogenital</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Male and female patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 12. Treatment-Emergent Adverse Reaction Incidence in 2 Placebo-Controlled Trials in Adult Patients With Bipolar I Disorder\textsuperscript{a} (Adverse reactions in at least 5% of patients treated with LAMICTAL as monotherapy and numerically more frequent than in the placebo group.)

<table>
<thead>
<tr>
<th>Body System/Adverse Reaction</th>
<th>Percent of Patients Receiving LAMICTAL (n = 227)</th>
<th>Percent of Patients Receiving Placebo (n = 190)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Fatigue</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>14</td>
<td>11</td>
</tr>
<tr>
<td>Constipation</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td>Somnolence</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Xerostomia (dry mouth)</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Exacerbation of cough</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash (nonserious)\textsuperscript{b}</td>
<td>7</td>
<td>5</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Patients in these trials were converted to LAMICTAL (100 to 400 mg/day) or placebo monotherapy from add-on therapy with other psychotrophic medications. Patients may have reported multiple adverse reactions during the trial; thus, patients may be included in more than 1 category.

\textsuperscript{b} In the overall bipolar and other mood disorders clinical trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received LAMICTAL as adjunctive therapy [see Warnings and Precautions (5.1)].

These adverse reactions were usually mild to moderate in intensity. Other reactions that occurred in 5% or more patients but equally or more frequently in the placebo group included: dizziness, mania, headache, infection, influenza, pain, accidental injury, diarrhea, and dyspepsia.

Adverse reactions that occurred with a frequency of less than 5% and greater than 1% of patients receiving LAMICTAL and numerically more frequent than placebo were:
General: Fever, neck pain.

Cardiovascular: Migraine.

Digestive: Flatulence.

Metabolic and Nutritional: Weight gain, edema.

Musculoskeletal: Arthralgia, myalgia.

Nervous System: Amnesia, depression, agitation, emotional lability, dyspraxia, abnormal thoughts, dream abnormality, hypoesthesia.

Respiratory: Sinusitis.

Urogenital: Urinary frequency.

Adverse Reactions Following Abrupt Discontinuation: In the 2 maintenance trials, there was no increase in the incidence, severity, or type of adverse reactions in patients with bipolar disorder after abruptly terminating therapy with LAMICTAL. In clinical trials in patients with bipolar disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL. However, there were confounding factors that may have contributed to the occurrence of seizures in these patients with bipolar disorder [see Warnings and Precautions (5.9)].

Mania/Hypomania/Mixed Episodes: During the double-blind, placebo-controlled clinical trials in bipolar I disorder in which patients were converted to monotherapy with LAMICTAL (100 to 400 mg/day) from other psychotropic medications and followed for up to 18 months, the rates of manic or hypomanic or mixed mood episodes reported as adverse reactions were 5% for patients treated with LAMICTAL (n = 227), 4% for patients treated with lithium (n = 166), and 7% for patients treated with placebo (n = 190). In all bipolar controlled trials combined, adverse reactions of mania (including hypomania and mixed mood episodes) were reported in 5% of patients treated with LAMICTAL (n = 956), 3% of patients treated with lithium (n = 280), and 4% of patients treated with placebo (n = 803).

6.2 Other Adverse Reactions Observed in All Clinical Trials

LAMICTAL has been administered to 6,694 individuals for whom complete adverse reaction data was captured during all clinical trials, only some of which were placebo controlled. During these trials, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of adverse reactions were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. The frequencies presented represent the proportion of the 6,694 individuals exposed to LAMICTAL who experienced an event of the type cited on at least 1 occasion while receiving LAMICTAL. All reported adverse reactions are included except those already listed in the previous tables or elsewhere in the labeling, those too general to be informative, and those not reasonably associated with the use of the drug.

Adverse reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse reactions are
defined as those occurring in at least 1/100 patients; **infrequent** adverse reactions are those occurring in 1/100 to 1/1,000 patients; **rare** adverse reactions are those occurring in fewer than 1/1,000 patients.

**Body as a Whole:** **Infrequent:** Allergic reaction, chills, malaise.

**Cardiovascular System:** **Infrequent:** Flushing, hot flashes, hypertension, palpitations, postural hypotension, syncope, tachycardia, vasodilation.

**Dermatological:** **Infrequent:** Acne, alopecia, hirsutism, maculopapular rash, skin discoloration, urticaria. **Rare:** Angioedema, erythema, exfoliative dermatitis, fungal dermatitis, herpes zoster, leukoderma, multiforme erythema, petechial rash, pustular rash, Stevens-Johnson syndrome, vesiculobullous rash.

**Digestive System:** **Infrequent:** Dysphagia, eructation, gastritis, gingivitis, increased appetite, increased salivation, liver function tests abnormal, mouth ulceration. **Rare:** Gastrointestinal hemorrhage, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic colitis, hepatitis, melena, stomach ulcer, stomatitis, tongue edema.

**Endocrine System:** **Rare:** Goiter, hypothyroidism.

**Hematologic and Lymphatic System:** **Infrequent:** Ecchymosis, leukopenia. **Rare:** Anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, lymphocytesis, macrocytic anemia, petechia, thrombocytopenia.

**Metabolic and Nutritional Disorders:** **Infrequent:** Aspartate transaminase increased. **Rare:** Alcohol intolerance, alkaline phosphatase increase, alanine transaminase increase, bilirubinemia, general edema, gamma glutamyl transpeptidase increase, hyperglycemia.

**Musculoskeletal System:** **Infrequent:** Arthritis, leg cramps, myasthenia, twitching. **Rare:** Bursitis, muscle atrophy, pathological fracture, tendinous contracture.

**Nervous System:** **Frequent:** Confusion, paresthesia. **Infrequent:** Akathisia, apathy, aphasia, central nervous system depression, depersonalization, dysarthria, dyskinesia, euphoria, hallucinations, hostility, hyperkinesia, hypertonia, libido decreased, memory decrease, mind racing, movement disorder, myoclonus, panic attack, paranoid reaction, personality disorder, psychosis, sleep disorder, stupor, suicidal ideation. **Rare:** Choreaathetosis, delirium, delusions, dysphoria, dystonia, extrapyramidal syndrome, faintness, grand mal convulsions, hemiplegia, hyperalgesia, hyperesthesia, hypokinesia, hypotonia, manic depression reaction, muscle spasm, neuralgia, neurosis, paralysis, peripheral neuritis.

**Respiratory System:** **Infrequent:** Yawn. **Rare:** Hiccups, hyperventilation.

**Special Senses:** **Frequent:** Amblyopia. **Infrequent:** Abnormality of accommodation, conjunctivitis, dry eyes, ear pain, photophobia, taste perversion, tinnitus. **Rare:** Deafness, lacrimation disorder, oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, visual field defect.

**Urogenital System:** **Infrequent:** Abnormal ejaculation, hematuria, impotence, menorrhagia, polyuria, urinary incontinence. **Rare:** Acute kidney failure, anorgasmia, breast
abscess, breast neoplasm, creatinine increase, cystitis, dysuria, epididymitis, female lactation,
kidney failure, kidney pain, nocturia, urinary retention, urinary urgency.

6.3 Postmarketing Experience

The following adverse events (not listed above in clinical trials or other sections of the
prescribing information) have been identified during postapproval use of LAMICTAL. Because
these events are reported voluntarily from a population of uncertain size, it is not always possible
to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic: Agranulocytosis, hemolytic anemia, lymphadenopathy not
associated with hypersensitivity disorder.

Gastrointestinal: Esophagitis.

Hepatobiliary Tract and Pancreas: Pancreatitis.

Immunologic: Lupus-like reaction, vasculitis.

Lower Respiratory: Apnea.

Musculoskeletal: Rhabdomyolysis has been observed in patients experiencing
hypersensitivity reactions.

Neurology: Exacerbation of Parkinsonian symptoms in patients with pre-existing
Parkinson’s disease, tics.

Non-site Specific: Progressive immunosuppression.

7 DRUG INTERACTIONS

Significant drug interactions with lamotrigine are summarized in Table 13. Additional
details of these drug interaction studies are provided in the Clinical Pharmacology section [see
Clinical Pharmacology (12.3)].

Table 13. Established and Other Potentially Significant Drug Interactions

<table>
<thead>
<tr>
<th>Concomitant Drug</th>
<th>Effect on Concentration of Lamotrigine or Concomitant Drug</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentrations approximately 50%. Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td>Carbamazepine and carbamazepine epoxide</td>
<td>↓ lamotrigine</td>
<td>Addition of carbamazepine decreases lamotrigine concentration approximately 40%. May increase carbamazepine epoxide levels.</td>
</tr>
<tr>
<td>? levonorgestrel</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reference ID: 3677876
### USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

**Teratogenic Effects:** Pregnancy Category C. No evidence of teratogenicity was found in mice, rats, or rabbits when lamotrigine was orally administered to pregnant animals during the period of organogenesis at doses up to 1.2, 0.5, and 1.1 times, respectively, on a mg/m² basis, the highest usual human maintenance dose (i.e., 500 mg/day). However, maternal toxicity and secondary fetal toxicity producing reduced fetal weight and/or delayed ossification were seen in mice and rats, but not in rabbits at these doses. Teratology studies were also conducted using bolus intravenous administration of the isethionate salt of lamotrigine in rats and rabbits. In rat dams administered an intravenous dose at 0.6 times the highest usual human maintenance dose, the incidence of intrauterine death without signs of teratogenicity was increased.

A behavioral teratology study was conducted in rats dosed during the period of organogenesis. At day 21 postpartum, offspring of dams receiving 5 mg/kg/day or higher displayed a significantly longer latent period for open field exploration and a lower frequency of rearing. In a swimming maze test performed on days 39 to 44 postpartum, time to completion

---

<table>
<thead>
<tr>
<th>Drug Combination</th>
<th>Effect on Lamotrigine</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/ritonavir</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentration approximately 50%.</td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine AUC approximately 32%.</td>
</tr>
<tr>
<td>Phenobarbital/primidone</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr>
<td>Rifampin</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine AUC approximately 40%.</td>
</tr>
</tbody>
</table>
| Valproate                 | ↑ lamotrigine          | Increased lamotrigine concentrations slightly more than 2-fold.
|                           | ? valproate            | There are conflicting study results regarding effect of lamotrigine on valproate concentrations: 1) a mean 25% decrease in valproate concentrations in healthy volunteers, 2) no change in valproate concentrations in controlled clinical trials in patients with epilepsy. |
was increased in offspring of dams receiving 25 mg/kg/day. These doses represent 0.1 and 0.5
times the clinical dose on a mg/m² basis, respectively.

Lamotrigine did not affect fertility, teratogenesis, or postnatal development when rats
were dosed prior to and during mating, and throughout gestation and lactation at doses
equivalent to 0.4 times the highest usual human maintenance dose on a mg/m² basis.

When pregnant rats were orally dosed at 0.1, 0.14, or 0.3 times the highest human
maintenance dose (on a mg/m² basis) during the latter part of gestation (days 15 to 20), maternal
toxicity and fetal death were seen. In dams, food consumption and weight gain were reduced,
and the gestation period was slightly prolonged (22.6 vs. 22.0 days in the control group).
Stillborn pups were found in all 3 drug-treated groups, with the highest number in the high-dose
group. Postnatal death was also seen, but only in the 2 highest doses, and occurred between days
1 and 20. Some of these deaths appear to be drug related and not secondary to the maternal
toxicity. A no-observed-effect level (NOEL) could not be determined for this study.

Although lamotrigine was not found to be teratogenic in the above studies, lamotrigine
decreases fetal folate concentrations in rats, an effect known to be associated with teratogenesis
in animals and humans. There are no adequate and well-controlled trials in pregnant women.
Because animal reproduction studies are not always predictive of human response, this drug
should be used during pregnancy only if the potential benefit justifies the potential risk to the
fetus.

**Nonteratogenic Effects:** As with other AEDs, physiological changes during pregnancy
may affect lamotrigine concentrations and/or therapeutic effect. There have been reports of
decreased lamotrigine concentrations during pregnancy and restoration of pre-partum
concentrations after delivery. Dosage adjustments may be necessary to maintain clinical
response.

**Pregnancy Registry:** To provide information regarding the effects of in utero exposure
to LAMICTAL, physicians are advised to recommend that pregnant patients taking LAMICTAL
enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be
done by calling the toll-free number 1-888-233-2334 and must be done by patients themselves.
Information on the registry can also be found at the website

### 8.2 Labor and Delivery

The effect of LAMICTAL on labor and delivery in humans is unknown.

### 8.3 Nursing Mothers

Lamotrigine is present in milk from lactating women taking LAMICTAL. Data from
multiple small studies indicate that lamotrigine plasma levels in human milk-fed infants have
been reported to be as high as 50% of the maternal serum levels. Neonates and young infants are
at risk for high serum levels because maternal serum and milk levels can rise to high levels
postpartum if lamotrigine dosage has been increased during pregnancy but not later reduced to
the pre-pregnancy dosage. Lamotrigine exposure is further increased due to the immaturity of the
infant glucuronidation capacity needed for drug clearance. Events including apnea, drowsiness, and poor sucking have been reported in infants who have been human milk-fed by mothers using lamotrigine; whether or not these events were caused by lamotrigine is unknown. Human milk-fed infants should be closely monitored for adverse events resulting from lamotrigine. Measurement of infant serum levels should be performed to rule out toxicity if concerns arise. Human milk-feeding should be discontinued in infants with lamotrigine toxicity. Caution should be exercised when LAMICTAL is administered to a nursing woman.

8.4 Pediatric Use

LAMICTAL is indicated for adjunctive therapy in patients aged 2 years and older for partial-onset seizures, the generalized seizures of Lennox-Gastaut syndrome, and PGTC seizures.

Safety and efficacy of LAMICTAL used as adjunctive treatment for partial-onset seizures were not demonstrated in a small, randomized, double-blind, placebo-controlled withdrawal trial in very young pediatric patients (aged 1 to 24 months). LAMICTAL was associated with an increased risk for infectious adverse reactions (LAMICTAL 37%, placebo 5%), and respiratory adverse reactions (LAMICTAL 26%, placebo 5%). Infectious adverse reactions included bronchiolitis, bronchitis, ear infection, eye infection, otitis externa, pharyngitis, urinary tract infection, and viral infection. Respiratory adverse reactions included nasal congestion, cough, and apnea.

Safety and effectiveness in patients younger than 18 years with bipolar disorder have not been established.

8.5 Geriatric Use

Clinical trials of LAMICTAL for epilepsy and bipolar disorder did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients or exhibit a different safety profile than that of younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

8.6 Patients With Hepatic Impairment

Experience in patients with hepatic impairment is limited. Based on a clinical pharmacology study in 24 subjects with mild, moderate, and severe liver impairment [see Clinical Pharmacology (12.3)], the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without ascites and 50% in patients with severe liver impairment with ascites. Escalation and maintenance doses may be adjusted according to clinical response [see Dosage and Administration (2.1)].

8.7 Patients With Renal Impairment

Lamotrigine is metabolized mainly by glucuronic acid conjugation, with the majority of the metabolites being recovered in the urine. In a small study comparing a single dose of
lamotrigine in subjects with varying degrees of renal impairment with healthy volunteers, the plasma half-life of lamotrigine was approximately twice as long in the subjects with chronic renal failure \?[see Clinical Pharmacology (12.3)].

Initial doses of LAMICTAL should be based on patients’ AED regimens; reduced maintenance doses may be effective for patients with significant renal impairment. Few patients with severe renal impairment have been evaluated during chronic treatment with lamotrigine. Because there is inadequate experience in this population, LAMICTAL should be used with caution in these patients \?[see Dosage and Administration (2.1)].

10 OVERDOSAGE

10.1 Human Overdose Experience

Overdoses involving quantities up to 15 g have been reported for LAMICTAL, some of which have been fatal. Overdose has resulted in ataxia, nystagmus, seizures (including tonic-clonic seizures), decreased level of consciousness, coma, and intraventricular conduction delay.

10.2 Management of Overdose

There are no specific antidotes for lamotrigine. Following a suspected overdose, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, emesis should be induced; usual precautions should be taken to protect the airway. It should be kept in mind that immediate-release lamotrigine is rapidly absorbed \?[see Clinical Pharmacology (12.3)]. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood. In 6 renal failure patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis during a 4-hour session. A Poison Control Center should be contacted for information on the management of overdosage of LAMICTAL.

11 DESCRIPTION

LAMICTAL (lamotrigine), an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine’s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, its molecular formula is C₉H₇N₅Cl₂, and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pKₐ of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is:

\[
\text{Cl} \quad \text{Cl} \\
\text{H₂N} \quad \text{N} \quad \text{N} \\
\text{N} \quad \text{N} \quad \text{NH₂}
\]

LAMICTAL Tablets are supplied for oral administration as 25-mg (white), 100-mg (peach), 150-mg (cream), and 200-mg (blue) tablets. Each tablet contains the labeled amount of
Lamotrigine and the following inactive ingredients: lactose; magnesium stearate; microcrystalline cellulose; povidone; sodium starch glycolate; FD&C Yellow No. 6 Lake (100-mg tablet only); ferric oxide, yellow (150-mg tablet only); and FD&C Blue No. 2 Lake (200-mg tablet only).

LAMICTAL Chewable Dispersible Tablets are supplied for oral administration. The tablets contain 2 mg (white), 5 mg (white), or 25 mg (white) of lamotrigine and the following inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, saccharin sodium, and sodium starch glycolate.

LAMICTAL ODT Orally Disintegrating Tablets are supplied for oral administration. The tablets contain 25 mg (white to off-white), 50 mg (white to off-white), 100 mg (white to off-white), or 200 mg (white to off-white) of lamotrigine and the following inactive ingredients: artificial cherry flavor, crospovidone, ethylcellulose, magnesium stearate, mannitol, polyethylene, and sucralose.

LAMICTAL ODT Orally Disintegrating Tablets are formulated using technologies (Microcaps® and AdvaTab®) designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile. Tablet characteristics including flavor, mouth-feel, after-taste, and ease of use were rated as favorable in a study in 108 healthy volunteers.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known.

One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate).

Although the relevance for human use is unknown, the following data characterize the performance of lamotrigine in receptor binding assays. Lamotrigine had a weak inhibitory effect on the serotonin 5-HT3 receptor (IC₅₀ = 18 µM). It does not exhibit high affinity binding (IC₅₀>100 µM) to the following neurotransmitter receptors: adenosine A₁ and A₂; adrenergic α₁, α₂, and β; dopamine D₁ and D₂; γ-aminobutyric acid (GABA) A and B; histamine H₁; kappa opioid; muscarinic acetylcholine; and serotonin 5-HT₂. Studies have failed to detect an effect of lamotrigine on dihydropyridine-sensitive calcium channels. It had weak effects at sigma opioid
receptors (IC$_{50}$ = 145 µM). Lamotrigine did not inhibit the uptake of norepinephrine, dopamine, or serotonin (IC$_{50}$$>$200 µM) when tested in rat synaptosomes and/or human platelets in vitro.

**Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity:**

Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC$_{50}$ for lamotrigine effects on NMDA-induced currents (in the presence of 3 µM of glycine) in cultured hippocampal neurons exceeded 100 µM.

The mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established.

### 12.2 Pharmacodynamics

**Folate Metabolism:** In vitro, lamotrigine inhibited dihydrofolate reductase, the enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may interfere with the biosynthesis of nucleic acids and proteins. When oral daily doses of lamotrigine were given to pregnant rats during organogenesis, fetal, placental, and maternal folate concentrations were reduced. Significantly reduced concentrations of folate are associated with teratogenesis [see Use in Specific Populations (8.1)]. Folate concentrations were also reduced in male rats given repeated oral doses of lamotrigine. Reduced concentrations were partially returned to normal when supplemented with folinic acid.

**Accumulation in Kidneys:** Lamotrigine accumulated in the kidney of the male rat, causing chronic progressive nephrosis, necrosis, and mineralization. These findings are attributed to α-2 microglobulin, a species- and sex-specific protein that has not been detected in humans or other animal species.

**Melanin Binding:** Lamotrigine binds to melanin-containing tissues, e.g., in the eye and pigmented skin. It has been found in the uveal tract up to 52 weeks after a single dose in rodents.

**Cardiovascular:** In dogs, lamotrigine is extensively metabolized to a 2-N-methyl metabolite. This metabolite causes dose-dependent prolongation of the PR interval, widening of the QRS complex, and, at higher doses, complete AV conduction block. Similar cardiovascular effects are not anticipated in humans because only trace amounts of the 2-N-methyl metabolite (<0.6% of lamotrigine dose) have been found in human urine [see Clinical Pharmacology (12.3)]. However, it is conceivable that plasma concentrations of this metabolite could be increased in patients with a reduced capacity to glucuronidate lamotrigine (e.g., in patients with liver disease, patients taking concomitant medications that inhibit glucuronidation).

### 12.3 Pharmacokinetics

The pharmacokinetics of lamotrigine have been studied in subjects with epilepsy, healthy young and elderly volunteers, and volunteers with chronic renal failure. Lamotrigine pharmacokinetic parameters for adult and pediatric subjects and healthy normal volunteers are summarized in Tables 14 and 16.
Table 14. Mean Pharmacokinetic Parameters\(^a\) in Healthy Volunteers and Adult Subjects With Epilepsy

<table>
<thead>
<tr>
<th>Adult Study Population</th>
<th>Number of Subjects</th>
<th>(T_{\text{max}}): Time of Maximum Plasma Concentration (h)</th>
<th>(t_{1/2}): Elimination Half-life (h)</th>
<th>CL/F: Apparent Plasma Clearance (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy volunteers taking no other medications:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose LAMICTAL</td>
<td>179</td>
<td>2.2 (0.25-12.0)</td>
<td>32.8 (14.0-103.0)</td>
<td>0.44 (0.12-1.10)</td>
</tr>
<tr>
<td>Multiple-dose LAMICTAL</td>
<td>36</td>
<td>1.7 (0.5-4.0)</td>
<td>25.4 (11.6-61.6)</td>
<td>0.58 (0.24-1.15)</td>
</tr>
<tr>
<td>Healthy volunteers taking valproate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose LAMICTAL</td>
<td>6</td>
<td>1.8 (1.0-4.0)</td>
<td>48.3 (31.5-88.6)</td>
<td>0.30 (0.14-0.42)</td>
</tr>
<tr>
<td>Multiple-dose LAMICTAL</td>
<td>18</td>
<td>1.9 (0.5-3.5)</td>
<td>70.3 (41.9-113.5)</td>
<td>0.18 (0.12-0.33)</td>
</tr>
<tr>
<td>Subjects with epilepsy taking valproate only:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose LAMICTAL</td>
<td>4</td>
<td>4.8 (1.8-8.4)</td>
<td>58.8 (30.5-88.8)</td>
<td>0.28 (0.16-0.40)</td>
</tr>
<tr>
<td>Subjects with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone(^b) plus valproate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose LAMICTAL</td>
<td>25</td>
<td>3.8 (1.0-10.0)</td>
<td>27.2 (11.2-51.6)</td>
<td>0.53 (0.27-1.04)</td>
</tr>
<tr>
<td>Subjects with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone: (^b)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose LAMICTAL</td>
<td>24</td>
<td>2.3 (0.5-5.0)</td>
<td>14.4 (6.4-30.4)</td>
<td>1.10 (0.51-2.22)</td>
</tr>
<tr>
<td>Multiple-dose LAMICTAL</td>
<td>17</td>
<td>2.0 (0.75-5.93)</td>
<td>12.6 (7.5-23.1)</td>
<td>1.21 (0.66-1.82)</td>
</tr>
</tbody>
</table>

\(^a\) The majority of parameter means determined in each study had coefficients of variation between 20% and 40% for half-life and CL/F and between 30% and 70% for \(T_{\text{max}}\). The overall
mean values were calculated from individual study means that were weighted based on the
number of volunteers/subjects in each study. The numbers in parentheses below each
parameter mean represent the range of individual volunteer/subject values across studies.

Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the
apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and other drugs,
such as rifampin and protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir, that
induce lamotrigine glucuronidation have also been shown to increase the apparent clearance
of lamotrigine [see Drug Interactions (7)].

Absorption: Lamotrigine is rapidly and completely absorbed after oral administration
with negligible first-pass metabolism (absolute bioavailability is 98%). The bioavailability is not
affected by food. Peak plasma concentrations occur anywhere from 1.4 to 4.8 hours following
drug administration. The lamotrigine chewable/dispersible tablets were found to be equivalent
whether administered as dispersed in water, chewed and swallowed, or swallowed as whole, to
the lamotrigine compressed tablets in terms of rate and extent of absorption. In terms of rate and
extent of absorption, lamotrigine orally disintegrating tablets whether disintegrated in the mouth
or swallowed whole with water were equivalent to the lamotrigine compressed tablets swallowed
with water.

Dose Proportionality: In healthy volunteers not receiving any other medications and
given single doses, the plasma concentrations of lamotrigine increased in direct proportion to the
dose administered over the range of 50 to 400 mg. In 2 small studies (n = 7 and 8) of patients
with epilepsy who were maintained on other AEDs, there also was a linear relationship between
dose and lamotrigine plasma concentrations at steady state following doses of 50 to 350 mg
twice daily.

Distribution: Estimates of the mean apparent volume of distribution (Vd/F) of
lamotrigine following oral administration ranged from 0.9 to 1.3 L/kg. Vd/F is independent of
dose and is similar following single and multiple doses in both patients with epilepsy and in
healthy volunteers.

Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately
55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL
(10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy
trials). Because lamotrigine is not highly bound to plasma proteins, clinically significant
interactions with other drugs through competition for protein binding sites are unlikely. The
binding of lamotrigine to plasma proteins did not change in the presence of therapeutic
concentrations of phenytoin, phenobarbital, or valproate. Lamotrigine did not displace other
AEDs (carbamazepine, phenytoin, phenobarbital) from protein-binding sites.

Metabolism: Lamotrigine is metabolized predominantly by glucuronic acid conjugation;
the major metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of
240 mg of $^{14}$C-lamotrigine (15 µCi) to 6 healthy volunteers, 94% was recovered in the urine and
2% was recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and other unidentified minor metabolites (4%).

**Enzyme Induction:** The effects of lamotrigine on the induction of specific families of mixed-function oxidase isozymes have not been systematically evaluated.

Following multiple administrations (150 mg twice daily) to normal volunteers taking no other medications, lamotrigine induced its own metabolism, resulting in a 25% decrease in $t_\text{1/2}$ and a 37% increase in CL/F at steady state compared with values obtained in the same volunteers following a single dose. Evidence gathered from other sources suggests that self-induction by lamotrigine may not occur when lamotrigine is given as adjunctive therapy in patients receiving enzyme-inducing drugs such as carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7)].

**Elimination:** The elimination half-life and apparent clearance of lamotrigine following oral administration of LAMICTAL to adult subjects with epilepsy and healthy volunteers is summarized in Table 14. Half-life and apparent oral clearance vary depending on concomitant AEDs.

**Drug Interactions:** The apparent clearance of lamotrigine is affected by the coadministration of certain medications [see Warnings and Precautions (5.8, 5.12), Drug Interactions (7)].

The net effects of drug interactions with lamotrigine are summarized in Tables 13 and 15, followed by details of the drug interaction studies below.

### Table 15. Summary of Drug Interactions With Lamotrigine

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug Plasma Concentration With Adjunctive Lamotrigine $a$</th>
<th>Lamotrigine Plasma Concentration With Adjunctive Drugs $b$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral contraceptives (e.g., ethinylestradiol/levonorgestrel)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>$\leftrightarrow$&lt;sup&gt;d&lt;/sup&gt;</td>
<td>$\downarrow$</td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td>$\leftrightarrow$&lt;sup&gt;e&lt;/sup&gt;</td>
<td>$\downarrow$</td>
</tr>
<tr>
<td>Bupropion</td>
<td>Not assessed</td>
<td>$\leftrightarrow$</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>$\leftrightarrow$</td>
<td>$\downarrow$</td>
</tr>
<tr>
<td>Carbamazepine epoxide&lt;sup&gt;f&lt;/sup&gt;</td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>Felbamate</td>
<td>Not assessed</td>
<td>$\leftrightarrow$</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>Not assessed</td>
<td>$\leftrightarrow$</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>$\leftrightarrow$</td>
<td>$\leftrightarrow$</td>
</tr>
<tr>
<td>Lithium</td>
<td>$\leftrightarrow$</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>$\leftrightarrow$&lt;sup&gt;e&lt;/sup&gt;</td>
<td>$\downarrow$</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>$\leftrightarrow$</td>
<td>$\leftrightarrow$&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Drug</td>
<td>Effect</td>
<td>Effect</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>10-Monohydroxy oxcarbazepine</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Phenobarbital/primidone</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Rifampin</td>
<td>Not assessed</td>
<td>↓</td>
</tr>
<tr>
<td>Risperidone</td>
<td>↔</td>
<td>Not assessed</td>
</tr>
<tr>
<td>9-hydroxyrisperidone</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Topiramate</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Valproate</td>
<td>Not assessed</td>
<td>↑</td>
</tr>
<tr>
<td>Valproate + phenytoin and/or</td>
<td>Not assessed</td>
<td>↓</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Zonisamide</td>
<td>Not assessed</td>
<td>↔</td>
</tr>
</tbody>
</table>

1. From adjunctive clinical trials and volunteer trials.
2. Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteer trials.
3. The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.
5. Compared to historical controls.
6. Not administered, but an active metabolite of carbamazepine.
7. Slight decrease, not expected to be clinically relevant.
8. Not administered, but an active metabolite of oxcarbazepine.
9. Not administered, but an active metabolite of risperidone.
10. Slight increase, not expected to be clinically relevant.

**Estrogen-Containing Oral Contraceptives:** In 16 female volunteers, an oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel increased the apparent clearance of lamotrigine (300 mg/day) by approximately 2-fold with mean decreases in AUC of 52% and in Cmax of 39%. In this study, trough serum lamotrigine concentrations gradually increased and were approximately 2-fold higher on average at the end of the week of the inactive hormone preparation compared with trough lamotrigine concentrations at the end of the active hormone cycle.
Gradual transient increases in lamotrigine plasma levels (approximate 2-fold increase) occurred during the week of inactive hormone preparation (pill-free week) for women not also taking a drug that increased the clearance of lamotrigine (carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation) [see Drug Interactions (7)]. The increase in lamotrigine plasma levels will be greater if the dose of LAMICTAL is increased in the few days before or during the pill-free week. Increases in lamotrigine plasma levels could result in dose-dependent adverse reactions.

In the same study, coadministration of lamotrigine (300 mg/day) in 16 female volunteers did not affect the pharmacokinetics of the ethinylestradiol component of the oral contraceptive preparation. There were mean decreases in the AUC and Cmax of the levonorgestrel component of 19% and 12%, respectively. Measurement of serum progesterone indicated that there was no hormonal evidence of ovulation in any of the 16 volunteers, although measurement of serum FSH, LH, and estradiol indicated that there was some loss of suppression of the hypothalamic-pituitary-ovarian axis.

The effects of doses of lamotrigine other than 300 mg/day have not been systematically evaluated in controlled clinical trials.

The clinical significance of the observed hormonal changes on ovulatory activity is unknown. However, the possibility of decreased contraceptive efficacy in some patients cannot be excluded. Therefore, patients should be instructed to promptly report changes in their menstrual pattern (e.g., break-through bleeding).

Dosage adjustments may be necessary for women receiving estrogen-containing oral contraceptive preparations [see Dosage and Administration (2.1)].

**Other Hormonal Contraceptives or Hormone Replacement Therapy:** The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of LAMICTAL in the presence of progestogens alone will likely not be needed.

**Atazanavir/Ritonavir:** In a study in healthy volunteers, daily doses of atazanavir/ritonavir (300 mg/100 mg) reduced the plasma AUC and Cmax of lamotrigine (single 100-mg dose) by an average of 32% and 6%, respectively, and shortened the elimination half-lives by 27%. In the presence of atazanavir/ritonavir (300 mg/100 mg), the metabolite-to-lamotrigine ratio was increased from 0.45 to 0.71 consistent with induction of glucuronidation. The pharmacokinetics of atazanavir/ritonavir were similar in the presence of concomitant lamotrigine to the historical data of the pharmacokinetics in the absence of lamotrigine.

**Bupropion:** The pharmacokinetics of a 100-mg single dose of lamotrigine in healthy volunteers (n = 12) were not changed by coadministration of bupropion sustained-release formulation (150 mg twice daily) starting 11 days before lamotrigine.
Carbamazepine: Lamotrigine has no appreciable effect on steady-state carbamazepine plasma concentration. Limited clinical data suggest there is a higher incidence of dizziness, diplopia, ataxia, and blurred vision in patients receiving carbamazepine with lamotrigine than in patients receiving other AEDs with lamotrigine [see Adverse Reactions (6.1)]. The mechanism of this interaction is unclear. The effect of lamotrigine on plasma concentrations of carbamazepine-epoxide is unclear. In a small subset of patients (n = 7) studied in a placebo-controlled trial, lamotrigine had no effect on carbamazepine-epoxide plasma concentrations, but in a small, uncontrolled study (n = 9), carbamazepine-epoxide levels increased. The addition of carbamazepine decreases lamotrigine steady-state concentrations by approximately 40%.

Felbamate: In a trial in 21 healthy volunteers, coadministration of felbamate (1,200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.

Folate Inhibitors: Lamotrigine is a weak inhibitor of dihydrofolate reductase. Prescribers should be aware of this action when prescribing other medications that inhibit folate metabolism.

Gabapentin: Based on a retrospective analysis of plasma levels in 34 subjects who received lamotrigine both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine.

Levetiracetam: Potential drug interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents during placebo-controlled clinical trials. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.

Lithium: The pharmacokinetics of lithium were not altered in healthy subjects (n = 20) by coadministration of lamotrigine (100 mg/day) for 6 days.

Lopinavir/Ritonavir: The addition of lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily) decreased the AUC, C\text{max}, and elimination half-life of lamotrigine by approximately 50% to 55.4% in 18 healthy subjects. The pharmacokinetics of lopinavir/ritonavir were similar with concomitant lamotrigine, compared to that in historical controls.

Olanzapine: The AUC and C\text{max} of olanzapine were similar following the addition of olanzapine (15 mg once daily) to lamotrigine (200 mg once daily) in healthy male volunteers (n = 16) compared with the AUC and C\text{max} in healthy male volunteers receiving olanzapine alone (n = 16). In the same trial, the AUC and C\text{max} of lamotrigine were reduced on average by 24% and 20%, respectively, following the addition of olanzapine to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. This reduction in lamotrigine plasma concentrations is not expected to be clinically relevant.

Oxcarbazepine: The AUC and C\text{max} of oxcarbazepine and its active 10-monohydroxy oxcarbazepine metabolite were not significantly different following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine (200 mg once daily) in healthy male volunteers.
volunteers (n = 13) compared with healthy male volunteers receiving oxcarbazepine alone (n = 13).

In the same trial, the AUC and C_max of lamotrigine were similar following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. Limited clinical data suggest a higher incidence of headache, dizziness, nausea, and somnolence with coadministration of lamotrigine and oxcarbazepine compared with lamotrigine alone or oxcarbazepine alone.

**Phenobarbital, Primidone:** The addition of phenobarbital or primidone decreases lamotrigine steady-state concentrations by approximately 40%.

**Phenytoin:** Lamotrigine has no appreciable effect on steady-state phenytoin plasma concentrations in patients with epilepsy. The addition of phenytoin decreases lamotrigine steady-state concentrations by approximately 40%.

**Pregabalin:** Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg 3 times daily) administration. There are no pharmacokinetic interactions between lamotrigine and pregabalin.

**Rifampin:** In 10 male volunteers, rifampin (600 mg/day for 5 days) significantly increased the apparent clearance of a single 25-mg dose of lamotrigine by approximately 2-fold (AUC decreased by approximately 40%).

**Risperidone:** In a 14 healthy volunteers study, multiple oral doses of lamotrigine 400 mg daily had no clinically significant effect on the single-dose pharmacokinetics of risperidone 2 mg and its active metabolite 9-OH risperidone. Following the coadministration of risperidone 2 mg with lamotrigine, 12 of the 14 volunteers reported somnolence compared with 1 out of 20 when risperidone was given alone, and none when lamotrigine was administered alone.

**Topiramate:** Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of lamotrigine resulted in a 15% increase in topiramate concentrations.

**Valproate:** When lamotrigine was administered to healthy volunteers (n = 18) receiving valproate, the trough steady-state valproate plasma concentrations decreased by an average of 25% over a 3-week period, and then stabilized. However, adding lamotrigine to the existing therapy did not cause a change in valproate plasma concentrations in either adult or pediatric patients in controlled clinical trials.

The addition of valproate increased lamotrigine steady-state concentrations in normal volunteers by slightly more than 2-fold. In 1 trial, maximal inhibition of lamotrigine clearance was reached at valproate doses between 250 and 500 mg/day and did not increase as the valproate dose was further increased.

**Zonisamide:** In a study in 18 patients with epilepsy, coadministration of zonisamide (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day for 35 days) had no significant effect on the pharmacokinetics of lamotrigine.

**Known Inducers or Inhibitors of Glucuronidation:** Drugs other than those listed above have not been systematically evaluated in combination with lamotrigine. Since lamotrigine is
metabolized predominately by glucuronic acid conjugation, drugs that are known to induce or
inhibit glucuronidation may affect the apparent clearance of lamotrigine and doses of lamotrigine
may require adjustment based on clinical response.

**Other:** Results of in vitro experiments suggest that clearance of lamotrigine is unlikely to
be reduced by concomitant administration of amitriptyline, clonazepam, clozapine, fluoxetine, haloperidol, lorazepam, phenelzine, sertraline, or trazodone.

Results of in vitro experiments suggest that lamotrigine does not reduce the clearance of
drugs eliminated predominantly by CYP2D6.

**Specific Populations: Subjects With Renal Impairment:** Twelve volunteers with
chronic renal failure (mean creatinine clearance: 13 mL/min, range: 6 to 23) and another 6
individuals undergoing hemodialysis were each given a single 100-mg dose of lamotrigine. The
mean plasma half-lives determined in the study were 42.9 hours (chronic renal failure),
13.0 hours (during hemodialysis), and 57.4 hours (between hemodialysis) compared with
26.2 hours in healthy volunteers. On average, approximately 20% (range: 5.6 to 35.1) of the
amount of lamotrigine present in the body was eliminated by hemodialysis during a 4-hour
session [see Dosage and Administration (2.1)].

**Hepatic Disease:** The pharmacokinetics of lamotrigine following a single 100-mg
dose of lamotrigine were evaluated in 24 subjects with mild, moderate, and severe hepatic
impairment (Child-Pugh Classification system) and compared with 12 subjects without hepatic
impairment. The subjects with severe hepatic impairment were without ascites (n = 2) or with
ascites (n = 5). The mean apparent clearances of lamotrigine in subjects with mild (n = 12),
moderate (n = 5), severe without ascites (n = 2), and severe with ascites (n = 5) liver impairment
were 0.30 ± 0.09, 0.24 ± 0.1, 0.21 ± 0.04, and 0.15 ± 0.09 mL/min/kg, respectively, as compared
with 0.37 ± 0.1 mL/min/kg in the healthy controls. Mean half-lives of lamotrigine in subjects
with mild, moderate, severe without ascites, and severe with ascites hepatic impairment were
46 ± 20, 72 ± 44, 67 ± 11, and 100 ± 48 hours, respectively, as compared with 33 ± 7 hours in
healthy controls [see Dosage and Administration (2.1)].

**Age: Pediatric Subjects:** The pharmacokinetics of lamotrigine following a single
2-mg/kg dose were evaluated in 2 studies in pediatric subjects (n = 29 for subjects aged 10
months to 5.9 years and n = 26 for subjects aged 5 to 11 years). Forty-three subjects received
concomitant therapy with other AEDs and 12 subjects received lamotrigine as monotherapy.
Lamotrigine pharmacokinetic parameters for pediatric patients are summarized in Table 16.
Population pharmacokinetic analyses involving subjects aged 2 to 18 years demonstrated
that lamotrigine clearance was influenced predominantly by total body weight and concurrent
AED therapy. The oral clearance of lamotrigine was higher, on a body weight basis, in pediatric
patients than in adults. Weight-normalized lamotrigine clearance was higher in those subjects
weighing less than 30 kg compared with those weighing greater than 30 kg. Accordingly,
patients weighing less than 30 kg may need an increase of as much as 50% in maintenance doses,
based on clinical response, as compared with subjects weighing more than 30 kg being
administered the same AEDs [see Dosage and Administration (2.2)]. These analyses also revealed that, after accounting for body weight, lamotrigine clearance was not significantly influenced by age. Thus, the same weight-adjusted doses should be administered to children irrespective of differences in age. Concomitant AEDs which influence lamotrigine clearance in adults were found to have similar effects in children.

<table>
<thead>
<tr>
<th>Pediatric Study Population</th>
<th>Number of Subjects</th>
<th>$T_{max}$ (h)</th>
<th>$t_{\frac{1}{2}}$ (h)</th>
<th>CL/F (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ages 10 months-5.3 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone$^a$</td>
<td>10</td>
<td>3.0 (1.0-5.9)</td>
<td>7.7 (5.7-11.4)</td>
<td>3.62 (2.44-5.28)</td>
</tr>
<tr>
<td>Subjects taking AEDs with no known effect on the apparent clearance of lamotrigine</td>
<td>7</td>
<td>5.2 (2.9-6.1)</td>
<td>19.0 (12.9-27.1)</td>
<td>1.2 (0.75-2.42)</td>
</tr>
<tr>
<td>Subjects taking valproate only</td>
<td>8</td>
<td>2.9 (1.0-6.0)</td>
<td>44.9 (29.5-52.5)</td>
<td>0.47 (0.23-0.77)</td>
</tr>
<tr>
<td><strong>Ages 5-11 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone$^a$</td>
<td>7</td>
<td>1.6 (1.0-3.0)</td>
<td>7.0 (3.8-9.8)</td>
<td>2.54 (1.35-5.58)</td>
</tr>
<tr>
<td>Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone$^a$ plus valproate</td>
<td>8</td>
<td>3.3 (1.0-6.4)</td>
<td>19.1 (7.0-31.2)</td>
<td>0.89 (0.39-1.93)</td>
</tr>
<tr>
<td>Subjects taking valproate only$^b$</td>
<td>3</td>
<td>4.5 (3.0-6.0)</td>
<td>65.8 (50.7-73.7)</td>
<td>0.24 (0.21-0.26)</td>
</tr>
<tr>
<td><strong>Ages 13-18 years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone$^a$</td>
<td>11</td>
<td>___$^c$</td>
<td>___$^c$</td>
<td>1.3</td>
</tr>
<tr>
<td>Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone$^a$ plus valproate</td>
<td>8</td>
<td>___$^c$</td>
<td>___$^c$</td>
<td>0.5</td>
</tr>
<tr>
<td>Subjects taking valproate only</td>
<td>4</td>
<td>___$^c$</td>
<td>___$^c$</td>
<td>0.3</td>
</tr>
</tbody>
</table>

$^a$ Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir have also been shown to increase the apparent clearance of lamotrigine [see Drug Interactions (7)].
Two subjects were included in the calculation for mean $T_{\text{max}}$.

Parameter not estimated.

**Elderly:** The pharmacokinetics of lamotrigine following a single 150-mg dose of lamotrigine were evaluated in 12 elderly volunteers between the ages of 65 and 76 years (mean creatinine clearance = 61 mL/min, range: 33 to 108 mL/min). The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).

**Gender:** The clearance of lamotrigine is not affected by gender. However, during dose escalation of lamotrigine in 1 clinical trial in patients with epilepsy on a stable dose of valproate ($n = 77$), mean trough lamotrigine concentrations unadjusted for weight were 24% to 45% higher (0.3 to 1.7 mcg/mL) in females than in males.

**Race:** The apparent oral clearance of lamotrigine was 25% lower in non-Caucasians than Caucasians.

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No evidence of carcinogenicity was seen in 1 mouse study or 2 rat studies following oral administration of lamotrigine for up to 2 years at maximum tolerated doses (30 mg/kg/day for mice and 10 to 15 mg/kg/day for rats, doses that are equivalent to 90 mg/m² and 60 to 90 mg/m², respectively). Steady-state plasma concentrations ranged from 1 to 4 mcg/mL in the mouse study and 1 to 10 mcg/mL in the rat study. Plasma concentrations associated with the recommended human doses of 300 to 500 mg/day are generally in the range of 2 to 5 mcg/mL, but concentrations as high as 19 mcg/mL have been recorded.

Lamotrigine was not mutagenic in the presence or absence of metabolic activation when tested in 2 gene mutation assays (the Ames test and the in vitro mammalian mouse lymphoma assay). In 2 cytogenetic assays (the in vitro human lymphocyte assay and the in vivo rat bone marrow assay), lamotrigine did not increase the incidence of structural or numerical chromosomal abnormalities.

No evidence of impairment of fertility was detected in rats given oral doses of lamotrigine up to 2.4 times the highest usual human maintenance dose of 8.33 mg/kg/day or 0.4 times the human dose on a mg/m² basis. The effect of lamotrigine on human fertility is unknown.

### 14 CLINICAL STUDIES

#### 14.1 Epilepsy

Monotherapy With LAMICTAL in Adults With Partial-Onset Seizures Already Receiving Treatment With Carbamazepine, Phenytoin, Phenobarbital, or Primidone as the Single Antiepileptic Drug: The effectiveness of monotherapy with LAMICTAL was established in a multicenter, double-blind clinical trial enrolling 156 adult outpatients with
partial-onset seizures. The patients experienced at least 4 simple partial-onset, complex partial-onset, and/or secondarily generalized seizures during each of 2 consecutive 4-week periods while receiving carbamazepine or phenytoin monotherapy during baseline. LAMICTAL (target dose of 500 mg/day) or valproate (1,000 mg/day) was added to either carbamazepine or phenytoin monotherapy over a 4-week period. Patients were then converted to monotherapy with LAMICTAL or valproate during the next 4 weeks, then continued on monotherapy for an additional 12-week period.

Trial endpoints were completion of all weeks of trial treatment or meeting an escape criterion. Criteria for escape relative to baseline were: (1) doubling of average monthly seizure count, (2) doubling of highest consecutive 2-day seizure frequency, (3) emergence of a new seizure type (defined as a seizure that did not occur during the 8-week baseline) that is more severe than seizure types that occur during study treatment, or (4) clinically significant prolongation of generalized tonic-clonic seizures. The primary efficacy variable was the proportion of patients in each treatment group who met escape criteria.

The percentages of patients who met escape criteria were 42% (32/76) in the group receiving LAMICTAL and 69% (55/80) in the valproate group. The difference in the percentage of patients meeting escape criteria was statistically significant ($P = 0.0012$) in favor of LAMICTAL. No differences in efficacy based on age, sex, or race were detected.

Patients in the control group were intentionally treated with a relatively low dose of valproate; as such, the sole objective of this trial was to demonstrate the effectiveness and safety of monotherapy with LAMICTAL, and cannot be interpreted to imply the superiority of LAMICTAL to an adequate dose of valproate.

**Adjunctive Therapy With LAMICTAL in Adults With Partial-Onset Seizures:** The effectiveness of LAMICTAL as adjunctive therapy (added to other AEDs) was initially established in 3 pivotal, multicenter, placebo-controlled, double-blind clinical trials in 355 adults with refractory partial-onset seizures. The patients had a history of at least 4 partial-onset seizures per month in spite of receiving 1 or more AEDs at therapeutic concentrations and in 2 of the trials were observed on their established AED regimen during baselines that varied between 8 to 12 weeks. In the third trial, patients were not observed in a prospective baseline. In patients continuing to have at least 4 seizures per month during the baseline, LAMICTAL or placebo was then added to the existing therapy. In all 3 trials, change from baseline in seizure frequency was the primary measure of effectiveness. The results given below are for all partial-onset seizures in the intent-to-treat population (all patients who received at least 1 dose of treatment) in each trial, unless otherwise indicated. The median seizure frequency at baseline was 3 per week while the mean at baseline was 6.6 per week for all patients enrolled in efficacy trials.

One trial ($n = 216$) was a double-blind, placebo-controlled, parallel trial consisting of a 24-week treatment period. Patients could not be on more than 2 other anticonvulsants and valproate was not allowed. Patients were randomized to receive placebo, a target dose of 300 mg/day of LAMICTAL, or a target dose of 500 mg/day of LAMICTAL. The median
reductions in the frequency of all partial-onset seizures relative to baseline were 8% in patients receiving placebo, 20% in patients receiving 300 mg/day of LAMICTAL, and 36% in patients receiving 500 mg/day of LAMICTAL. The seizure frequency reduction was statistically significant in the 500-mg/day group compared with the placebo group, but not in the 300-mg/day group.

A second trial (n = 98) was a double-blind, placebo-controlled, randomized, crossover trial consisting of two 14-week treatment periods (the last 2 weeks of which consisted of dose tapering) separated by a 4-week washout period. Patients could not be on more than 2 other anticonvulsants and valproate was not allowed. The target dose of LAMICTAL was 400 mg/day. When the first 12 weeks of the treatment periods were analyzed, the median change in seizure frequency was a 25% reduction on LAMICTAL compared with placebo (P < 0.001).

The third trial (n = 41) was a double-blind, placebo-controlled, crossover trial consisting of two 12-week treatment periods separated by a 4-week washout period. Patients could not be on more than 2 other anticonvulsants. Thirteen patients were on concomitant valproate; these patients received 150 mg/day of LAMICTAL. The 28 other patients had a target dose of 300 mg/day of LAMICTAL. The median change in seizure frequency was a 26% reduction on LAMICTAL compared with placebo (P < 0.01).

No differences in efficacy based on age, sex, or race, as measured by change in seizure frequency, were detected.

**Adjunctive Therapy With LAMICTAL in Pediatric Patients With Partial-Onset Seizures:** The effectiveness of LAMICTAL as adjunctive therapy in pediatric patients with partial-onset seizures was established in a multicenter, double-blind, placebo-controlled trial in 199 patients aged 2 to 16 years (n = 98 on LAMICTAL, n = 101 on placebo). Following an 8-week baseline phase, patients were randomized to 18 weeks of treatment with LAMICTAL or placebo added to their current AED regimen of up to 2 drugs. Patients were dosed based on body weight and valproate use. Target doses were designed to approximate 5 mg/kg/day for patients taking valproate (maximum dose: 250 mg/day) and 15 mg/kg/day for the patients not taking valproate (maximum dose: 750 mg/day). The primary efficacy endpoint was percentage change from baseline in all partial-onset seizures. For the intent-to-treat population, the median reduction of all partial-onset seizures was 36% in patients treated with LAMICTAL and 7% on placebo, a difference that was statistically significant (P < 0.01).

**Adjunctive Therapy With LAMICTAL in Pediatric and Adult Patients With Lennox-Gastaut Syndrome:** The effectiveness of LAMICTAL as adjunctive therapy in patients with Lennox-Gastaut syndrome was established in a multicenter, double-blind, placebo-controlled trial in 169 patients aged 3 to 25 years (n = 79 on LAMICTAL, n = 90 on placebo). Following a 4-week, single-blind, placebo phase, patients were randomized to 16 weeks of treatment with LAMICTAL or placebo added to their current AED regimen of up to 3 drugs. Patients were dosed on a fixed-dose regimen based on body weight and valproate use. Target doses were designed to approximate 5 mg/kg/day for patients taking valproate (maximum dose: 200 mg/day).
and 15 mg/kg/day for patients not taking valproate (maximum dose: 400 mg/day). The primary
efficacy endpoint was percentage change from baseline in major motor seizures (atonic, tonic,
major myoclonic, and tonic-clonic seizures). For the intent-to-treat population, the median
reduction of major motor seizures was 32% in patients treated with LAMICTAL and 9% on
placebo, a difference that was statistically significant ($P<0.05$). Drop attacks were significantly
reduced by LAMICTAL (34%) compared with placebo (9%), as were tonic-clonic seizures (36%
reduction versus 10% increase for LAMICTAL and placebo, respectively).

**Adjunctive Therapy With LAMICTAL in Pediatric and Adult Patients With Primary
Generalized Tonic-Clonic Seizures:** The effectiveness of LAMICTAL as adjunctive therapy
in patients with PGTC seizures was established in a multicenter, double-blind, placebo-
controlled trial in 117 pediatric and adult patients aged 2 years and older ($n=58$ on
LAMICTAL, $n=59$ on placebo). Patients with at least 3 PGTC seizures during an 8-week
baseline phase were randomized to 19 to 24 weeks of treatment with LAMICTAL or placebo
added to their current AED regimen of up to 2 drugs. Patients were dosed on a fixed-dose
regimen, with target doses ranging from 3 to 12 mg/kg/day for pediatric patients and from 200 to
400 mg/day for adult patients based on concomitant AEDs.

The primary efficacy endpoint was percentage change from baseline in PGTC seizures.
For the intent-to-treat population, the median percent reduction in PGTC seizures was 66% in
patients treated with LAMICTAL and 34% on placebo, a difference that was statistically
significant ($P=0.006$).

**14.2 Bipolar Disorder**

The effectiveness of LAMICTAL in the maintenance treatment of bipolar I disorder was
established in 2 multicenter, double-blind, placebo-controlled trials in adult patients who met
DSM-IV criteria for bipolar I disorder. Trial 1 enrolled patients with a current or recent (within
60 days) depressive episode as defined by DSM-IV and Trial 2 included patients with a current
or recent (within 60 days) episode of mania or hypomania as defined by DSM-IV. Both trials
included a cohort of patients (30% of 404 subjects in Trial 1 and 28% of 171 patients in Trial 2)
with rapid cycling bipolar disorder (4 to 6 episodes per year).

In both trials, patients were titrated to a target dose of 200 mg of LAMICTAL as add-on
therapy or as monotherapy with gradual withdrawal of any psychotropic medications during an
8- to 16-week open-label period. Overall 81% of 1,305 patients participating in the open-label
period were receiving 1 or more other psychotropic medications, including benzodiazepines,
selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics (including olanzapine),
valproate, or lithium, during titration of LAMICTAL. Patients with a CGI-severity score of 3 or
less maintained for at least 4 continuous weeks, including at least the final week on monotherapy
with LAMICTAL, were randomized to a placebo-controlled, double-blind treatment period for
up to 18 months. The primary endpoint was TIME (time to intervention for a mood episode or
one that was emerging, time to discontinuation for either an adverse event that was judged to be
related to bipolar disorder, or for lack of efficacy). The mood episode could be depression, mania, hypomania, or a mixed episode.

In Trial 1, patients received double-blind monotherapy with LAMICTAL 50 mg/day (n = 50), LAMICTAL 200 mg/day (n = 124), LAMICTAL 400 mg/day (n = 47), or placebo (n = 121). LAMICTAL (200- and 400-mg/day treatment groups combined) was superior to placebo in delaying the time to occurrence of a mood episode. Separate analyses of the 200- and 400-mg/day dose groups revealed no added benefit from the higher dose.

In Trial 2, patients received double-blind monotherapy with LAMICTAL (100 to 400 mg/day, n = 59), or placebo (n = 70). LAMICTAL was superior to placebo in delaying time to occurrence of a mood episode. The mean dose of LAMICTAL was about 211 mg/day.

Although these trials were not designed to separately evaluate time to the occurrence of depression or mania, a combined analysis for the 2 trials revealed a statistically significant benefit for LAMICTAL over placebo in delaying the time to occurrence of both depression and mania, although the finding was more robust for depression.

16 HOW SUPPLIED/STORAGE AND HANDLING

LAMICTAL (lamotrigine) Tablets
25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25”, bottles of 100 (NDC 0173-0633-02).

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in a dry place.

100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, bottles of 100 (NDC 0173-0642-55).

150 mg, cream, scored, shield-shaped tablets debossed with “LAMICTAL” and “150”, bottles of 60 (NDC 0173-0643-60).

200 mg, blue, scored, shield-shaped tablets debossed with “LAMICTAL” and “200”, bottles of 60 (NDC 0173-0644-60).

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.

LAMICTAL (lamotrigine) Starter Kit for Patients Taking Valproate (Blue Kit)
25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25”, blisterpack of 35 tablets (NDC 0173-0633-10).

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in a dry place.

LAMICTAL (lamotrigine) Starter Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate (Green Kit)
25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25” and 100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, blisterpack of 98 tablets (84/25-mg tablets and 14/100-mg tablets) (NDC 0173-0817-28).
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.

**LAMICTAL (lamotrigine) Starter Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange Kit)**

25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25” and 100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, blisterpack of 49 tablets (42/25-mg tablets and 7/100-mg tablets) (NDC 0173-0594-02).

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.

**LAMICTAL (lamotrigine) Chewable Dispersible Tablets**

2 mg, white to off-white, round tablets debossed with “LTG” over “2”, bottles of 30 (NDC 0173-0699-00). ORDER DIRECTLY FROM GlaxoSmithKline 1-800-334-4153.

5 mg, white to off-white, caplet-shaped tablets debossed with “GX CL2”, bottles of 100 (NDC 0173-0526-00).

25 mg, white, super elliptical-shaped tablets debossed with “GX CL5”, bottles of 100 (NDC 0173-0527-00).

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in a dry place.

**LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets**

25 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “25” on the other, Maintenance Packs of 30 (NDC 0173-0772-02).

50 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “50” on the other, Maintenance Packs of 30 (NDC 0173-0774-02).

100 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LAMICTAL” on one side and “100” on the other, Maintenance Packs of 30 (NDC 0173-0776-02).

200 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LAMICTAL” on one side and “200” on the other, Maintenance Packs of 30 (NDC 0173-0777-02).

Store between 20°C and 25°C (68°F and 77°F); with excursions permitted between 15°C and 30°C (59°F and 86°F).

**LAMICTAL ODT (lamotrigine) Patient Titration Kit for Patients Taking Valproate (Blue ODT Kit)**

25 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “25” on the other, and 50 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “50” on the other, blisterpack of 28 tablets (21/25-mg tablets and 7/50-mg tablets) (NDC 0173-0779-00).
LAMICTAL ODT (lamotrigine) Patient Titration Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate (Green ODT Kit)

50 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “50” on the other, and 100 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LAMICTAL” on one side and “100” on the other, blisterpack of 56 tablets (42/50-mg tablets and 14/100-mg tablets) (NDC 0173-0780-00).

LAMICTAL ODT (lamotrigine) Patient Titration Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange ODT Kit)

25 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “25” on the other, 50 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LMT” on one side and “50” on the other, and 100 mg, white to off-white, round, flat-faced, radius-edged tablets debossed with “LAMICTAL” on one side and “100” on the other, blisterpack of 35 (14/25-mg tablets, 14/50-mg tablets, and 7/100-mg tablets) (NDC 0173-0778-00).

Store between 20°C and 25°C (68°F and 77°F); with excursions permitted between 15°C and 30°C (59°F and 86°F).

Blisterpacks: If the product is dispensed in a blisterpack, the patient should be advised to examine the blisterpack before use and not use if blisters are torn, broken, or missing.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Rash: Prior to initiation of treatment with LAMICTAL, inform patients that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and instruct them to report any such occurrence to their physician immediately.

Multiorgan Hypersensitivity Reactions, Blood Dyscrasias, and Organ Failure: Inform patients that multiorgan hypersensitivity reactions and acute multiorgan failure may occur with LAMICTAL. Isolated organ failure or isolated blood dyscrasias without evidence of multiorgan hypersensitivity may also occur. Instruct patients to contact their physician immediately if they experience any signs or symptoms of these conditions [see Warnings and Precautions (5.2, 5.3)].

Suicidal Thinking and Behavior: Inform patients, their caregivers, and families that AEDs, including LAMICTAL, may increase the risk of suicidal thoughts and behavior. Instruct them to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior or thoughts about self-harm. They should immediately report behaviors of concern to their physician.

Worsening of Seizures: Advise patients to notify their physician if worsening of seizure control occurs.

Central Nervous System Adverse Effects: Inform patients that LAMICTAL may cause dizziness, somnolence, and other symptoms and signs of central nervous system
depression. Accordingly, instruct them neither to drive a car nor to operate other complex
machinery until they have gained sufficient experience on LAMICTAL to gauge whether or not
it adversely affects their mental and/or motor performance.

**Pregnancy and Nursing:** Instruct patients to notify their physician if they become
pregnant or intend to become pregnant during therapy and if they intend to breastfeed or are
breastfeeding an infant.

Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant.
This registry is collecting information about the safety of antiepileptic drugs during pregnancy.
To enroll, patients can call the toll-free number 1-888-233-2334 [see Use in Specific Populations
(8.1)].

Inform patients who intend to breastfeed that LAMICTAL is present in breast milk and
advise them to monitor their child for potential adverse effects of this drug. Discuss the benefits
and risks of continuing breastfeeding.

**Oral Contraceptive Use:** Instruct women to notify their physician if they plan to start or
stop use of oral contraceptives or other female hormonal preparations. Starting estrogen-
containing oral contraceptives may significantly decrease lamotrigine plasma levels and stopping
estrogen-containing oral contraceptives (including the pill-free week) may significantly increase
lamotrigine plasma levels [see Warnings and Precautions (5.8), Clinical Pharmacology (12.3)].

Also instruct women to promptly notify their physician if they experience adverse reactions or
changes in menstrual pattern (e.g., break-through bleeding) while receiving LAMICTAL in
combination with these medications.

**Discontinuing LAMICTAL:** Instruct patients to notify their physician if they stop taking
LAMICTAL for any reason and not to resume LAMICTAL without consulting their physician.

**Aseptic Meningitis:** Inform patients that LAMICTAL may cause aseptic meningitis.

Instruct them to notify their physician immediately if they develop signs and symptoms of
meningitis such as headache, fever, nausea, vomiting, stiff neck, rash, abnormal sensitivity to
light, myalgia, chills, confusion, or drowsiness while taking LAMICTAL.

**Potential Medication Errors:** Medication errors involving LAMICTAL have occurred.
In particular the names LAMICTAL or lamotrigine can be confused with the names of other
commonly used medications. Medication errors may also occur between the different
formulations of LAMICTAL. To reduce the potential of medication errors, write and say
LAMICTAL clearly. Depictions of the LAMICTAL Tablets, Chewable Dispersible Tablets, and
Orally Disintegrating Tablets can be found in the Medication Guide that accompanies the
product to highlight the distinctive markings, colors, and shapes that serve to identify the
different presentations of the drug and thus may help reduce the risk of medication errors. To
avoid a medication error of using the wrong drug or formulation, strongly advise patients
to visually inspect their tablets to verify that they are LAMICTAL, as well as the correct
formulation of LAMICTAL, each time they fill their prescription [see Dosage Forms and
Strengths (3.1, 3.2, 3.3), How Supplied/Storage and Handling (16)].
LAMICTAL and LAMICTAL ODT are registered trademarks of the GSK group of companies. The other brands listed are trademarks of their respective owners and are not trademarks of the GSK group of companies. The makers of these brands are not affiliated with and do not endorse the GSK group of companies or its products.

Distributed by

GlaxoSmithKline
Research Triangle Park, NC 27709

©2014, the GSK group of companies. All rights reserved.

MEDICATION GUIDE

LAMICTAL® (la-MI-k-tal) (lamotrigine) Tablets and Chewable Dispersible Tablets
LAMICTAL ODT® (lamotrigine) Orally Disintegrating Tablets

Read this Medication Guide before you start taking LAMICTAL and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about LAMICTAL, ask your healthcare provider or pharmacist.

What is the most important information I should know about LAMICTAL?

1. LAMICTAL may cause a serious skin rash that may cause you to be hospitalized or even cause death.

There is no way to tell if a mild rash will become more serious. A serious skin rash can happen at any time during your treatment with LAMICTAL, but is more likely to happen within the first 2 to 8 weeks of treatment. Children aged between 2 and 16 years have a higher chance of getting this serious skin rash while taking LAMICTAL.

The risk of getting a serious skin rash is higher if you:
• take LAMICTAL while taking valproate [DEPAKENE® (valproic acid) or DEPAKOTE® (divalproex sodium)].
• take a higher starting dose of LAMICTAL than your healthcare provider prescribed.
• increase your dose of LAMICTAL faster than prescribed.

**Call your healthcare provider right away if you have any of the following:**

- a skin rash
- blistering or peeling of your skin
- hives
- painful sores in your mouth or around your eyes

These symptoms may be the first signs of a serious skin reaction. A healthcare provider should examine you to decide if you should continue taking LAMICTAL.

**2. Other serious reactions, including serious blood problems or liver problems.** LAMICTAL can also cause other types of allergic reactions or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away if you have any of these symptoms:

- fever
- frequent infections
- severe muscle pain
- swelling of your face, eyes, lips, or tongue
- swollen lymph glands
- unusual bruising or bleeding
- weakness, fatigue
- yellowing of your skin or the white part of your eyes

**3. Like other antiepileptic drugs, LAMICTAL may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.**

**Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:**

- thoughts about suicide or dying
- attempt to commit suicide
- new or worse depression
- new or worse anxiety
- feeling agitated or restless
- panic attacks
- trouble sleeping (insomnia)
new or worse irritability
• acting aggressive, being angry, or violent
• acting on dangerous impulses
• an extreme increase in activity and talking (mania)
• other unusual changes in behavior or mood

Do not stop LAMICTAL without first talking to a healthcare provider.
• Stopping LAMICTAL suddenly can cause serious problems.
• Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

How can I watch for early symptoms of suicidal thoughts and actions?
• Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
• Keep all follow-up visits with your healthcare provider as scheduled.
• Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

4. LAMICTAL may rarely cause aseptic meningitis, a serious inflammation of the protective membrane that covers the brain and spinal cord.

Call your healthcare provider right away if you have any of the following symptoms:
• headache
• fever
• nausea
• vomiting
• stiff neck
• rash
• unusual sensitivity to light
• muscle pains
• chills
• confusion
• drowsiness

Meningitis has many causes other than LAMICTAL, which your doctor would check for if you developed meningitis while taking LAMICTAL.

LAMICTAL can have other serious side effects. For more information ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you. Be sure to read the section below entitled “What are the possible side effects of LAMICTAL?”
5. Patients prescribed LAMICTAL have sometimes been given the wrong medicine because many medicines have names similar to LAMICTAL, so always check that you receive LAMICTAL.

Taking the wrong medication can cause serious health problems. When your healthcare provider gives you a prescription for LAMICTAL:

- Make sure you can read it clearly.
- Talk to your pharmacist to check that you are given the correct medicine.
- Each time you fill your prescription, check the tablets you receive against the pictures of the tablets below.

These pictures show the distinct wording, colors, and shapes of the tablets that help to identify the right strength of LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets. Immediately call your pharmacist if you receive a LAMICTAL tablet that does not look like one of the tablets shown below, as you may have received the wrong medication.

### LAMICTAL (lamotrigine) Tablets

<table>
<thead>
<tr>
<th>25 mg, white</th>
<th>100 mg, peach</th>
<th>150 mg, cream</th>
<th>200 mg, blue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imprinted with LAMICTAL 25</td>
<td>Imprinted with LAMICTAL 100</td>
<td>Imprinted with LAMICTAL 150</td>
<td>Imprinted with LAMICTAL 200</td>
</tr>
</tbody>
</table>

### LAMICTAL (lamotrigine) Chewable Dispersible Tablets

<table>
<thead>
<tr>
<th>2 mg, white</th>
<th>5 mg, white</th>
<th>25 mg, white</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imprinted with LTG 2</td>
<td>Imprinted with GX CL2</td>
<td>Imprinted with GX CL5</td>
</tr>
</tbody>
</table>
LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets

<table>
<thead>
<tr>
<th>Strength</th>
<th>Color</th>
<th>Imprint</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mg</td>
<td>white</td>
<td>LMT 25</td>
</tr>
<tr>
<td>50 mg</td>
<td>white</td>
<td>LMT 50</td>
</tr>
<tr>
<td>100 mg</td>
<td>white</td>
<td>LAMICTAL 100</td>
</tr>
<tr>
<td>200 mg</td>
<td>white</td>
<td>LAMICTAL 200</td>
</tr>
</tbody>
</table>

What is LAMICTAL?

LAMICTAL is a prescription medicine used:

1. together with other medicines to treat certain types of seizures (partial-onset seizures, primary generalized tonic-clonic seizures, generalized seizures of Lennox-Gastaut syndrome) in people aged 2 years and older.

2. alone when changing from 1 other medicine used to treat partial-onset seizures in people aged 16 years and older.

3. for the long-term treatment of bipolar I disorder to lengthen the time between mood episodes in people aged 18 years and older who have been treated for mood episodes with other medicine.

It is not known if LAMICTAL is safe or effective in children or teenagers younger than 18 years with mood disorders such as bipolar disorder or depression.

It is not known if LAMICTAL is safe or effective when used alone as the first treatment of seizures.

Who should not take LAMICTAL?

You should not take LAMICTAL if you have had an allergic reaction to lamotrigine or to any of the inactive ingredients in LAMICTAL. See the end of this leaflet for a complete list of ingredients in LAMICTAL.

What should I tell my healthcare provider before taking LAMICTAL?

Before taking LAMICTAL, tell your healthcare provider about all of your medical conditions, including if you:
• have had a rash or allergic reaction to another antiseizure medicine.
• have or have had depression, mood problems, or suicidal thoughts or behavior.
• have had aseptic meningitis after taking LAMICTAL or LAMICTAL XR (lamotrigine).
• are taking oral contraceptives (birth control pills) or other female hormonal medicines. Do not start or stop taking birth control pills or other female hormonal medicine until you have talked with your healthcare provider. Tell your healthcare provider if you have any changes in your menstrual pattern such as breakthrough bleeding. Stopping these medicines may cause side effects (such as dizziness, lack of coordination, or double vision). Starting these medicines may lessen how well LAMICTAL works.
• are pregnant or plan to become pregnant. It is not known if LAMICTAL will harm your unborn baby. If you become pregnant while taking LAMICTAL, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.
• are breastfeeding. LAMICTAL passes into breast milk and may cause side effects in a breastfed baby. If you breastfeed while taking LAMICTAL, watch your baby closely for trouble breathing, episodes of temporarily stopping breathing, sleepiness, or poor sucking. Call your baby’s healthcare provider right away if you see any of these problems. Talk to your healthcare provider about the best way to feed your baby if you take LAMICTAL.

Tell your healthcare provider about all the medicines you take or if you are planning to take a new medicine, including prescription and non-prescription medicines, vitamins, and herbal supplements. If you use LAMICTAL with certain other medicines, they can affect each other, causing side effects.

**How should I take LAMICTAL?**

• Take LAMICTAL exactly as prescribed.
• Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.
• Do not stop taking LAMICTAL without talking to your healthcare provider. Stopping LAMICTAL suddenly may cause serious problems. For example, if you have epilepsy and you stop taking LAMICTAL suddenly, you may have seizures that do not stop. Talk with your healthcare provider about how to stop LAMICTAL slowly.
• If you miss a dose of LAMICTAL, take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your
regular time. **Do not take 2 doses at the same time.**

- If you take too much LAMICTAL, call your healthcare provider or your local Poison Control Center or go to the nearest hospital emergency room right away.
- If you take too much LAMICTAL, call your healthcare provider or your local Poison Control Center or go to the nearest hospital emergency room right away.
- You may not feel the full effect of LAMICTAL for several weeks.
- If you have epilepsy, tell your healthcare provider if your seizures get worse or if you have any new types of seizures.
- Swallow LAMICTAL Tablets whole.
- If you have trouble swallowing LAMICTAL Tablets, tell your healthcare provider because there may be another form of LAMICTAL you can take.
- LAMICTAL ODT should be placed on the tongue and moved around the mouth. The tablet will rapidly disintegrate, can be swallowed with or without water, and can be taken with or without food.
- LAMICTAL Chewable Dispersible tablets may be swallowed whole, chewed, or mixed in water or diluted fruit juice. If the tablets are chewed, drink a small amount of water or diluted fruit juice to help in swallowing. To break up LAMICTAL Chewable Dispersible tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medicine) in a glass or spoon. Wait at least 1 minute or until the tablets are completely broken up, mix the solution together, and take the whole amount right away.
- If you receive LAMICTAL in a blisterpack, examine the blisterpack before use. Do not use if blisters are torn, broken, or missing.

**What should I avoid while taking LAMICTAL?**

Do not drive a car or operate complex, hazardous machinery until you know how LAMICTAL affects you.

**What are the possible side effects of LAMICTAL?**

See “What is the most important information I should know about LAMICTAL?”

Common side effects of LAMICTAL include:
- dizziness
- tremor
- headache
- rash
- blurred or double vision
- fever
- lack of coordination
• abdominal pain
• sleepiness
• back pain
• nausea, vomiting
• tiredness
• insomnia
• dry mouth

Tell your healthcare provider about any side effect that bothers you or that does not go away.

These are not all the possible side effects of LAMICTAL. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store LAMICTAL?

• Store LAMICTAL at room temperature between 68°F and 77°F (20°C and 25°C).
• Keep LAMICTAL and all medicines out of the reach of children.

General information about LAMICTAL

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LAMICTAL for a condition for which it was not prescribed. Do not give LAMICTAL to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about LAMICTAL. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about LAMICTAL that is written for healthcare professionals.

For more information, go to www.lamictal.com or call 1-888-825-5249.

What are the ingredients in LAMICTAL?

LAMICTAL Tablets
Active ingredient: lamotrigine.

Inactive ingredients: lactose; magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, FD&C Yellow No. 6 Lake (100-mg tablet only), ferric oxide, yellow (150-mg tablet only), and FD&C Blue No. 2 Lake (200-mg tablet only).
LAMICTAL Chewable Dispersible Tablets

Active ingredient: lamotrigine.

Inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, saccharin sodium, and sodium starch glycolate.

LAMICTAL ODT Orally Disintegrating Tablets

Active ingredient: lamotrigine.

Inactive ingredients: artificial cherry flavor, crospovidone, ethylcellulose, magnesium stearate, mannitol, polyethylene, and sucralose.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

LAMICTAL and LAMICTAL ODT are registered trademarks of the GSK group of companies. The other brands listed are trademarks of their respective owners and are not trademarks of the GSK group of companies. The makers of these brands are not affiliated with and do not endorse the GSK group of companies or its products.

Distributed by

GlaxoSmithKline
Research Triangle Park, NC 27709

©2014, the GSK group of companies. All rights reserved.

December 2014

LMT:xMG
LAMICTAL XR (lamotrigine) Extended-Release Tablets
Initial U.S. Approval: 1994

WARNING: SERIOUS SKIN RASHES
See full prescribing information for complete boxed warning.
• Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:
  • coadministration with valproate.
  • exceeding recommended initial dose of LAMICTAL XR.
  • exceeding recommended dose escalation for LAMICTAL XR.
  • Benign rashes are also caused by lamotrigine; however, it is not possible to predict which rashes will prove to be serious or life threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)

RECENT MAJOR CHANGES
12/2014

INDICATIONS AND USAGE
LAMICTAL XR is an antiepileptic drug (AED) indicated for:
• adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. (1.1)
• conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single AED. (1.2)

Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. (1.3)

DOSAGE AND ADMINISTRATION
• Do not exceed the recommended initial dosage and subsequent dose escalation. (2.1)
• Initiation of adjunctive therapy and conversion to monotherapy requires slow titration dependent on concomitant AEDs; the prescriber must refer to the appropriate algorithm in Dosage and Administration. (2.2, 2.3)
  • Adjunct therapy target therapeutic dose range is 200 to 600 mg daily and is dependent on concomitant AEDs. (2.2)
  • Conversion to monotherapy: Target therapeutic dosage range is 250 to 300 mg daily. (2.3)
• Conversion from immediate-release lamotrigine to LAMICTAL XR: The initial dose of LAMICTAL XR should match the total daily dose of the immediate-release lamotrigine. Patients should be closely monitored for seizure control after conversion. (2.4)
• Do not restart LAMICTAL XR in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. (2.1, 5.1)
• Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. (2.1, 5.7)
• Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). (2.1, 5.8)

Dosage and Administration (2.1, 2.2) for LAMICTAL XR.
These highlights do not include all the information needed to use LAMICTAL XR safely and effectively. See full prescribing information for LAMICTAL XR.

Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. (1.3)

Dosage and Administration (2.1, 2.2)

Recent major changes

Indications and usage

Dosage and administration

Recent major changes

Instructions for use

Adverse reactions

Drug interactions

Use in specific populations

References

See 17 for Patient Counseling Information and Medication Guide.

Revised: 12/2014
FULL PRESCRIBING INFORMATION

WARNING: SERIOUS SKIN RASHES

LAMICTAL® XR™ can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate-release lamotrigine, there was 1 rash-related death. LAMICTAL XR is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
The risk of serious rash caused by treatment with LAMICTAL XR is not expected to differ from that with immediate-release lamotrigine. However, the relatively limited treatment experience with LAMICTAL XR makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with LAMICTAL XR.

Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by LAMICTAL XR. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of LAMICTAL XR with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of LAMICTAL XR, or (3) exceeding the recommended dose escalation for LAMICTAL XR. However, cases have occurred in the absence of these factors.

Nearly all cases of life-threatening rashes caused by immediate-release lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.

Although benign rashes are also caused by LAMICTAL XR, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, LAMICTAL XR should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

1.1 Adjunctive Therapy

LAMICTAL XR is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.

1.2 Monotherapy

LAMICTAL XR is indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED).

Safety and effectiveness of LAMICTAL XR have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

1.3 Limitation of Use

Safety and effectiveness of LAMICTAL XR for use in patients younger than 13 years have not been established.
2 DOSAGE AND ADMINISTRATION

LAMICTAL XR Extended-Release Tablets are taken once daily, with or without food. Tablets must be swallowed whole and must not be chewed, crushed, or divided.

2.1 General Dosing Considerations

Rash: There are suggestions, yet to be proven, that the risk of severe, potentially life-threatening rash may be increased by (1) coadministration of LAMICTAL XR with valproate, (2) exceeding the recommended initial dose of LAMICTAL XR, or (3) exceeding the recommended dose escalation for LAMICTAL XR. However, cases have occurred in the absence of these factors [see Boxed Warning]. Therefore, it is important that the dosing recommendations be followed closely.

The risk of nonserious rash may be increased when the recommended initial dose and/or the rate of dose escalation for LAMICTAL XR is exceeded and in patients with a history of allergy or rash to other AEDs.

LAMICTAL XR Patient Titration Kits provide LAMICTAL XR at doses consistent with the recommended titration schedule for the first 5 weeks of treatment, based upon concomitant medications, for patients with partial-onset seizures and are intended to help reduce the potential for rash. The use of LAMICTAL XR Patient Titration Kits is recommended for appropriate patients who are starting or restarting LAMICTAL XR [see How Supplied/Storage and Handling (16)].

It is recommended that LAMICTAL XR not be restarted in patients who discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefits clearly outweigh the risks. If the decision is made to restart a patient who has discontinued LAMICTAL XR, the need to restart with the initial dosing recommendations should be assessed. The greater the interval of time since the previous dose, the greater consideration should be given to restarting with the initial dosing recommendations. If a patient has discontinued lamotrigine for a period of more than 5 half-lives, it is recommended that initial dosing recommendations and guidelines be followed. The half-life of lamotrigine is affected by other concomitant medications [see Clinical Pharmacology (12.3)].

LAMICTAL XR Added to Drugs Known to Induce or Inhibit Glucuronidation:

Because lamotrigine is metabolized predominantly by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine. Drugs that induce glucuronidation include carbamazepine, phenytoin, phenobarbital, primidone, rifampin, estrogen-containing oral contraceptives, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Valproate inhibits glucuronidation. For dosing considerations for LAMICTAL XR in patients on estrogen-containing contraceptives and atazanavir/ritonavir, see below and Table 5. For dosing considerations for LAMICTAL XR in patients on other drugs known to induce or inhibit glucuronidation, see Table 1 and Table 5.

Target Plasma Levels: A therapeutic plasma concentration range has not been established for lamotrigine. Dosing of LAMICTAL XR should be based on therapeutic response [see Clinical Pharmacology (12.3)].
Women Taking Estrogen-Containing Oral Contraceptives: Starting LAMICTAL XR in Women Taking Estrogen-Containing Oral Contraceptives: Although estrogen-containing oral contraceptives have been shown to increase the clearance of lamotrigine [see Clinical Pharmacology (12.3)], no adjustments to the recommended dose-escalation guidelines for LAMICTAL XR should be necessary solely based on the use of estrogen-containing oral contraceptives. Therefore, dose escalation should follow the recommended guidelines for initiating adjunctive therapy with LAMICTAL XR based on the concomitant AED or other concomitant medications (see Table 1). See below for adjustments to maintenance doses of LAMICTAL XR in women taking estrogen-containing oral contraceptives.

Adjustments to the Maintenance Dose of LAMICTAL XR in Women Taking Estrogen-Containing Oral Contraceptives:

1. Taking Estrogen-Containing Oral Contraceptives: In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical Pharmacology (12.3)], the maintenance dose of LAMICTAL XR will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level.

2. Starting Estrogen-Containing Oral Contraceptives: In women taking a stable dose of LAMICTAL XR and not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical Pharmacology (12.3)], the maintenance dose will in most cases need to be increased by as much as 2-fold to maintain a consistent lamotrigine plasma level. The dose increases should begin at the same time that the oral contraceptive is introduced and continue, based on clinical response, no more rapidly than 50 to 100 mg/day every week. Dose increases should not exceed the recommended rate (see Table 1) unless lamotrigine plasma levels or clinical response support larger increases. Gradual transient increases in lamotrigine plasma levels may occur during the week of inactive hormonal preparation (pill-free week), and these increases will be greater if dose increases are made in the days before or during the week of inactive hormonal preparation. Increased lamotrigine plasma levels could result in additional adverse reactions, such as dizziness, ataxia, and diplopia. If adverse reactions attributable to LAMICTAL XR consistently occur during the pill-free week, dose adjustments to the overall maintenance dose may be necessary. Dose adjustments limited to the pill-free week are not recommended. For women taking LAMICTAL XR in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical Pharmacology (12.3)], no adjustment to the dose of LAMICTAL XR should be necessary.

3. Stopping Estrogen-Containing Oral Contraceptives: In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine...
glucuronidation [see Drug Interactions (7), Clinical Pharmacology (12.3)], the maintenance
dose of LAMICTAL XR will in most cases need to be decreased by as much as 50% in order to
maintain a consistent lamotrigine plasma level. The decrease in dose of LAMICTAL XR should
not exceed 25% of the total daily dose per week over a 2-week period, unless clinical response or
lamotrigine plasma levels indicate otherwise [see Clinical Pharmacology (12.3)]. In women
taking LAMICTAL XR in addition to carbamazepine, phenytoin, phenobarbital, primidone, or
other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and
atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Clinical
Pharmacology (12.3)], no adjustment to the dose of LAMICTAL XR should be necessary.

Women and Other Hormonal Contraceptive Preparations or Hormone Replacement Therapy: The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically
evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of
lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels.
Therefore, adjustments to the dosage of LAMICTAL XR in the presence of progestogens alone
will likely not be needed.

Patients Taking Atazanavir/Ritonavir: While atazanavir/ritonavir does reduce the
lamotrigine plasma concentration, no adjustments to the recommended dose-escalation
guidelines for LAMICTAL XR should be necessary solely based on the use of
atazanavir/ritonavir. Dose escalation should follow the recommended guidelines for initiating
adjunctive therapy with LAMICTAL XR based on concomitant AED or other concomitant
medications (see Tables 1 and 5). In patients already taking maintenance doses of LAMICTAL
XR and not taking glucuronidation inducers, the dose of LAMICTAL XR may need to be
increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued [see
Clinical Pharmacology (12.3)].

Patients With Hepatic Impairment: Experience in patients with hepatic impairment is
limited. Based on a clinical pharmacology study in 24 subjects with mild, moderate, and severe
liver impairment [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)], the
following general recommendations can be made. No dosage adjustment is needed in patients
with mild liver impairment. Initial, escalation, and maintenance doses should generally be
reduced by approximately 25% in patients with moderate and severe liver impairment without
ascites and 50% in patients with severe liver impairment with ascites. Escalation and
maintenance doses may be adjusted according to clinical response.

Patients With Renal Impairment: Initial doses of LAMICTAL XR should be based on
patients’ concomitant medications (see Table 1); reduced maintenance doses may be effective for
patients with significant renal impairment [see Use in Specific Populations (8.7), Clinical
Pharmacology (12.3)]. Few patients with severe renal impairment have been evaluated during
chronic treatment with immediate-release lamotrigine. Because there is inadequate experience in
this population, LAMICTAL XR should be used with caution in these patients.
Discontinuation Strategy: For patients receiving LAMICTAL XR in combination with other AEDs, a re-evaluation of all AEDs in the regimen should be considered if a change in seizure control or an appearance or worsening of adverse reactions is observed.

If a decision is made to discontinue therapy with LAMICTAL XR, a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety concerns require a more rapid withdrawal [see Warnings and Precautions (5.8)].

Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine; discontinuing valproate should shorten the half-life of lamotrigine.

2.2 Adjunctive Therapy for Primary Generalized Tonic-Clonic and Partial-Onset Seizures

This section provides specific dosing recommendations for patients aged 13 years and older. Specific dosing recommendations are provided depending upon concomitant AEDs or other concomitant medications.

| Table 1. Escalation Regimen for LAMICTAL XR in Patients Aged 13 Years and Older |
|-----------------|-----------------|-----------------|-----------------|
|                 | In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate | In Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate | In Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone and NOT TAKING Valproate |
| Weeks 1 and 2   | 25 mg every other day | 25 mg every day | 50 mg every day |
| Weeks 3 and 4   | 25 mg every day | 50 mg every day | 100 mg every day |
| Week 5          | 50 mg every day | 100 mg every day | 200 mg every day |
| Week 6          | 100 mg every day | 150 mg every day | 300 mg every day |
| Week 7          | 150 mg every day | 200 mg every day | 400 mg every day |
| Maintenance range (week 8 and onward) | 200 to 250 mg every day | 300 to 400 mg every day | 400 to 600 mg every day |

* Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see Drug Interactions (7), Clinical Pharmacology (12.3)].

* Drugs that induce lamotrigine glucuronidation and increase clearance, other than the specified antiepileptic drugs, include estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir. Dosing recommendations for oral contraceptives and the protease inhibitor atazanavir/ritonavir can be found in General Dosing Considerations [see Dosage and Administration (2.1)]. Patients on rifampin and the protease inhibitor lopinavir/ritonavir should follow the same dosing titration/maintenance regimen used.
with antiepileptic drugs that induce glucuronidation and increase clearance [see Dosage and Administration (2.1), Drug Interactions (7), and Clinical Pharmacology (12.3)].

Dose increases at week 8 or later should not exceed 100 mg daily at weekly intervals.

2.3 Conversion From Adjunctive Therapy to Monotherapy

The goal of the transition regimen is to attempt to maintain seizure control while mitigating the risk of serious rash associated with the rapid titration of LAMICTAL XR.

To avoid an increased risk of rash, the recommended maintenance dosage range of LAMICTAL XR as monotherapy is 250 to 300 mg given once daily.

The recommended initial dose and subsequent dose escalations for LAMICTAL XR should not be exceeded [see Boxed Warning].

Conversion From Adjunctive Therapy With Carbamazepine, Phenytoin, Phenobarbital, or Primidone to Monotherapy With LAMICTAL XR: After achieving a dose of 500 mg/day of LAMICTAL XR using the guidelines in Table 1, the concomitant enzyme-inducing AED should be withdrawn by 20% decrements each week over a 4-week period. Two weeks after completion of withdrawal of the enzyme-inducing AED, the dosage of LAMICTAL XR may be decreased no faster than 100 mg/day each week to achieve the monotherapy maintenance dosage range of 250 to 300 mg/day.

The regimen for the withdrawal of the concomitant AED is based on experience gained in the controlled monotherapy clinical trial using immediate-release lamotrigine.

Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL XR: The conversion regimen involves the 4 steps outlined in Table 2.

Table 2. Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL XR in Patients Aged 13 Years and Older With Epilepsy

<table>
<thead>
<tr>
<th>LAMICTAL XR</th>
<th>Valproate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>Achieve a dose of 150 mg/day according to guidelines in Table 1.</td>
</tr>
<tr>
<td>Step 2</td>
<td>Maintain at 150 mg/day.</td>
</tr>
<tr>
<td>Step 3</td>
<td>Increase to 200 mg/day.</td>
</tr>
<tr>
<td>Step 4</td>
<td>Increase to 250 or 300 mg/day.</td>
</tr>
</tbody>
</table>

Conversion From Adjunctive Therapy With Antiepileptic Drugs Other Than Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate to Monotherapy With LAMICTAL XR: After achieving a dosage of 250 to 300 mg/day of LAMICTAL XR using the guidelines in Table 1, the concomitant AED should be withdrawn by 20% decrements each
225 week over a 4-week period. No adjustment to the monotherapy dose of LAMICTAL XR is
226 needed.

227 2.4 Conversion From Immediate-Release Lamotrigine Tablets to LAMICTAL XR
228
229 Patients may be converted directly from immediate-release lamotrigine to LAMICTAL
230 XR Extended-Release Tablets. The initial dose of LAMICTAL XR should match the total daily
231 dose of immediate-release lamotrigine. However, some subjects on concomitant enzyme-
232 inducing agents may have lower plasma levels of lamotrigine on conversion and should be
233 monitored [see Clinical Pharmacology (12.3)].
234
235 Following conversion to LAMICTAL XR, all patients (but especially those on drugs that
236 induce lamotrigine glucuronidation) should be closely monitored for seizure control [see Drug
237 Interactions (7)]. Depending on the therapeutic response after conversion, the total daily dose
238 may need to be adjusted within the recommended dosing instructions (Table 1).

3 DOSAGE FORMS AND STRENGTHS

3.1 Extended-Release Tablets

25 mg, yellow with white center, round, biconvex, film-coated tablets printed with
“LAMICTAL” and “XR 25.”

50 mg, green with white center, round, biconvex, film-coated tablets printed with
“LAMICTAL” and “XR 50.”

100 mg, orange with white center, round, biconvex, film-coated tablets printed with
“LAMICTAL” and “XR 100.”

200 mg, blue with white center, round, biconvex, film-coated tablets printed with
“LAMICTAL” and “XR 200.”

250 mg, purple with white center, caplet-shaped, film-coated tablets printed with
“LAMICTAL” and “XR 250.”

300 mg, gray with white center, caplet-shaped, film-coated tablets printed with
“LAMICTAL” and “XR 300.”

3.2 Potential Medication Errors

Patients should be strongly advised to visually inspect their tablets to verify that they are
receiving LAMICTAL XR, as opposed to other medications, and that they are receiving the
correct formulation of lamotrigine each time they fill their prescription. Depictions of the
LAMICTAL XR tablets can be found in the Medication Guide.

4 CONTRAINDICATIONS

LAMICTAL XR is contraindicated in patients who have demonstrated hypersensitivity
(e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its
ingredients [see Boxed Warning, Warnings and Precautions (5.1, 5.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Serious Skin Rashes [see Boxed Warning]
The risk of serious rash caused by treatment with LAMICTAL XR is not expected to
differ from that with immediate-release lamotrigine [see Boxed Warning]. However, the
relatively limited treatment experience with LAMICTAL XR makes it difficult to characterize
the frequency and risk of serious rashes caused by treatment with LAMICTAL XR.

**Pediatric Population:** The incidence of serious rash associated with hospitalization and
discontinuation of immediate-release lamotrigine in a prospectively followed cohort of pediatric
patients (aged 2 to 16 years) with epilepsy receiving adjunctive therapy with immediate-release
lamotrigine was approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed by 3
expert dermatologists, there was considerable disagreement as to their proper classification. To
illustrate, one dermatologist considered none of the cases to be Stevens-Johnson syndrome;
another assigned 7 of the 14 to this diagnosis. There was 1 rash-related death in this
1,983-patient cohort. Additionally, there have been rare cases of toxic epidermal necrolysis with
and without permanent sequelae and/or death in US and foreign postmarketing experience.

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk
of serious, potentially life-threatening rash in pediatric patients. In pediatric patients who used
valproate concomitantly, 1.2% (6 of 482) experienced a serious rash compared with 0.6% (6 of
952) patients not taking valproate.

LAMICTAL XR is not approved in patients younger than 13 years.

**Adult Population:** Serious rash associated with hospitalization and discontinuation of
immediate-release lamotrigine occurred in 0.3% (11 of 3,348) of adult patients who received
immediate-release lamotrigine in premarketing clinical trials of epilepsy. In worldwide
postmarketing experience, rare cases of rash-related death have been reported, but their numbers
are too few to permit a precise estimate of the rate.

Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic
erpidermal necrolysis, angioedema, and those associated with multiorgan hypersensitivity [see
Warnings and Precautions (5.2)].

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk
of serious, potentially life-threatening rash in adults. Specifically, of 584 patients administered
immediate-release lamotrigine with valproate in epilepsy clinical trials, 6 (1%) were hospitalized
in association with rash; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers
administered immediate-release lamotrigine in the absence of valproate were hospitalized.

**Patients With History of Allergy or Rash to Other Antiepileptic Drugs:** The risk of
nonserious rash may be increased when the recommended initial dose and/or the rate of dose
escalation for LAMICTAL XR is exceeded and in patients with a history of allergy or rash to
other AEDs.

**5.2 Multiorgan Hypersensitivity Reactions and Organ Failure**

Multiorgan hypersensitivity reactions, also known as drug reaction with eosinophilia and
systemic symptoms (DRESS), have occurred with lamotrigine. Some have been fatal or life
threatening. DRESS typically, although not exclusively, presents with fever, rash, and/or
lymphadenopathy in association with other organ system involvement, such as hepatitis,
nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression and other organ systems not noted here may be involved.

Fatalities associated with acute multiorgan failure and various degrees of hepatic failure have been reported in 2 of 3,796 adult patients and 4 of 2,435 pediatric patients who received lamotrigine in epilepsy clinical trials. Rare fatalities from multiorgan failure have also been reported in postmarketing use.

Isolated liver failure without rash or involvement of other organs has also been reported with lamotrigine.

It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. LAMICTAL XR should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

Prior to initiation of treatment with LAMICTAL XR, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

5.3 Blood Dyscrasias

There have been reports of blood dyscrasias with immediate-release lamotrigine that may or may not be associated with multiorgan hypersensitivity (also known as DRESS) [see Warnings and Precautions (5.2)]. These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.

5.4 Suicidal Behavior and Ideation

AEDs, including LAMICTAL XR, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated. There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed.
Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanism of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 3 shows absolute and relative risk by indication for all evaluated AEDs.

### Table 3. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

<table>
<thead>
<tr>
<th>Indication</th>
<th>Placebo Patients With Events per 1,000 Patients</th>
<th>Drug Patients With Events per 1,000 Patients</th>
<th>Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th>Risk Difference: Additional Drug Patients With Events per 1,000 Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy</td>
<td>1.0</td>
<td>3.4</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>5.7</td>
<td>8.5</td>
<td>1.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
<td>1.8</td>
<td>1.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Total</td>
<td>2.4</td>
<td>4.3</td>
<td>1.8</td>
<td>1.9</td>
</tr>
</tbody>
</table>

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing LAMICTAL XR or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, the emergence of suicidal thoughts or suicidal behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

### 5.5 Aseptic Meningitis

Therapy with lamotrigine increases the risk of developing aseptic meningitis. Because of the potential for serious outcomes of untreated meningitis due to other causes, patients should also be evaluated for other causes of meningitis and treated as appropriate.

Postmarketing cases of aseptic meningitis have been reported in pediatric and adult patients taking lamotrigine for various indications. Symptoms upon presentation have included headache, fever, nausea, vomiting, and nuchal rigidity. Rash, photophobia, myalgia, chills,
altered consciousness, and somnolence were also noted in some cases. Symptoms have been
reported to occur within 1 day to one and a half months following the initiation of treatment. In
most cases, symptoms were reported to resolve after discontinuation of lamotrigine. Re-exposure
resulted in a rapid return of symptoms (from within 30 minutes to 1 day following re-initiation of
treatment) that were frequently more severe. Some of the patients treated with lamotrigine who
developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus or other
autoimmune diseases.

Cerebrospinal fluid (CSF) analyzed at the time of clinical presentation in reported cases
was characterized by a mild to moderate pleocytosis, normal glucose levels, and mild to
moderate increase in protein. CSF white blood cell count differentials showed a predominance of
neutrophils in a majority of the cases, although a predominance of lymphocytes was reported in
approximately one third of the cases. Some patients also had new onset of signs and symptoms
of involvement of other organs (predominantly hepatic and renal involvement), which may
suggest that in these cases the aseptic meningitis observed was part of a hypersensitivity reaction
[see Warnings and Precautions (5.2)].

5.6 Potential Medication Errors

Medication errors involving LAMICTAL have occurred. In particular, the names
LAMICTAL or lamotrigine can be confused with the names of other commonly used
medications. Medication errors may also occur between the different formulations of
LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL XR
clearly. Depictions of the LAMICTAL XR Extended-Release Tablets can be found in the
Medication Guide. Each LAMICTAL XR tablet has a distinct color and white center, and is
printed with “LAMICTAL XR” and the tablet strength. These distinctive features serve to
identify the different presentations of the drug and thus may help reduce the risk of medication
errors. LAMICTAL XR is supplied in round, unit-of-use bottles with orange caps containing
30 tablets. The label on the bottle includes a depiction of the tablets that further communicates to
patients and pharmacists that the medication is LAMICTAL XR and the specific tablet strength
included in the bottle. The unit-of-use bottle with a distinctive orange cap and distinctive bottle
label features serves to identify the different presentations of the drug and thus may help to
reduce the risk of medication errors. To avoid the medication error of using the wrong drug or
formulation, patients should be strongly advised to visually inspect their tablets to verify that
they are LAMICTAL XR each time they fill their prescription.

5.7 Concomitant Use With Oral Contraceptives

Some estrogen-containing oral contraceptives have been shown to decrease serum
concentrations of lamotrigine [see Clinical Pharmacology (12.3)]. Dosage adjustments will be
necessary in most patients who start or stop estrogen-containing oral contraceptives while
taking LAMICTAL XR [see Dosage and Administration (2.1)]. During the week of inactive
hormone preparation (pill-free week) of oral contraceptive therapy, plasma lamotrigine levels are
expected to rise, as much as doubling at the end of the week. Adverse reactions consistent with
elevated levels of lamotrigine, such as dizziness, ataxia, and diplopia, could occur.
5.8 Withdrawing Seizures

As with other AEDs, LAMICTAL XR should not be abruptly discontinued. In patients
with epilepsy there is a possibility of increasing seizure frequency. Unless safety concerns
require a more rapid withdrawal, the dose of LAMICTAL XR should be tapered over a period of
at least 2 weeks (approximately 50% reduction per week) [see Dosage and Administration
(2.1)].

5.9 Status Epilepticus

Valid estimates of the incidence of treatment-emergent status epilepticus among patients
treated with immediate-release lamotrigine are difficult to obtain because reporters participating
in clinical trials did not all employ identical rules for identifying cases. At a minimum, 7 of 2,343
adult patients had episodes that could unequivocally be described as status epilepticus. In
addition, a number of reports of variably defined episodes of seizure exacerbation (e.g., seizure
clusters, seizure flurries) were made.

5.10 Sudden Unexplained Death in Epilepsy (SUDEP)

During the premarketing development of immediate-release lamotrigine, 20 sudden and
unexplained deaths were recorded among a cohort of 4,700 patients with epilepsy (5,747 patient-
years of exposure).

Some of these could represent seizure-related deaths in which the seizure was not
observed, e.g., at night. This represents an incidence of 0.0035 deaths per patient-year. Although
this rate exceeds that expected in a healthy population matched for age and sex, it is within the
range of estimates for the incidence of sudden unexplained death in epilepsy (SUDEP) in
patients not receiving lamotrigine (ranging from 0.0005 for the general population of patients
with epilepsy, to 0.004 for a recently studied clinical trial population similar to that in the clinical
development program for immediate-release lamotrigine, to 0.005 for patients with refractory
epilepsy). Consequently, whether these figures are reassuring or suggest concern depends on the
comparability of the populations reported upon with the cohort receiving immediate-release
lamotrigine and the accuracy of the estimates provided. Probably most reassuring is the
similarity of estimated SUDEP rates in patients receiving immediate-release lamotrigine and
those receiving other AEDs, chemically unrelated to each other, that underwent clinical testing in
similar populations. Importantly, that drug is chemically unrelated to lamotrigine. This evidence
suggests, although it certainly does not prove, that the high SUDEP rates reflect population rates,
not a drug effect.

5.11 Addition of LAMICTAL XR to a Multidrug Regimen That Includes Valproate

Because valproate reduces the clearance of lamotrigine, the dosage of lamotrigine in the
presence of valproate is less than half of that required in its absence [see Dosage and
Administration (2.1, 2.2), Drug Interactions (7)].

5.12 Binding in the Eye and Other Melanin-Containing Tissues

Because lamotrigine binds to melanin, it could accumulate in melanin-rich tissues over
time. This raises the possibility that lamotrigine may cause toxicity in these tissues after
extended use. Although ophthalmological testing was performed in 1 controlled clinical trial, the
testing was inadequate to exclude subtle effects or injury occurring after long-term exposure. Moreover, the capacity of available tests to detect potentially adverse consequences, if any, of lamotrigine’s binding to melanin is unknown.

Accordingly, although there are no specific recommendations for periodic ophthalmological monitoring, prescribers should be aware of the possibility of long-term ophthalmologic effects.

5.13 Laboratory Tests

**Plasma Concentrations of Lamotrigine:** The value of monitoring plasma concentrations of lamotrigine in patients treated with LAMICTAL XR has not been established. Because of the possible pharmacokinetic interactions between lamotrigine and other drugs, including AEDs (see Table 6), monitoring of the plasma levels of lamotrigine and concomitant drugs may be indicated, particularly during dosage adjustments. In general, clinical judgment should be exercised regarding monitoring of plasma levels of lamotrigine and other drugs and whether or not dosage adjustments are necessary.

**Effect on Leukocytes:** Treatment with LAMICTAL XR caused an increased incidence of subnormal (below the reference range) values in some hematology analytes (e.g., total white blood cells, monocytes). The treatment effect (LAMICTAL XR % - Placebo %) incidence of subnormal counts was 3% for total white blood cells and 4% for monocytes.

6 ADVERSE REACTIONS

The following adverse reactions are described in more detail in the *Warnings and Precautions* section of the label:

- Serious skin rashes [see *Warnings and Precautions (5.1)*]
- Multiorgan hypersensitivity reactions and organ failure [see *Warnings and Precautions (5.2)*]
- Blood dyscrasias [see *Warnings and Precautions (5.3)*]
- Suicidal behavior and ideation [see *Warnings and Precautions (5.4)*]
- Aseptic meningitis [see *Warnings and Precautions (5.5)*]
- Withdrawal seizures [see *Warnings and Precautions (5.8)*]
- Status epilepticus [see *Warnings and Precautions (5.9)*]
- Sudden unexplained death in epilepsy [see *Warnings and Precautions (5.10)*]

6.1 Clinical Trial Experience With LAMICTAL XR for Treatment of Primary Generalized Tonic-Clonic and Partial-Onset Seizures

Most Common Adverse Reactions in Clinical Trials: *Adjunctive Therapy in Patients With Epilepsy:* Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

LAMICTAL XR has been evaluated for safety in patients aged 13 years and older with PGTC and partial-onset seizures. The most commonly observed adverse reactions in these 2 double-blind, placebo-controlled trials of adjunctive therapy with LAMICTAL XR were, in
order of decreasing incidence (treatment difference between LAMICTAL XR and placebo ≥4%): dizziness, tremor/intention tremor, vomiting, and diplopia.

In these 2 trials, adverse reactions led to withdrawal of 4 (2%) patients in the group receiving placebo and 10 (5%) patients in the group receiving LAMICTAL XR. Dizziness was the most common reason for withdrawal in the group receiving LAMICTAL XR (5 patients [3%]). The next most common adverse reactions leading to withdrawal in 2 patients each (1%) were rash, headache, nausea, and nystagmus.

Table 4 displays the incidence of adverse reactions in these two 19-week, double-blind, placebo-controlled trials of patients with PGTC and partial onset seizures.

**Table 4. Adverse Reaction Incidence in Double-Blind, Placebo-Controlled Adjunctive Trials in Patients With Epilepsy (Adverse reactions ≥2% of patients treated with LAMICTAL XR and numerically more frequent than in the placebo group.)**

<table>
<thead>
<tr>
<th>Body System/Adverse Reaction</th>
<th>Percent of Patients Receiving Adjunctive LAMICTAL XR (n = 190)</th>
<th>Percent of Patients Receiving Adjunctive Placebo (n = 195)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>3</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diplopia</td>
<td>5</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Vision blurred</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Constipation</td>
<td>2</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia and fatigue</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Metabolic and nutritional disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>
Nervous system
- Dizziness: 14, 6
- Tremor and intention tremor: 6, 1
- Somnolence: 5, 3
- Cerebellar coordination and balance disorder: 3, 0
- Nystagmus: 2, <1

Psychiatric disorders
- Depression: 3, <1
- Anxiety: 3, 0

Respiratory, thoracic, and mediastinal disorders
- Pharyngolaryngeal pain: 3, 2

Vascular disorder
- Hot flush: 2, 0

Note: In these trials the incidence of nonserious rash was 2% for LAMICTAL XR and 3% for placebo. In clinical trials evaluating immediate-release lamotrigine, the rate of serious rash was 0.3% in adults on adjunctive therapy for epilepsy [see Boxed Warning].

Adverse reactions were also analyzed to assess the incidence of the onset of an event in the titration period, and in the maintenance period, and if adverse reactions occurring in the titration phase persisted in the maintenance phase.

The incidence for many adverse reactions caused by treatment with LAMICTAL XR was increased relative to placebo (i.e., treatment difference between LAMICTAL XR and placebo ≥2%) in either the titration or maintenance phases of the trial. During the titration phase, an increased incidence (shown in descending order of % treatment difference) was observed for diarrhea, nausea, vomiting, somnolence, vertigo, myalgia, hot flush, and anxiety. During the maintenance phase, an increased incidence was observed for dizziness, tremor, and diplopia. Some adverse reactions developing in the titration phase were notable for persisting (>7 days) into the maintenance phase. These persistent adverse reactions included somnolence and dizziness.

There were inadequate data to evaluate the effect of dose and/or concentration on the incidence of adverse reactions because, although patients were randomized to different target doses based upon concomitant AEDs, the plasma exposure was expected to be generally similar among all patients receiving different doses. However, in a randomized, parallel trial comparing placebo with 300 and 500 mg/day of immediate-release lamotrigine, the incidence of the most common adverse reactions (≥5%) such as ataxia, blurred vision, diplopia, and dizziness were dose related. Less common adverse reactions (<5%) were not assessed for dose-response relationships.
Monotherapy in Patients With Epilepsy: Adverse reactions observed in this trial were generally similar to those observed and attributed to drug in adjunctive and monotherapy immediate-release lamotrigine and adjunctive LAMICTAL XR placebo-controlled trials. Only 2 adverse events, nasopharyngitis and upper respiratory tract infection, were observed at a rate of ≥3% and not reported at a similar rate in previous trials. Because this trial did not include a placebo control group, causality could not be established [see Clinical Studies (14.3)].

6.2 Other Adverse Reactions Observed During the Clinical Development of Immediate-Release Lamotrigine

All reported reactions are included except those already listed in the previous tables or elsewhere in the labeling, those too general to be informative, and those not reasonably associated with the use of the drug.

Adjunctive Therapy in Adults With Epilepsy: In addition to the adverse reactions reported above from the development of LAMICTAL XR, the following adverse reactions with an uncertain relationship to lamotrigine were reported during the clinical development of immediate-release lamotrigine for treatment of epilepsy in adults. These reactions occurred in ≥2% of patients receiving immediate-release lamotrigine and more frequently than in the placebo group.

Body as a Whole: Headache, flu syndrome, fever, neck pain.

Musculoskeletal: Arthralgia.

Nervous: Insomnia, convulsion, irritability, speech disorder, concentration disturbance.

Respiratory: Pharyngitis, cough increased.

Skin and Appendages: Rash, pruritus.

Urogenital (female patients only): Vaginitis, amenorrhea, dysmenorrhea.

Monotherapy in Adults With Epilepsy: In addition to the adverse reactions reported above from the development of LAMICTAL XR, the following adverse reactions with an uncertain relationship to lamotrigine were reported during the clinical development of immediate-release lamotrigine for treatment of epilepsy in adults. These reactions occurred in >2% of patients receiving immediate-release lamotrigine and more frequently than in the placebo group.

Body as a Whole: Chest pain.

Digestive: Rectal hemorrhage, peptic ulcer.

Metabolic and Nutritional: Weight decrease, peripheral edema.

Nervous: Hypesthesia, libido increase, decreased reflexes.

Respiratory: Epistaxis, dyspnea.

Skin and Appendages: Contact dermatitis, dry skin, sweating.

Special Senses: Vision abnormality.

Urogenital (female patients only): Dysmenorrhea.
Other Clinical Trial Experience: Immediate-release lamotrigine has been administered to 6,694 individuals for whom complete adverse reaction data was captured during all clinical trials, only some of which were placebo controlled.

Adverse reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse reactions are defined as those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients; rare adverse reactions are those occurring in fewer than 1/1,000 patients.

Cardiovascular System: Infrequent: Hypertension, palpitations, postural hypotension, syncope, tachycardia, vasodilation.

Dermatological: Infrequent: Acne, alopecia, hirsutism, maculopapular rash, urticaria.

Rare: Leukoderma, multiforme erythema, petechial rash, pustular rash.

Digestive System: Infrequent: Dysphagia, liver function tests abnormal, mouth ulceration. Rare: Gastrointestinal hemorrhage, hemorrhagic colitis, hepatitis, melena and stomach ulcer.

Endocrine System: Rare: Goiter, hypothyroidism.

Hematologic and Lymphatic System: Infrequent: Ecchymosis, leukopenia. Rare: Anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, lymphocytosis, macrocytic anemia, petechia, thrombocytopenia.

Metabolic and Nutritional Disorders: Infrequent: Aspartate transaminase increased.

Rare: Alcohol intolerance, alkaline phosphatase increase, alanine transaminase increase, bilirubinemia, gamma glutamyl transpeptidase increase, hyperglycemia.

Musculoskeletal System: Rare: Muscle atrophy, pathological fracture, tendinous contracture.

Nervous System: Frequent: Confusion. Infrequent: Akathisia, apathy, aphasia, depersonalization, dysarthria, dyskinesia, euphoria, hallucinations, hostility, hyperkinesia, hypertonia, libido decreased, memory decrease, mind racing, movement disorder, myoclonus, panic attack, paranoid reaction, personality disorder, psychosis, stupor. Rare: Choreaathetosis, delirium, delusions, dysphoria, dystonia, extrapyramidal syndrome, hemiplegia, hyperalgesia, hyperesthesia, hypokinesia, hypotonia, manic depression reaction, neuralgia, paralysis, peripheral neuritis.

Respiratory System: Rare: Hiccups, hyperventilation.

Special Senses: Frequent: Amblyopia. Infrequent: Abnormality of accommodation, conjunctivitis, dry eyes, ear pain, photophobia, taste perversion, tinnitus. Rare: Deafness, lacrimation disorder, oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, visual field defect.

6.3 Postmarketing Experience With Immediate-Release Lamotrigine

The following adverse events (not listed above in clinical trials or other sections of the prescribing information) have been identified during postapproval use of immediate-release lamotrigine. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Blood and Lymphatic:** Agranulocytosis, hemolytic anemia, lymphadenopathy not associated with hypersensitivity disorder.

**Gastrointestinal:** Esophagitis.

**Hepatobiliary Tract and Pancreas:** Pancreatitis.

**Immunologic:** Lupus-like reaction, vasculitis.

**Lower Respiratory:** Apnea.

**Musculoskeletal:** Rhabdomyolysis has been observed in patients experiencing hypersensitivity reactions.

**Neurology:** Exacerbation of Parkinsonian symptoms in patients with pre-existing Parkinson’s disease, tics.

**Non-site Specific:** Progressive immunosuppression.

7 DRUG INTERACTIONS

Significant drug interactions with lamotrigine are summarized in Table 5. Additional details of these drug interaction studies, which were conducted using immediate-release lamotrigine, are provided in the Clinical Pharmacology section [see Clinical Pharmacology (12.3)].
### Table 5. Established and Other Potentially Significant Drug Interactions

<table>
<thead>
<tr>
<th>Concomitant Drug</th>
<th>Effect on Concentration of Lamotrigine or Concomitant Drug</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td>↓ lamotrigine  ↓ levonorgestrel</td>
<td>Decreased lamotrigine concentrations approximately 50%. Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td>Carbamazepine and carbamazepine epoxide</td>
<td>↓ lamotrigine  ? carbamazepine epoxide</td>
<td>Addition of carbamazepine decreases lamotrigine concentration approximately 40%. May increase carbamazepine epoxide levels.</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentration approximately 50%.</td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine AUC approximately 32%.</td>
</tr>
<tr>
<td>Phenobarbital/primidone</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr>
<td>Rifampin</td>
<td>↓ lamotrigine</td>
<td>Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr>
<td>Valproate</td>
<td>↑ lamotrigine  ? valproate</td>
<td>Increased lamotrigine concentrations slightly more than 2-fold. There are conflicting study results regarding effect of lamotrigine on valproate concentrations: 1) a mean 25% decrease in valproate concentrations in healthy volunteers, 2) no change in valproate concentrations in controlled clinical trials in patients with epilepsy.</td>
</tr>
</tbody>
</table>

↓ = Decreased (induces lamotrigine glucuronidation).  
↑ = Increased (inhibits lamotrigine glucuronidation).  
? = Conflicting data.
USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category C. There are no adequate and well-controlled trials in pregnant women. In animal studies, lamotrigine was developmentally toxic at doses lower than those administered clinically. LAMICTAL XR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

When lamotrigine was administered to pregnant mice, rats, or rabbits during the period of organogenesis (oral doses of up to 125, 25, and 30 mg/kg, respectively), reduced fetal body weight and increased incidences of fetal skeletal variations were seen in mice and rats at doses that were also maternally toxic. The no-effect doses for embryo-fetal developmental toxicity in mice, rats, and rabbits (75, 6.25, and 30 mg/kg, respectively) are similar to (mice and rabbits) or less than the human dose of 400 mg/day on a body surface area (mg/m²) basis.

In a study in which pregnant rats were administered lamotrigine (oral doses of 5 or 25 mg/kg) during the period of organogenesis and offspring were evaluated postnatally, behavioral abnormalities were observed in exposed offspring at both doses. The lowest effect dose for developmental neurotoxicity in rats is less than the human dose of 400 mg/day on a mg/m² basis. Maternal toxicity was observed at the higher dose tested.

When pregnant rats were administered lamotrigine (oral doses of 5, 10, or 20 mg/kg) during the latter part of gestation, increased offspring mortality (including stillbirths) was seen at all doses. The lowest effect dose for peri/postnatal developmental toxicity in rats is less than the human dose of 400 mg/day on a mg/m² basis. Maternal toxicity was observed at the 2 highest doses tested.

Lamotrigine decreases fetal folate concentrations in rats, an effect known to be associated with adverse pregnancy outcomes in animals and humans.

Nonteratogenic Effects: As with other AEDs, physiological changes during pregnancy may affect lamotrigine concentrations and/or therapeutic effect. There have been reports of decreased lamotrigine concentrations during pregnancy and restoration of pre-partum concentrations after delivery. Dosage adjustments may be necessary to maintain clinical response.

Pregnancy Registry: To provide information regarding the effects of in utero exposure to LAMICTAL XR, physicians are advised to recommend that pregnant patients taking LAMICTAL XR enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334 and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org.

8.2 Labor and Delivery

The effect of LAMICTAL XR on labor and delivery in humans is unknown.

8.3 Nursing Mothers

Lamotrigine is present in milk from lactating women taking LAMICTAL XR. Data from multiple small studies indicate that lamotrigine plasma levels in human milk-fed infants have
Neonates and young infants are at risk for high serum levels because maternal serum and milk levels can rise to high levels postpartum if lamotrigine dosage has been increased during pregnancy but not later reduced to the pre-pregnancy dosage. Lamotrigine exposure is further increased due to the immaturity of the infant glucuronidation capacity needed for drug clearance. Events including apnea, drowsiness, and poor sucking have been reported in infants who have been human milk-fed by mothers using lamotrigine; whether or not these events were caused by lamotrigine is unknown. Human milk-fed infants should be closely monitored for adverse events resulting from lamotrigine. Measurement of infant serum levels should be performed to rule out toxicity if concerns arise. Human milk-feeding should be discontinued in infants with lamotrigine toxicity. Caution should be exercised when LAMICTAL XR is administered to a nursing woman.

8.4 Pediatric Use

LAMICTAL XR is indicated for adjunctive therapy for PGTC and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. Safety and effectiveness of LAMICTAL XR for any use in patients younger than 13 years have not been established.

Immediate-release lamotrigine is indicated for adjunctive therapy in patients aged 2 years and older for partial-onset seizures, the generalized seizures of Lennox-Gastaut syndrome, and PGTC seizures.

Safety and efficacy of immediate-release lamotrigine used as adjunctive treatment for partial-onset seizures were not demonstrated in a small, randomized, double-blind, placebo-controlled withdrawal trial in very young pediatric patients (aged 1 to 24 months). Immediate-release lamotrigine was associated with an increased risk for infectious adverse reactions (lamotrigine 37%, placebo 5%), and respiratory adverse reactions (lamotrigine 26%, placebo 5%). Infectious adverse reactions included bronchiolitis, bronchitis, ear infection, eye infection, otitis externa, pharyngitis, urinary tract infection, and viral infection. Respiratory adverse reactions included nasal congestion, cough, and apnea.

In a juvenile animal study in which lamotrigine (oral doses of 5, 15, or 30 mg/kg) was administered to young rats (postnatal days 7 to 62), decreased viability and growth were seen at the highest dose tested and long-term behavioral abnormalities (decreased locomotor activity, increased reactivity, and learning deficits in animals tested as adults) were observed at the 2 highest doses. The no-effect dose for adverse effects on neurobehavioral development is less than the human dose of 400 mg/day on a mg/m² basis.

8.5 Geriatric Use

Clinical trials of LAMICTAL XR for epilepsy did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients or exhibit a different safety profile than that of younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
8.6 Patients With Hepatic Impairment

Experience in patients with hepatic impairment is limited. Based on a clinical pharmacology study with immediate-release lamotrigine in 24 subjects with mild, moderate, and severe liver impairment [see Clinical Pharmacology (12.3)], the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without ascites and 50% in patients with severe liver impairment with ascites. Escalation and maintenance doses may be adjusted according to clinical response [see Dosage and Administration (2.1)].

8.7 Patients With Renal Impairment

Lamotrigine is metabolized mainly by glucuronic acid conjugation, with the majority of the metabolites being recovered in the urine. In a small study comparing a single dose of immediate-release lamotrigine in subjects with varying degrees of renal impairment with healthy volunteers, the plasma half-life of lamotrigine was approximately twice as long in the subjects with chronic renal failure [see Clinical Pharmacology (12.3)].

Initial doses of LAMICTAL XR should be based on patients’ AED regimens; reduced maintenance doses may be effective for patients with significant renal impairment. Few patients with severe renal impairment have been evaluated during chronic treatment with lamotrigine. Because there is inadequate experience in this population, LAMICTAL XR should be used with caution in these patients [see Dosage and Administration (2.1)].

10 OVERDOSE

10.1 Human Overdose Experience

Overdoses involving quantities up to 15 g have been reported for immediate-release lamotrigine, some of which have been fatal. Overdose has resulted in ataxia, nystagmus, seizures (including tonic-clonic seizures), decreased level of consciousness, coma, and intraventricular conduction delay.

10.2 Management of Overdose

There are no specific antidotes for lamotrigine. Following a suspected overdose, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, emesis should be induced; usual precautions should be taken to protect the airway. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood. In 6 renal failure patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis during a 4-hour session. A Poison Control Center should be contacted for information on the management of overdosage of LAMICTAL XR.

11 DESCRIPTION

LAMICTAL XR (lamotrigine), an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine’s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, its molecular formula is C$_9$H$_7$N$_5$Cl$_2$, and its molecular weight is
Lamotrigine is a white to pale cream-colored powder and has a pKa of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is:

![structural_formula]

LAMICTAL XR Extended-Release Tablets are supplied for oral administration as 25-mg (yellow with white center), 50-mg (green with white center), 100-mg (orange with white center), 200-mg (blue with white center), 250-mg (purple with white center), and 300-mg (gray with white center) tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: glycerol monostearate, hypromellose, lactose monohydrate; magnesium stearate; methacrylic acid copolymer dispersion, polyethylene glycol 400, polysorbate 80, silicon dioxide (25- and 50-mg tablets only), titanium dioxide, triethyl citrate, carmine (250-mg tablet only), iron oxide black (50-, 250-, and 300-mg tablets only), iron oxide yellow (25-, 50-, and 100-mg tablets only), iron oxide red (100-mg tablet only), FD&C Blue No. 2 Aluminum Lake (200- and 250-mg tablets only). Tablets are printed with edible black ink.

LAMICTAL XR Extended-Release Tablets contain a modified-release eroding formulation as the core. The tablets are coated with a clear enteric coat and have an aperture drilled through the coats on both faces of the tablet (DiffCORE™) to enable a controlled release of drug in the acidic environment of the stomach. The combination of this and the modified-release core are designed to control the dissolution rate of lamotrigine over a period of approximately 12 to 15 hours, leading to a gradual increase in serum lamotrigine levels.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known.

One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate).
Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity:
Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices nor NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC$_{50}$ for lamotrigine effects on NMDA-induced currents (in the presence of 3 µM of glycine) in cultured hippocampal neurons exceeded 100 µM.

12.2 Pharmacodynamics

Folate Metabolism: In vitro, lamotrigine inhibited dihydrofolate reductase, the enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may interfere with the biosynthesis of nucleic acids and proteins. When oral daily doses of lamotrigine were given to pregnant rats during organogenesis, fetal, placental, and maternal folate concentrations were reduced. Significantly reduced concentrations of folate are associated with teratogenesis [see Use in Specific Populations (8.1)]. Folate concentrations were also reduced in male rats given repeated oral doses of lamotrigine. Reduced concentrations were partially returned to normal when supplemented with folinic acid.

Cardiovascular: In dogs, lamotrigine is extensively metabolized to a 2-N-methyl metabolite. This metabolite causes dose-dependent prolongation of the PR interval, widening of the QRS complex, and, at higher doses, complete AV conduction block. Similar cardiovascular effects are not anticipated in humans because only trace amounts of the 2-N-methyl metabolite (<0.6% of lamotrigine dose) have been found in human urine [see Clinical Pharmacology (12.3)]. However, it is conceivable that plasma concentrations of this metabolite could be increased in patients with a reduced capacity to glucuronidate lamotrigine (e.g., in patients with liver disease, patients taking concomitant medications that inhibit glucuronidation).

12.3 Pharmacokinetics

In comparison with immediate-release lamotrigine, the plasma lamotrigine levels following administration of LAMICTAL XR are not associated with any significant changes in trough plasma concentrations, and are characterized by lower peaks, longer time to peaks, and lower peak-to-trough fluctuation, as described in detail below.

Absorption: Lamotrigine is absorbed after oral administration with negligible first-pass metabolism. The bioavailability of lamotrigine is not affected by food.

In an open-label, crossover study of 44 subjects with epilepsy receiving concomitant AEDs, the steady-state pharmacokinetics of lamotrigine were compared following administration of equivalent total doses of LAMICTAL XR given once daily with those of lamotrigine immediate-release given twice daily. In this study, the median time to peak concentration (T$_{\text{max}}$) following administration of LAMICTAL XR was 4 to 6 hours in subjects taking carbamazepine, phenytoin, phenobarbital, or primidone; 9 to 11 hours in subjects taking valproate; and 6 to 10 hours in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. In comparison, the median T$_{\text{max}}$ following administration of immediate-release lamotrigine was between 1 and 1.5 hours.
The steady-state trough concentrations for extended-release lamotrigine were similar to or higher than those of immediate-release lamotrigine depending on concomitant AED (Table 6). A mean reduction in the lamotrigine $C_{\text{max}}$ by 11% to 29% was observed for LAMICTAL XR compared with immediate-release lamotrigine, resulting in a decrease in the peak-to-trough fluctuation in serum lamotrigine concentrations. However, in some subjects receiving enzyme-inducing AEDs, a reduction in $C_{\text{max}}$ of 44% to 77% was observed. The degree of fluctuation was reduced by 17% in subjects taking enzyme-inducing AEDs; 34% in subjects taking valproate; and 37% in subjects taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. LAMICTAL XR and immediate-release lamotrigine regimens were similar with respect to area under the curve (AUC, a measure of the extent of bioavailability) for subjects receiving AEDs other than those known to induce the metabolism of lamotrigine. The relative bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-release lamotrigine in subjects receiving enzyme-inducing AEDs. However, a reduction in exposure of up to 70% was observed in some subjects in this group when they switched to LAMICTAL XR. Therefore, doses may need to be adjusted in some patients based on therapeutic response.

<table>
<thead>
<tr>
<th>Concomitant Antiepileptic Drug</th>
<th>$AUC_{(0-24\text{ss})}$</th>
<th>$C_{\text{max}}$</th>
<th>$C_{\text{min}}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enzyme-inducing antiepileptic drugs$^a$</td>
<td>0.79 (0.69, 0.90)</td>
<td>0.71 (0.61, 0.82)</td>
<td>0.99 (0.89, 1.09)</td>
</tr>
<tr>
<td>Valproate</td>
<td>0.94 (0.81, 1.08)</td>
<td>0.88 (0.75, 1.03)</td>
<td>0.99 (0.88, 1.10)</td>
</tr>
<tr>
<td>Antiepileptic drugs other than enzyme-inducing antiepileptic drugs$^a$ or valproate</td>
<td>1.00 (0.88, 1.14)</td>
<td>0.89 (0.78, 1.03)</td>
<td>1.14 (1.03, 1.25)</td>
</tr>
</tbody>
</table>

$^a$ Enzyme-inducing antiepileptic drugs include carbamazepine, phenytoin, phenobarbital, and primidone.

**Dose Proportionality:** In healthy volunteers not receiving any other medications and given LAMICTAL XR once daily, the systemic exposure to lamotrigine increased in direct proportion to the dose administered over the range of 50 to 200 mg. At doses between 25 and 50 mg, the increase was less than dose proportional, with a 2-fold increase in dose resulting in an approximately 1.6-fold increase in systemic exposure.

**Distribution:** Estimates of the mean apparent volume of distribution ($Vd/F$) of lamotrigine following oral administration ranged from 0.9 to 1.3 L/kg. $Vd/F$ is independent of dose and is similar following single and multiple doses in both patients with epilepsy and in healthy volunteers.
Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials). Because lamotrigine is not highly bound to plasma proteins, clinically significant interactions with other drugs through competition for protein binding sites are unlikely. The binding of lamotrigine to plasma proteins did not change in the presence of therapeutic concentrations of phenytoin, phenobarbital, or valproate. Lamotrigine did not displace other AEDs (carbamazepine, phenytoin, phenobarbital) from protein-binding sites.

Metabolism: Lamotrigine is metabolized predominantly by glucuronic acid conjugation; the major metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of 240 mg of 14C-lamotrigine (15 µCi) to 6 healthy volunteers, 94% was recovered in the urine and 2% was recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and other unidentified minor metabolites (4%).

Enzyme Induction: The effects of lamotrigine on the induction of specific families of mixed-function oxidase isozymes have not been systematically evaluated. Following multiple administrations (150 mg twice daily) to normal volunteers taking no other medications, lamotrigine induced its own metabolism, resulting in a 25% decrease in t½ and a 37% increase in CL/F at steady state compared with values obtained in the same volunteers following a single dose. Evidence gathered from other sources suggests that self-induction by lamotrigine may not occur when lamotrigine is given as adjunctive therapy in patients receiving enzyme-inducing drugs such as carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir [see Drug Interactions (7)].

Elimination: The elimination half-life and apparent clearance of lamotrigine following oral administration of immediate-release lamotrigine to adult subjects with epilepsy and healthy volunteers is summarized in Table 7. Half-life and apparent oral clearance vary depending on concomitant AEDs. Since the half-life of lamotrigine following administration of single doses of immediate-release lamotrigine is comparable with that observed following administration of LAMICTAL XR, similar changes in the half-life of lamotrigine would be expected for LAMICTAL XR.
Table 7. Mean Pharmacokinetic Parameters\(^a\) of Immediate-Release Lamotrigine in Healthy Volunteers and Adult Subjects With Epilepsy

<table>
<thead>
<tr>
<th>Adult Study Population</th>
<th>Number of Subjects</th>
<th>(t_{\frac{1}{2}}): Elimination Half-life (h)</th>
<th>CL/F: Apparent Plasma Clearance (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy volunteers taking no other medications:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>179</td>
<td>32.8 (14.0-103.0)</td>
<td>0.44 (0.12-1.10)</td>
</tr>
<tr>
<td>Multiple-dose lamotrigine</td>
<td>36</td>
<td>25.4 (11.6-61.6)</td>
<td>0.58 (0.24-1.15)</td>
</tr>
<tr>
<td>Healthy volunteers taking valproate:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>6</td>
<td>48.3 (31.5-88.6)</td>
<td>0.30 (0.14-0.42)</td>
</tr>
<tr>
<td>Multiple-dose lamotrigine</td>
<td>18</td>
<td>70.3 (41.9-113.5)</td>
<td>0.18 (0.12-0.33)</td>
</tr>
<tr>
<td>Subjects with epilepsy taking valproate only:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>4</td>
<td>58.8 (30.5-88.8)</td>
<td>0.28 (0.16-0.40)</td>
</tr>
<tr>
<td>Subjects with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone(^b) plus valproate:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>25</td>
<td>27.2 (11.2-51.6)</td>
<td>0.53 (0.27-1.04)</td>
</tr>
<tr>
<td>Subjects with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone(^b)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>24</td>
<td>14.4 (6.4-30.4)</td>
<td>1.10 (0.51-2.22)</td>
</tr>
<tr>
<td>Multiple-dose lamotrigine</td>
<td>17</td>
<td>12.6 (7.5-23.1)</td>
<td>1.21 (0.66-1.82)</td>
</tr>
</tbody>
</table>

\(^a\) The majority of parameter means determined in each study had coefficients of variation between 20% and 40% for half-life and CL/F and between 30% and 70% for \(T_{\text{max}}\). The overall mean values were calculated from individual study means that were weighted based on the number of volunteers/subjects in each study. The numbers in parentheses below each parameter mean represent the range of individual volunteer/subject values across studies.
Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and other drugs, such as rifampin and protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir, that induce lamotrigine glucuronidation have also been shown to increase the apparent clearance of lamotrigine [see Drug Interactions (7)].

**Drug Interactions:** The apparent clearance of lamotrigine is affected by the coadministration of certain medications [see Warnings and Precautions (5.7, 5.11), Drug Interactions (7)].

The net effects of drug interactions with lamotrigine, based on drug interaction studies using immediate-release lamotrigine, are summarized in Tables 5 and 8, followed by details of the drug interaction studies below.

**Table 8. Summary of Drug Interactions With Lamotrigine**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug Plasma Concentration With Adjunctive Lamotrigine&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Lamotrigine Plasma Concentration With Adjunctive Drugs&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral contraceptives (e.g., ethinylestradiol/levonorgestrel)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>↔&lt;sup&gt;d&lt;/sup&gt;</td>
<td>↓</td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td>↔&lt;sup&gt;e&lt;/sup&gt;</td>
<td>↓</td>
</tr>
<tr>
<td>Bupropion</td>
<td>Not assessed</td>
<td>↔</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Carbamazepine epoxide&lt;sup&gt;f&lt;/sup&gt;</td>
<td>?</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Felbamate</td>
<td>Not assessed</td>
<td>↔</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>Not assessed</td>
<td>↔</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Lithium</td>
<td>↔</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>↔&lt;sup&gt;e&lt;/sup&gt;</td>
<td>↓</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>↔</td>
<td>↔&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>10-Monohydroxy oxcarbazepine metabolite&lt;sup&gt;h&lt;/sup&gt;</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Phenobarbital/primidone</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Rifampin</td>
<td>Not assessed</td>
<td>↓</td>
</tr>
<tr>
<td>Risperidone</td>
<td>↔</td>
<td>Not assessed</td>
</tr>
<tr>
<td>9-hydroxyrisperidone&lt;sup&gt;i&lt;/sup&gt;</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Topiramate</td>
<td>↔&lt;sup&gt;j&lt;/sup&gt;</td>
<td>↔</td>
</tr>
<tr>
<td>Valproate</td>
<td>↓</td>
<td>↑</td>
</tr>
</tbody>
</table>
Valproate + phenytoin and/or carbamazepine
Zonisamide

<table>
<thead>
<tr>
<th></th>
<th>Not assessed</th>
<th>↔</th>
</tr>
</thead>
</table>

a. From adjunctive clinical trials and volunteer trials.
b. Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteer trials.
c. The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.
d. Modest decrease in levonorgestrel.
e. Compared to historical controls.
f. Not administered, but an active metabolite of carbamazepine.
g. Slight decrease, not expected to be clinically relevant.
h. Not administered, but an active metabolite of oxcarbazepine.
i. Not administered, but an active metabolite of risperidone.
j. Slight increase, not expected to be clinically relevant.

↔ = No significant effect.
? = Conflicting data.

Estrogen-Containing Oral Contraceptives: In 16 female volunteers, an oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel increased the apparent clearance of lamotrigine (300 mg/day) by approximately 2-fold with mean decreases in AUC of 52% and in C<sub>max</sub> of 39%. In this study, trough serum lamotrigine concentrations gradually increased and were approximately 2-fold higher on average at the end of the week of the inactive hormone preparation compared with trough lamotrigine concentrations at the end of the active hormone cycle.

Gradual transient increases in lamotrigine plasma levels (approximate 2-fold increase) occurred during the week of inactive hormone preparation (pill-free week) for women not also taking a drug that increased the clearance of lamotrigine (carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation) [see Drug Interactions (7)]. The increase in lamotrigine plasma levels will be greater if the dose of LAMICTAL XR is increased in the few days before or during the pill-free week. Increases in lamotrigine plasma levels could result in dose-dependent adverse reactions.

In the same study, coadministration of lamotrigine (300 mg/day) in 16 female volunteers did not affect the pharmacokinetics of the ethinylestradiol component of the oral contraceptive preparation. There were mean decreases in the AUC and C<sub>max</sub> of the levonorgestrel component of 19% and 12%, respectively. Measurement of serum progesterone indicated that there was no hormonal evidence of ovulation in any of the 16 volunteers, although measurement of serum...
FSH, LH, and estradiol indicated that there was some loss of suppression of the hypothalamic-pituitary-ovarian axis.

The effects of doses of lamotrigine other than 300 mg/day have not been systematically evaluated in controlled clinical trials.

The clinical significance of the observed hormonal changes on ovulatory activity is unknown. However, the possibility of decreased contraceptive efficacy in some patients cannot be excluded. Therefore, patients should be instructed to promptly report changes in their menstrual pattern (e.g., break-through bleeding).

Dosage adjustments may be necessary for women receiving estrogen-containing oral contraceptive preparations [see Dosage and Administration (2.1)].

Other Hormonal Contraceptives or Hormone Replacement Therapy: The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of LAMICTAL XR in the presence of progestogens alone will likely not be needed.

Atazanavir/Ritonavir: In a study in healthy volunteers, daily doses of atazanavir/ritonavir (300 mg/100 mg) reduced the plasma AUC and C_max of lamotrigine (single 100-mg dose) by an average of 32% and 6%, respectively, and shortened the elimination half-lives by 27%. In the presence of atazanavir/ritonavir (300 mg/100 mg), the metabolite-to-lamotrigine ratio was increased from 0.45 to 0.71 consistent with induction of glucuronidation. The pharmacokinetics of atazanavir/ritonavir were similar in the presence of concomitant lamotrigine to the historical data of the pharmacokinetics in the absence of lamotrigine.

Bupropion: The pharmacokinetics of a 100-mg single dose of lamotrigine in healthy volunteers (n = 12) were not changed by coadministration of bupropion sustained-release formulation (150 mg twice daily) starting 11 days before lamotrigine.

Carbamazepine: Lamotrigine has no appreciable effect on steady-state carbamazepine plasma concentration. Limited clinical data suggest there is a higher incidence of dizziness, diplopia, ataxia, and blurred vision in patients receiving carbamazepine with lamotrigine than in patients receiving other AEDs with lamotrigine [see Adverse Reactions (6.1)]. The mechanism of this interaction is unclear. The effect of lamotrigine on plasma concentrations of carbamazepine-epoxide is unclear. In a small subset of patients (n = 7) studied in a placebo-controlled trial, lamotrigine had no effect on carbamazepine-epoxide plasma concentrations, but in a small, uncontrolled study (n = 9), carbamazepine-epoxide levels increased.

The addition of carbamazepine decreases lamotrigine steady-state concentrations by approximately 40%.

Esomeprazole: In a study of 30 subjects, coadministration of LAMICTAL XR with esomeprazole resulted in no significant change in lamotrigine levels and a small decrease in T_max.

The levels of gastric pH were not altered compared with pre-lamotrigine dosing.
Felbamate: In a trial in 21 healthy volunteers, coadministration of felbamate (1,200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.

Folate Inhibitors: Lamotrigine is a weak inhibitor of dihydrofolate reductase. Prescribers should be aware of this action when prescribing other medications that inhibit folate metabolism.

Gabapentin: Based on a retrospective analysis of plasma levels in 34 subjects who received lamotrigine both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine.

Levetiracetam: Potential drug interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents during placebo-controlled clinical trials. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.

Lithium: The pharmacokinetics of lithium were not altered in healthy subjects (n = 20) by coadministration of lamotrigine (100 mg/day) for 6 days.

Lopinavir/Ritonavir: The addition of lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily) decreased the AUC, $C_{\text{max}}$, and elimination half-life of lamotrigine by approximately 50% to 55.4% in 18 healthy subjects. The pharmacokinetics of lopinavir/ritonavir were similar with concomitant lamotrigine, compared to that in historical controls.

Olanzapine: The AUC and $C_{\text{max}}$ of olanzapine were similar following the addition of olanzapine (15 mg once daily) to lamotrigine (200 mg once daily) in healthy male volunteers (n = 16) compared with the AUC and $C_{\text{max}}$ in healthy male volunteers receiving olanzapine alone (n = 16).

In the same trial, the AUC and $C_{\text{max}}$ of lamotrigine were reduced on average by 24% and 20%, respectively, following the addition of olanzapine to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. This reduction in lamotrigine plasma concentrations is not expected to be clinically relevant.

Oxcarbazepine: The AUC and $C_{\text{max}}$ of oxcarbazepine and its active 10-monohydroxy oxcarbazepine metabolite were not significantly different following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine (200 mg once daily) in healthy male volunteers (n = 13) compared with healthy male volunteers receiving oxcarbazepine alone (n = 13).

In the same trial, the AUC and $C_{\text{max}}$ of lamotrigine were similar following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. Limited clinical data suggest a higher incidence of headache, dizziness, nausea, and somnolence with coadministration of lamotrigine and oxcarbazepine compared with lamotrigine alone or oxcarbazepine alone.

Phenobarbital, Primidone: The addition of phenobarbital or primidone decreases lamotrigine steady-state concentrations by approximately 40%.
Phenytoin: Lamotrigine has no appreciable effect on steady-state phenytoin plasma concentrations in patients with epilepsy. The addition of phenytoin decreases lamotrigine steady-state concentrations by approximately 40%.

Pregabalin: Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg 3 times daily) administration. There are no pharmacokinetic interactions between lamotrigine and pregabalin.

Rifampin: In 10 male volunteers, rifampin (600 mg/day for 5 days) significantly increased the apparent clearance of a single 25-mg dose of lamotrigine by approximately 2-fold (AUC decreased by approximately 40%).

Risperidone: In a 14 healthy volunteers study, multiple oral doses of lamotrigine 400 mg daily had no clinically significant effect on the single-dose pharmacokinetics of risperidone 2 mg and its active metabolite 9-OH risperidone. Following the coadministration of risperidone 2 mg with lamotrigine, 12 of the 14 volunteers reported somnolence compared with 1 out of 20 when risperidone was given alone, and none when lamotrigine was administered alone.

Topiramate: Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of lamotrigine resulted in a 15% increase in topiramate concentrations.

Valproate: When lamotrigine was administered to healthy volunteers (n = 18) receiving valproate, the trough steady-state valproate plasma concentrations decreased by an average of 25% over a 3-week period, and then stabilized. However, adding lamotrigine to the existing therapy did not cause a change in valproate plasma concentrations in either adult or pediatric patients in controlled clinical trials.

The addition of valproate increased lamotrigine steady-state concentrations in normal volunteers by slightly more than 2-fold. In 1 trial, maximal inhibition of lamotrigine clearance was reached at valproate doses between 250 and 500 mg/day and did not increase as the valproate dose was further increased.

Zonisamide: In a study in 18 patients with epilepsy, coadministration of zonisamide (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day for 35 days) had no significant effect on the pharmacokinetics of lamotrigine.

Known Inducers or Inhibitors of Glucuronidation: Drugs other than those listed above have not been systematically evaluated in combination with lamotrigine. Since lamotrigine is metabolized predominately by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine, and doses of LAMICTAL XR may require adjustment based on clinical response.

Other: Results of in vitro experiments suggest that clearance of lamotrigine is unlikely to be reduced by concomitant administration of amitriptyline, clonazepam, clozapine, fluoxetine, haloperidol, lorazepam, phenelzine, sertraline, or trazodone.

Results of in vitro experiments suggest that lamotrigine does not reduce the clearance of drugs eliminated predominantly by CYP2D6.

Specific Populations: Subjects With Renal Impairment: Twelve volunteers with chronic renal failure (mean creatinine clearance: 13 mL/min, range: 6 to 23) and another 6
individuals undergoing hemodialysis were each given a single 100-mg dose of immediate-release
lamotrigine. The mean plasma half-lives determined in the study were 42.9 hours (chronic renal
failure), 13.0 hours (during hemodialysis), and 57.4 hours (between hemodialysis) compared
with 26.2 hours in healthy volunteers. On average, approximately 20% (range: 5.6 to 35.1) of the
amount of lamotrigine present in the body was eliminated by hemodialysis during a 4-hour
session [see Dosage and Administration (2.1)].

**Hepatic Disease:** The pharmacokinetics of lamotrigine following a single 100-mg
dose of immediate-release lamotrigine were evaluated in 24 subjects with mild, moderate, and
severe hepatic impairment (Child-Pugh Classification system) and compared with 12 subjects
without hepatic impairment. The subjects with severe hepatic impairment were without ascites
(n = 2) or with ascites (n = 5). The mean apparent clearances of lamotrigine in subjects with mild
(n = 12), moderate (n = 5), severe without ascites (n = 2), and severe with ascites (n = 5) liver
impairment were 0.30 ± 0.09, 0.24 ± 0.1, 0.21 ± 0.04, and 0.15 ± 0.09 mL/min/kg, respectively,
as compared with 0.37 ± 0.1 mL/min/kg in the healthy controls. Mean half-lives of lamotrigine
in subjects with mild, moderate, severe without ascites, and severe with ascites hepatic
impairment were 46 ± 20, 72 ± 44, 67 ± 11, and 100 ± 48 hours, respectively, as compared with
33 ± 7 hours in healthy controls [see Dosage and Administration (2.1)].

**Elderly:** The pharmacokinetics of lamotrigine following a single 150-mg dose of
immediate-release lamotrigine were evaluated in 12 elderly volunteers between the ages of 65
and 76 years (mean creatinine clearance: 61 mL/min, range: 33 to 108 mL/min). The mean
half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean
clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).

**Gender:** The clearance of lamotrigine is not affected by gender. However, during
dose escalation of immediate-release lamotrigine in 1 clinical trial in patients with epilepsy on a
stable dose of valproate (n = 77), mean trough lamotrigine concentrations unadjusted for weight
were 24% to 45% higher (0.3 to 1.7 mcg/mL) in females than in males.

**Race:** The apparent oral clearance of lamotrigine was 25% lower in non-Caucasians
than Caucasians.

**Pediatric Patients:** Safety and effectiveness of LAMICTAL XR for use in patients
younger than 13 years have not been established.

**13** **NONCLINICAL TOXICOLOGY**

**13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

No evidence of carcinogenicity was seen in mouse or rat following oral administration of
lamotrigine for up to 2 years at doses up to 30 mg/kg/day and 10 to 15 mg/kg/day in mouse and
rat, respectively. The highest doses tested are less than the human dose of 400 mg/day on a body
surface area (mg/m²) basis.

Lamotrigine was negative in in vitro gene mutation (Ames and mouse lymphoma tk)
assays and in elastogenicity (in vitro human lymphocyte and in vivo rat bone marrow) assays.
No evidence of impaired fertility was detected in rats given oral doses of lamotrigine up to 20 mg/kg/day. The highest dose tested is less than the human dose of 400 mg/day on a mg/m² basis.

14 CLINICAL STUDIES

14.1 Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures

The effectiveness of LAMICTAL XR as adjunctive therapy in subjects with PGTC seizures was established in a 19-week, international, multicenter, double-blind, randomized, placebo-controlled trial in 143 patients aged 13 years and older (n = 70 on LAMICTAL XR, n = 73 on placebo). Patients with at least 3 PGTC seizures during an 8-week baseline phase were randomized to 19 weeks of treatment with LAMICTAL XR or placebo added to their current AED regimen of up to 2 drugs. Patients were dosed on a fixed-dose regimen, with target doses ranging from 200 to 500 mg/day of LAMICTAL XR based on concomitant AEDs (target dose = 200 mg for valproate, 300 mg for AEDs not altering plasma lamotrigine levels, and 500 mg for enzyme-inducing AEDs).

The primary efficacy endpoint was percent change from baseline in PGTC frequency during the double-blind treatment phase. For the intent-to-treat population, the median percent reduction in PGTC seizure frequency was 75% in patients treated with LAMICTAL XR and 32% in patients treated with placebo, a difference that was statistically significant, defined as a 2-sided P value <0.05.

Figure 1 presents the percentage of patients (X-axis) with a percent reduction in PGTC seizure frequency (responder rate) from baseline through the entire treatment period at least as great as that represented on the Y-axis. A positive value on the Y-axis indicates an improvement from baseline (i.e., a decrease in seizure frequency), while a negative value indicates a worsening from baseline (i.e., an increase in seizure frequency). Thus, in a display of this type, a curve for an effective treatment is shifted to the left of the curve for placebo. The proportion of patients achieving any particular level of reduction in PGTC seizure frequency was consistently higher for the group treated with LAMICTAL XR compared with the placebo group. For example, 70% of patients randomized to LAMICTAL XR experienced a 50% or greater reduction in PGTC seizure frequency, compared with 32% of patients randomized to placebo. Patients with an increase in seizure frequency >100% are represented on the Y-axis as equal to or greater than -100%.
14.2 Adjunctive Therapy for Partial-Onset Seizures

The effectiveness of immediate-release lamotrigine as adjunctive therapy was initially established in 3 pivotal, multicenter, placebo-controlled, double-blind clinical trials in 355 adults with refractory partial-onset seizures.

The effectiveness of LAMICTAL XR as adjunctive therapy in partial-onset seizures, with or without secondary generalization, was established in a 19-week, multicenter, double-blind, placebo-controlled trial in 236 patients aged 13 years and older (approximately 93% of patients were aged 16 to 65 years). Approximately 36% were from the U.S. and approximately 64% were from other countries including Argentina, Brazil, Chile, Germany, India, Korea, Russian Federation, and Ukraine. Patients with at least 8 partial-onset seizures during an 8-week prospective baseline phase (or 4-week prospective baseline coupled with a 4-week historical baseline documented with seizure diary data) were randomized to treatment with LAMICTAL XR (n = 116) or placebo (n = 120) added to their current regimen of 1 or 2 AEDs. Approximately half of the patients were taking 2 concomitant AEDs at baseline. Target doses ranged from 200 to 500 mg/day of LAMICTAL XR based on concomitant AED (target dose = 200 mg for valproate, 300 mg for AEDs not altering plasma lamotrigine, and 500 mg for enzyme-inducing AEDs). The median partial seizure frequency per week at baseline was 2.3 for LAMICTAL XR and 2.1 for placebo.
The primary endpoint was the median percent change from baseline in partial-onset seizure frequency during the entire double-blind treatment phase. The median percent reductions in weekly partial-onset seizures were 47% in patients treated with LAMICTAL XR and 25% on placebo, a difference that was statistically significant, defined as a 2-sided $P$ value $\leq 0.05$.

Figure 2 presents the percentage of patients (X-axis) with a percent reduction in partial-onset seizure frequency (responder rate) from baseline through the entire treatment period at least as great as that represented on the Y-axis. The proportion of patients achieving any particular level of reduction in partial-onset seizure frequency was consistently higher for the group treated with LAMICTAL XR compared with the placebo group. For example, 44% of patients randomized to LAMICTAL XR experienced a 50% or greater reduction in partial-onset seizure frequency compared with 21% of patients randomized to placebo.

**Figure 2. Proportion of Patients by Responder Rate for LAMICTAL XR and Placebo Group (Partial-Onset Seizure Study)**

### 14.3 Conversion to Monotherapy for Partial-Onset Seizures

The effectiveness of LAMICTAL XR as monotherapy for partial-onset seizures was established in a historical control trial in 223 adults with partial-onset seizures. The historical control methodology is described in a publication by French, et al. [see References (15)]. Briefly, in this study, patients were randomized to ultimately receive either LAMICTAL XR 300 or
250 mg once a day, and their responses were compared with those of a historical control group. The historical control consisted of a pooled analysis of the control groups from 8 studies of similar design, which utilized a subtherapeutic dose of an AED as a comparator. Statistical superiority to the historical control was considered to be demonstrated if the upper 95% confidence interval for the proportion of patients meeting escape criteria in patients receiving LAMICTAL XR remained below the lower 95% prediction interval of 65.3% derived from the historical control data.

In this study, patients aged 13 years and older experienced at least 4 partial-onset seizures during an 8-week baseline period with at least 2 seizures occurring during each of 2 consecutive 4-week periods while receiving valproate or a non–enzyme-inducing AED. LAMICTAL XR was added to either valproate or a non–enzyme-inducing AED over a 6- to 7-week period followed by the gradual withdrawal of the background AED. Patients were then continued on monotherapy with LAMICTAL XR for 12 weeks. The escape criteria were 1 or more of the following: (1) doubling of average monthly seizure count during any 28 consecutive days, (2) doubling of highest consecutive 2-day seizure frequency during the entire treatment phase, (3) emergence of a new seizure type compared with baseline (4) clinically significant prolongation of generalized tonic-clonic seizures or worsening of seizure considered by the investigator to require intervention. These criteria were similar to those in the 8 controlled trials from which the historical control group was constituted.

The upper 95% confidence limits of the proportion of subjects meeting escape criteria (40.2% at 300 mg/day and 44.5% at 250 mg/day) were below the threshold of 65.3% derived from the historical control data.

Although the study population was not fully comparable with the historical controlled population and the study was not fully blinded, numerous sensitivity analyses supported the primary results. Efficacy was further supported by the established effectiveness of the immediate-release formulation as monotherapy.

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING
LAMICTAL XR (lamotrigine) Extended-Release Tablets
25 mg, yellow with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 25”, unit-of-use bottles of 30 with orange caps (NDC 0173-0754-00).
50 mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 50”, unit-of-use bottles of 30 with orange caps (NDC 0173-0755-00).
100 mg, orange with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 100”, unit-of-use bottles of 30 with orange caps (NDC 0173-0756-00).

200 mg, blue with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 200”, unit-of-use bottles of 30 with orange caps (NDC 0173-0757-00).

250 mg, purple with a white center, caplet-shaped, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 250”, unit-of-use bottles of 30 with orange caps (NDC 0173-0781-00).

300 mg, gray with a white center, caplet-shaped, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 300”, unit-of-use bottles of 30 with orange caps (NDC 0173-0761-00).

LAMICTAL XR (lamotrigine) Patient Titration Kit for Patients Taking Valproate (Blue XR Kit)

25 mg, yellow with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 25” and 50 mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 50”; blisterpack of 21/25-mg tablets and 7/50-mg tablets (NDC 0173-0758-00).

LAMICTAL XR (lamotrigine) Patient Titration Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone, and Not Taking Valproate (Green XR Kit)

50 mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 50”; 100 mg, orange with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 100”; and 200 mg, blue with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 200”; blisterpack of 14/50-mg tablets, 14/100-mg tablets, and 7/200-mg tablets (NDC 0173-0759-00).

LAMICTAL XR (lamotrigine) Patient Titration Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange XR Kit)

25 mg, yellow with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 25”; 50 mg, green with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 50”; and 100 mg, orange with a white center, round, biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 100”; blisterpack of 14/25-mg tablets, 14/50-mg tablets, and 7/100-mg tablets (NDC 0173-0760-00).

Storage: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Rash: Prior to initiation of treatment with LAMICTAL XR, inform patients that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and instruct them to report any such occurrence to their physician immediately.

Multiorgan Hypersensitivity Reactions, Blood Dyscrasias, and Organ Failure:
Inform patients that multiorgan hypersensitivity reactions and acute multiorgan failure may occur with LAMICTAL. Isolated organ failure or isolated blood dyscrasias without evidence of multiorgan hypersensitivity may also occur. Instruct patients to contact their physician immediately if they experience any signs or symptoms of these conditions [see Warnings and Precautions (5.2, 5.3)].

Suicidal Thinking and Behavior: Inform patients, their caregivers, and families that AEDs, including LAMICTAL XR, may increase the risk of suicidal thoughts and behavior. Instruct them to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior or thoughts about self-harm. They should immediately report behaviors of concern to their physician.

Worsening of Seizures: Advise patients to notify their physician if worsening of seizure control occurs.

Central Nervous System Adverse Effects: Inform patients that LAMICTAL XR may cause dizziness, somnolence, and other symptoms and signs of central nervous system depression. Accordingly, instruct them neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on LAMICTAL XR to gauge whether or not it adversely affects their mental and/or motor performance.

Pregnancy and Nursing: Instruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy and if they intend to breastfeed or are breastfeeding an infant.

Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 [see Use in Specific Populations (8.1)].

Inform patients who intend to breastfeed that LAMICTAL XR is present in breast milk and advise them to monitor their child for potential adverse effects of this drug. Discuss the benefits and risks of continuing breastfeeding.

Oral Contraceptive Use: Instruct women to notify their physician if they plan to start or stop use of oral contraceptives or other female hormonal preparations. Starting estrogen-containing oral contraceptives may significantly decrease lamotrigine plasma levels and stopping estrogen-containing oral contraceptives (including the pill-free week) may significantly increase lamotrigine plasma levels [see Warnings and Precautions (5.7), Clinical Pharmacology (12.3)]. Also instruct women to promptly notify their physician if they experience adverse reactions or changes in menstrual pattern (e.g., break-through bleeding) while receiving LAMICTAL XR in combination with these medications.
Discontinuing LAMICTAL XR: Instruct patients to notify their physician if they stop taking LAMICTAL XR for any reason and not to resume LAMICTAL XR without consulting their physician.

Aseptic Meningitis: Inform patients that LAMICTAL XR may cause aseptic meningitis. Instruct them to notify their physician immediately if they develop signs and symptoms of meningitis such as headache, fever, nausea, vomiting, stiff neck, rash, abnormal sensitivity to light, myalgia, chills, confusion, or drowsiness while taking LAMICTAL XR.

Potential Medication Errors: Medication errors involving LAMICTAL have occurred. In particular, the names LAMICTAL or lamotrigine can be confused with the names of other commonly used medications. Medication errors may also occur between the different formulations of LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL XR clearly. Depictions of the LAMICTAL XR Extended-Release Tablets can be found in the Medication Guide. Each LAMICTAL XR tablet has a distinct color and white center, and is printed with “LAMICTAL XR” and the tablet strength. These distinctive features serve to identify the different presentations of the drug and thus may help reduce the risk of medication errors. LAMICTAL XR is supplied in round, unit-of-use bottles with orange caps containing 30 tablets. The label on the bottle includes a depiction of the tablets that further communicates to patients and pharmacists that the medication is LAMICTAL XR and the specific tablet strength included in the bottle. The unit-of-use bottle with a distinctive orange cap and distinctive bottle label features serves to identify the different presentations of the drug and thus may help to reduce the risk of medication errors. To avoid a medication error of using the wrong drug or formulation, strongly advise patients to visually inspect their tablets to verify that they are LAMICTAL XR each time they fill their prescription and to immediately talk to their doctor/pharmacist if they receive a LAMICTAL XR tablet without a white center and without “LAMICTAL XR” and the strength printed on the tablet as they may have received the wrong medication [see Dosage Forms and Strengths (3), How Supplied/Storage and Handling (16)].

LAMICTAL XR and DiffCORE are trademarks of the GSK group of companies.

GlaxoSmithKline
Research Triangle Park, NC 27709

©2014, the GSK group of companies. All rights reserved.

LXR:xPI
MEDICATION GUIDE

LAMICTAL® (la-MIK-tal) XR™ (lamotrigine) Extended-Release Tablets

Read this Medication Guide before you start taking LAMICTAL XR and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about LAMICTAL XR, ask your healthcare provider or pharmacist.

What is the most important information I should know about LAMICTAL XR?

1. LAMICTAL XR may cause a serious skin rash that may cause you to be hospitalized or even cause death.

   There is no way to tell if a mild rash will become more serious. A serious skin rash can happen at any time during your treatment with LAMICTAL XR, but is more likely to happen within the first 2 to 8 weeks of treatment. Children aged between 2 and 16 years have a higher chance of getting this serious skin rash while taking LAMICTAL XR. LAMICTAL XR is not approved for use in children younger than 13 years.

   The risk of getting a serious skin rash is higher if you:
   - take LAMICTAL XR while taking valproate [DEPAKENE® (valproic acid) or DEPAKOTE® (divalproex sodium)].
   - take a higher starting dose of LAMICTAL XR than your healthcare provider prescribed.
   - increase your dose of LAMICTAL XR faster than prescribed.

   Call your healthcare provider right away if you have any of the following:
   - a skin rash
   - blistering or peeling of your skin
   - hives
   - painful sores in your mouth or around your eyes

   These symptoms may be the first signs of a serious skin reaction. A healthcare provider should examine you to decide if you should continue taking LAMICTAL XR.
2. Other serious reactions, including serious blood problems or liver problems. LAMICTAL XR can also cause other types of allergic reactions or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away if you have any of these symptoms:

- fever
- frequent infections
- severe muscle pain
- swelling of your face, eyes, lips, or tongue
- swollen lymph glands
- unusual bruising or bleeding
- weakness, fatigue
- yellowing of your skin or the white part of your eyes

3. Like other antiepileptic drugs, LAMICTAL XR may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

- thoughts about suicide or dying
- attempt to commit suicide
- new or worse depression
- new or worse anxiety
- feeling agitated or restless
- panic attacks
- trouble sleeping (insomnia)
- new or worse irritability
- acting aggressive, being angry, or violent
- acting on dangerous impulses
- an extreme increase in activity and talking (mania)
- other unusual changes in behavior or mood

Do not stop LAMICTAL XR without first talking to a healthcare provider.

- Stopping LAMICTAL XR suddenly can cause serious problems.
- Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

How can I watch for early symptoms of suicidal thoughts and actions?

- Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
• Keep all follow-up visits with your healthcare provider as scheduled.
• Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

4. LAMICTAL XR may rarely cause aseptic meningitis, a serious inflammation of the protective membrane that covers the brain and spinal cord.

Call your healthcare provider right away if you have any of the following symptoms:
• headache
• fever
• nausea
• vomiting
• stiff neck
• rash
• unusual sensitivity to light
• muscle pains
• chills
• confusion
• drowsiness

Meningitis has many causes other than LAMICTAL XR, which your doctor would check for if you developed meningitis while taking LAMICTAL XR.

LAMICTAL XR can have other serious side effects. For more information ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you. Be sure to read the section below entitled “What are the possible side effects of LAMICTAL XR?”

5. Patients prescribed LAMICTAL have sometimes been given the wrong medicine because many medicines have names similar to LAMICTAL, so always check that you receive LAMICTAL XR.

Taking the wrong medication can cause serious health problems. When your healthcare provider gives you a prescription for LAMICTAL XR:
• Make sure you can read it clearly.
• Talk to your pharmacist to check that you are given the correct medicine.
• Each time you fill your prescription, check the tablets you receive against the pictures of the tablets below.

These pictures show the distinct wording, colors, and shapes of the tablets that help to identify the right strength of LAMICTAL XR. Immediately call your
pharmacist if you receive a LAMICTAL XR tablet that does not look like one of the tablets shown below, as you may have received the wrong medication.

<table>
<thead>
<tr>
<th>LAMICTAL XR (lamotrigine) Extended-Release Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="25 mg, yellow with white center" /> Imprinted with LAMICTAL XR 25</td>
</tr>
<tr>
<td><img src="image" alt="50 mg, green with white center" /> Imprinted with LAMICTAL XR 50</td>
</tr>
<tr>
<td><img src="image" alt="100 mg, orange with white center" /> Imprinted with LAMICTAL XR 100</td>
</tr>
<tr>
<td><img src="image" alt="200 mg, blue with white center" /> Imprinted with LAMICTAL XR 200</td>
</tr>
<tr>
<td><img src="image" alt="250 mg, purple with white center" /> Imprinted with LAMICTAL XR 250</td>
</tr>
<tr>
<td><img src="image" alt="300 mg, gray with white center" /> Imprinted with LAMICTAL XR 300</td>
</tr>
</tbody>
</table>

What is LAMICTAL XR?

LAMICTAL XR is a prescription medicine used:

- together with other medicines to treat primary generalized tonic-clonic seizures and partial onset seizures in people aged 13 years and older.
- alone when changing from 1 other medicine used to treat partial-onset seizures in people aged 13 years and older.

It is not known if LAMICTAL XR is safe or effective in children younger than 13 years. Other forms of LAMICTAL can be used in children aged 2 to 12 years.

It is not known if LAMICTAL XR is safe or effective when used alone as the first treatment of seizures.

Who should not take LAMICTAL XR?

You should not take LAMICTAL XR if you have had an allergic reaction to lamotrigine or to any of the inactive ingredients in LAMICTAL XR. See the end of this leaflet for a complete list of ingredients in LAMICTAL XR.

What should I tell my healthcare provider before taking LAMICTAL XR?
Before taking LAMICTAL XR, tell your healthcare provider about all of your medical
conditions, including if you:

• have had a rash or allergic reaction to another antiseizure medicine.
• have or have had depression, mood problems, or suicidal thoughts or behavior.
• have had aseptic meningitis after taking LAMICTAL (lamotrigine) or LAMICTAL XR.
• are taking oral contraceptives (birth control pills) or other female hormonal
medicines. Do not start or stop taking birth control pills or other female
hormonal medicine until you have talked with your healthcare provider. Tell your
healthcare provider if you have any changes in your menstrual pattern such as
breakthrough bleeding. Stopping these medicines may cause side effects (such
as dizziness, lack of coordination, or double vision). Starting these medicines
may lessen how well LAMICTAL XR works.
• are pregnant or plan to become pregnant. It is not known if LAMICTAL XR will
harm your unborn baby. If you become pregnant while taking LAMICTAL XR, talk
to your healthcare provider about registering with the North American
Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling
1-888-233-2334. The purpose of this registry is to collect information about the
safety of antiepileptic drugs during pregnancy.
• are breastfeeding. LAMICTAL XR passes into breast milk and may cause side
effects in a breastfed baby. If you breastfeed while taking LAMICTAL XR, watch
your baby closely for trouble breathing, episodes of temporarily stopping
breathing, sleepiness, or poor sucking. Call your baby’s healthcare provider right
away if you see any of these problems. Talk to your healthcare provider about
the best way to feed your baby if you take LAMICTAL XR.

Tell your healthcare provider about all the medicines you take or if you are planning
to take a new medicine, including prescription and non-prescription medicines,
vitamins, and herbal supplements. If you use LAMICTAL XR with certain other
medicines, they can affect each other, causing side effects.

How should I take LAMICTAL XR?

• Take LAMICTAL XR exactly as prescribed.
• Your healthcare provider may change your dose. Do not change your dose
without talking to your healthcare provider.
• Do not stop taking LAMICTAL XR without talking to your healthcare provider.
Stopping LAMICTAL XR suddenly may cause serious problems. For example, if
you have epilepsy and you stop taking LAMICTAL XR suddenly, you may have
seizures that do not stop. Talk with your healthcare provider about how to stop
LAMICTAL XR slowly.
If you miss a dose of LAMICTAL XR, take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. **Do not take 2 doses at the same time.**

If you take too much LAMICTAL XR, call your healthcare provider or your local Poison Control Center or go to the nearest hospital emergency room right away.

You may not feel the full effect of LAMICTAL XR for several weeks.

If you have epilepsy, tell your healthcare provider if your seizures get worse or if you have any new types of seizures.

LAMICTAL XR can be taken with or without food.

Do not chew, crush, or divide LAMICTAL XR.

Swallow LAMICTAL XR Tablets whole.

If you have trouble swallowing LAMICTAL XR Tablets, tell your healthcare provider because there may be another form of LAMICTAL you can take.

If you receive LAMICTAL XR in a blisterpack, examine the blisterpack before use. Do not use if blisters are torn, broken, or missing.

**What should I avoid while taking LAMICTAL XR?**

Do not drive a car or operate complex, hazardous machinery until you know how LAMICTAL XR affects you.

**What are the possible side effects of LAMICTAL XR?**

See “What is the most important information I should know about LAMICTAL XR?”

Common side effects of LAMICTAL XR include:

- dizziness
- tremor
- double vision
- nausea
- vomiting
- trouble with balance and coordination
- anxiety

Other common side effects that have been reported with another form of LAMICTAL include headache, sleepiness, blurred vision, runny nose, and rash.

Tell your healthcare provider about any side effect that bothers you or that does not go away.

These are not all the possible side effects of LAMICTAL XR. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store LAMICTAL XR?

• Store LAMICTAL XR at room temperature between 59°F and 86°F (15°C and 30°C).
• Keep LAMICTAL XR and all medicines out of the reach of children.

General information about LAMICTAL XR

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LAMICTAL XR for a condition for which it was not prescribed. Do not give LAMICTAL XR to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about LAMICTAL XR. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about LAMICTAL XR that is written for healthcare professionals.

For more information, go to www.lamictalxr.com or call 1-888-825-5249.

What are the ingredients in LAMICTAL XR?

Active ingredient: lamotrigine.

Inactive ingredients: glycerol monostearate, hypromellose, lactose monohydrate, magnesium stearate, methacrylic acid copolymer dispersion, polyethylene glycol 400, polysorbate 80, silicon dioxide (25- and 50-mg tablets only), titanium dioxide, triethyl citrate, carmine (250-mg tablet only), iron oxide black (50-, 250-, and 300-mg tablets only), iron oxide yellow (25-, 50-, and 100-mg tablets only), iron oxide red (100-mg tablet only), FD&C Blue No. 2 Aluminum Lake (200- and 250-mg tablets only). Tablets are printed with edible black ink.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

LAMICTAL XR is a trademark of the GSK group of companies. The other brands listed are trademarks of their respective owners and are not trademarks of the GSK group of companies. The makers of these brands are not affiliated with and do not endorse the GSK group of companies or its products.